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A B S T R A C T
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and survival.
Melanoma and squamous cell carcinoma (SCC) are high-risk skin cancers which have the potential to metastasise and ultimately lead
to death, whereas basal cell carcinoma (BCC) is usually localised with potential to infiltrate and damage surrounding tissue. Anxiety
around missing early curable cases needs to be balanced against inappropriate referral and unnecessary excision of benign lesions.
Teledermatology provides a way for generalist clinicians to access the opinion of a specialist dermatologist for skin lesions that they
consider to be suspicious without referring the patients through the normal referral pathway. Teledermatology consultations can be
’store-and-forward’ with electronic digital images of a lesion sent to a dermatologist for review at a later time, or can be live and
interactive consultations using videoconferencing to connect the patient, referrer and dermatologist in real time.
Objectives
To determine the diagnostic accuracy of teledermatology for the detection of any skin cancer (melanoma, BCC or cutaneous squamous
cell carcinoma (cSCC)) in adults, and to compare its accuracy with that of in-person diagnosis.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of
Controlled Trials, MEDLINE, Embase, CINAHL, CPCI, Zetoc, Science Citation Index, US National Institutes of Health Ongoing
Trials Register, NIHR Clinical Research Network Portfolio Database and the World Health Organization International Clinical Trials
Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies evaluating skin cancer diagnosis for teledermatology alone, or in comparison with face-to-face diagnosis by a specialist clinician,
compared with a reference standard of histological confirmation or clinical follow-up and expert opinion. We also included studies
evaluating the referral accuracy of teledermatology compared with a reference standard of face-to-face diagnosis by a specialist clinician.
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Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on
QUADAS-2). We contacted authors of included studies where there were information related to the target condition of any skin
cancer missing. Data permitting, we estimated summary sensitivities and specificities using the bivariate hierarchical model. Due to the
scarcity of data, we undertook no covariate investigations for this review. For illustrative purposes, we plotted estimates of sensitivity
and specificity on coupled forest plots for diagnostic threshold and target condition under consideration.
Main results
The review included 22 studies reporting diagnostic accuracy data for 4057 lesions and 879 malignant cases (16 studies) and referral
accuracy data for reported data for 1449 lesions and 270 ’positive’ cases as determined by the reference standard face-to-face decision
(six studies). Methodological quality was variable with poor reporting hindering assessment. The overall risk of bias was high or unclear
for participant selection, reference standard, and participant flow and timing in at least half of all studies; the majority were at low risk
of bias for the index test. The applicability of study findings were of high or unclear concern for most studies in all domains assessed
due to the recruitment of participants from secondary care settings or specialist clinics rather than from primary or community-based
settings in which teledermatology is more likely to be used and due to the acquisition of lesion images by dermatologists or in specialist
imaging units rather than by primary care clinicians.
Seven studies provided data for the primary target condition of any skin cancer (1588 lesions and 638 malignancies). For the correct
diagnosis of lesions as malignant using photographic images, summary sensitivity was 94.9% (95% confidence interval (CI) 90.1%
to 97.4%) and summary specificity was 84.3% (95% CI 48.5% to 96.8%) (from four studies). Individual study estimates using
dermoscopic images or a combination of photographic and dermoscopic images generally suggested similarly high sensitivities with
highly variable specificities. Limited comparative data suggested similar diagnostic accuracy between teledermatology assessment and
in-person diagnosis by a dermatologist; however, data were too scarce to draw firm conclusions. For the detection of invasive melanoma
or atypical intraepidermal melanocytic variants both sensitivities and specificities were more variable. Sensitivities ranged from 59%
(95% CI 42% to 74%) to 100% (95% CI 48% to 100%) and specificities from 30% (95% CI 22% to 40%) to 100% (95% CI 93%
to 100%), with reported diagnostic thresholds including the correct diagnosis of melanoma, classification of lesions as ’atypical’ or
’typical, and the decision to refer or to excise a lesion.
Referral accuracy data comparing teledermatology against a face-to-face reference standard suggested good agreement for lesions
considered to require some positive action by face-to-face assessment (sensitivities of over 90%). For lesions considered of less concern
when assessed face-to-face (e.g. for lesions not recommended for excision or referral), agreement was more variable with teledermatology
specificities ranging from 57% (95% CI 39% to 73%) to 100% (95% CI 86% to 100%), suggesting that remote assessment is more
likely recommend excision, referral or follow-up compared to in-person decisions.
Authors’ conclusions
Studies were generally small and heterogeneous andmethodological quality was difficult to judge due to poor reporting. Bearing inmind
concerns regarding the applicability of study participants and of lesion image acquisition in specialist settings, our results suggest that
teledermatology can correctly identify the majority of malignant lesions. Using a more widely defined threshold to identify ’possibly’
malignant cases or lesions that should be considered for excision is likely to appropriately triage those lesions requiring face-to-face
assessment by a specialist. Despite the increasing use of teledermatology on an international level, the evidence base to support its ability
to accurately diagnose lesions and to triage lesions from primary to secondary care is lacking and further prospective and pragmatic
evaluation is needed.
P L A I N L A N G U A G E S U M M A R Y
What is the diagnostic accuracy of teledermatology for the diagnosis of skin cancer in adults?
Why is improving the diagnosis of skin cancer important?
There are different types of skin cancer. Melanoma is one of the most dangerous forms and it is important to identify it early so that
it can be removed. If it is not recognised when first brought to the attention of doctors (also known as a false-negative test result)
treatment can be delayed resulting in the melanoma spreading to other organs in the body and possibly causing early death. Cutaneous
squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) are usually localised skin cancers, although cSCC can spread to other
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parts of the body and BCC can cause disfigurement if not recognised early. Calling something a skin cancer when it is not really a skin
cancer (a false-positive result) may result in unnecessary surgery and other investigations that can cause stress and worry to the patient.
Making the correct diagnosis is important. Mistaking one skin cancer for another can lead to the wrong treatment being used or lead
to a delay in effective treatment.
What is the aim of the review?
The aim of this Cochrane Review was to find out whether teledermatology is accurate enough to identify which people with skin lesions
need to be referred to see a specialist dermatologist (a doctor concerned with disease of the skin) and who can be safely reassured that
their lesion (damage or change of the skin) is not malignant. We included 22 studies to answer this question.
What was studied in the review?
Teledermatology means sending pictures of skin lesions or rashes to a specialist for advice on diagnosis or management. It is a way for
primary care doctors (general practitioners (GPs)) to get an opinion from a specialist dermatologist without having to refer patients
through the normal referral pathway. Teledermatology can involve sending photographs or magnified images of a skin lesion taken with
a special camera (dermatoscope) to a skin specialist to look at or it might involve immediate discussion about a skin lesion between a
GP and a skin specialist using videoconferencing.
What are the main results of the review?
The review included 22 studies, 16 studies comparing teledermatology diagnoses to the final lesion diagnoses (diagnostic accuracy) for
4057 lesions and 879 malignant cases and five studies comparing teledermatology decisions to the decisions that would be made with
the patient present (referral accuracy) for 1449 lesions and 270 ’positive’ cases.
The studies were very different from each other in terms of the types of people with suspicious skin cancer lesions included and the
type of teledermatology used. A single reliable estimate of the accuracy of teledermatology could not be made. For the correct diagnosis
of a lesion to be a skin cancer, data suggested that less than 7% of malignant skin lesions were missed by teledermatology. Study results
were too variable to tell us how many people would be referred unnecessarily for a specialist dermatology appointment following a
teledermatology consultation. Without access to teledermatology services however, most of the lesions included in these studies would
likely be referred to a dermatologist.
How reliable are the results of the studies of this review?
In the included studies, the final diagnosis of skin cancer was made by lesion biopsy (taking a small sample of the lesion so it could
be examined under a microscope) and the absence of skin cancer was confirmed by biopsy or by follow-up over time to make sure the
skin lesion remained negative for melanoma. This is likely to have been a reliable method for deciding whether people really had skin
cancer. In a few studies, a diagnosis of no skin cancer was made by a skin specialist rather than biopsy. This is less likely to have been a
reliable method for deciding whether people really had skin cancer*. Poor reporting of what was done in the study made it difficult for
us to say how reliable the study results are. Selecting some patients from specialist clinics instead of primary care along with different
ways of doing teledermatology were common problems.
Who do the results of this review apply to?
Studies were conducted in: Europe (64%), North America (18%), South America (9%) or Oceania (9%). The average age of people
who were studied was 52 years; however, several studies included at least some people under the age of 16 years. The percentage of
people with skin cancer ranged between 2% and 88% with an average of 30%, which is much higher than would be observed in a
primary care setting in the UK.
What are the implications of this review?
Teledermatology is likely to be a good way of helping GPs to decide which skin lesions need to be seen by a skin specialist. Our review
suggests that using magnified images, in addition to photographs of the lesion, improves accuracy. More research is needed to establish
the best way of providing teledermatology services.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies, biopsy, clinical follow-up or specialist clinician diagnosis were the reference comparisons.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question: What is the diagnostic accuracy of teledermatology for the detection of skin cancer in adults?
Population: Adults with lesions suspicious for skin cancer
Index test: TD using photographic or dermoscopic (or both) images
Comparator test: Face-to-face diagnosis using visual inspect ion or dermoscopy (or both)
Target condition: Any skin cancer, including invasive melanoma and atypical intraepidermal melanocyt ic variants, BCC and cSCC
Reference standard: Histology with or without long-term follow-up (diagnost ic accuracy); expert face-to-face diagnosis (for referral accuracy)
Action: If accurate, posit ive results ensure the malignant lesions are not missed but are appropriately referred for specialist assessment
or are treated appropriately in a non-referred sett ing, and those with negat ive results can be safely reassured and discharged
Quantity of evidence Number of studies Total lesions Total cases
Diagnost ic accuracy 16 4057 879
Referral accuracy 6 1449 270
Limitations
Risk of bias: Low risk for part icipant select ion in 7 studies; high risk (5) f rom case-control design (2) or inappropriate exclusion criteria (4). Low
risk for teledermatology assessments (22). Low risk for comparison with face-to-face diagnosis (2/ 5); unclear (3). Low risk for
reference standard (10/ 22); high risk f rom use of expert diagnosis alone - referral accuracy (6) or inadequate reference standard
(6). High risk for part icipant f low (17) due to dif ferent ial verif icat ion (5), and exclusions following recruitment (14); t im ing of tests
not mentioned in 14 studies
Applicability of evidence to question: High concern (14/ 22) for applicability of part icipants due to recruitment f rom secondary care or specialist clinics (12) or inclusion
of mult iple lesions per part icipant (6). High concern for applicability of teledermatology assessments (12/ 22) due to images
acquired by dermatologists secondary care sett ings or in medical imaging units rather than images acquired in primary care. Low
concern for reference standard (6/ 22); unclear concern due to lack of information concerning the expert ise of the histopathologist
(13) or expert face-to-face diagnosis (3)
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Findings:
7 studies reported diagnost ic accuracy data for the primary target condit ion of any skin cancer; 9 studies for the detect ion of invasive melanoma or atypical intraepidermal
melanocyt ic variants; 2 studies for invasive melanoma alone; and 4 studies for BCC alone. 6 studies reported only referral accuracy data (teledermatology decisions versus
face-to-face decisions). The f indings presented are based on results for the primary target condit ion of any skin cancer and for the detect ion of invasive melanoma or atypical
intraepidermal melanocyt ic variants
Diagnostic accuracy data Number of datasets Total lesions Total malignant
Test: TD using photographic images for
any skin cancer
4 717 452
3 studies reported a cross-tabulat ion of lesion f inal diagnoses against the diagnosis on teledermatology such that data could
be extracted for the detect ion of any malignancy, regardless of any misclassif icat ion of 1 skin cancer for another, e.g. a BCC
diagnosed as a melanoma or vice versa; and 1 study presented data for the detect ion of ’malignant ’ versus benign cases with no
breakdown of individual lesion diagnoses given. Summary sensit ivity was 94.9% (95%CI 90.1% to 97.4%) and summary specif icity
84.3% (95% CI 48.5% to 96.8%). 2 studies providing a direct comparison between TD assessment and in-person diagnosis by a
dermatologist the data suggested sim ilar accuracy between approaches; however, data were too scarce to draw f irm conclusions
Test: TD using clinical and dermoscopic
images for any skin cancer
3 928 215
Sensit ivit ies were 100% in all 3 studies. Specif icit ies ranged f rom 25% (95% CI 5% to 57%) to 92% (95% CI 74% to 99%). Studies
used varying thresholds to decide test posit ivity and included highly selected populat ions. No stat ist ical pooling was undertaken
Test: TD using photographic images for
invasive melanoma or atypical intraepi-
dermal melanocytic variants
4 1834 106
Sensit ivit ies ranged f rom 59% (95%CI 42% to 74%) to 100% (95%CI 48% to 100%) and specif icit ies f rom 30% (95%CI 22% to 40%)
to 100% (95% CI 93% to 100%). Diagnost ic thresholds were correct diagnosis of melanoma (3) or classif icat ion as ’atypical’ or
’typical.’ Populat ions also varied, some including only atypical or higher-risk pigmented lesions and excluding equivocal lesions
and others including both pigmented and non-pigmented lesions who were either self -referred or were deemed to require lesion
excision. The number of melanomas missed ranged f rom 0 to 17
Test: TD using photographic and dermo-
scopic images for invasive melanoma or
atypical intraepidermal melanocytic vari-
ants
4 664 93
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Summary est imates were 85.4% (95% CI 68.3% to 94.1%) for sensit ivity and 91.6% (95% CI 81.1% to 96.5%) for specif icity.
Sensit ivit ies were lower for the correct diagnosis of melanoma (71% to 81%) compared to the decision to refer or to excise a lesion
(96% to 100%). The number of melanomas missed ranged f rom 0 to 7
All data (referral accuracy) 6 1449 270
TD diagnoses were reported based on photographic images alone (4), photographic and dermoscopic images (1) and using live-
link TD (1). Diagnost ic decisions on TD varied, including the diagnosis of malignancy, the decision to excise a lesion, the decision
to refer versus not refer, or to excise or follow-up at a later date. For store-and-forward TD sensit ivit ies were generally above 90%
indicat ing good agreement between remote image-based decisions with the face-to-face reference standard for lesions considered
to require some posit ive act ion by face-to-face assessment. Specif icit ies were more variable ranging f rom 57% (95% CI 39% to
73%) to 100% (95% CI 86% to 100%) suggest ing that remote assessment is more likely to recommend excision, referral or follow-
up for lesions considered of less concern when assessed face-to-face
BCC: basal cell carcinoma; CI: conf idence interval; cSCC: cutaneous squamous cell carcinoma; TD: teledermatology.
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Ac-
curacy (DTA) reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers conducted for theNational Institute
for Health Research (NIHR) Cochrane Systematic Reviews Pro-
gramme. For the purposes of these reviews, diagnostic accuracy
is assessed by the sensitivity and specificity of a test. Appendix 1
shows the content and structure of the programme, Appendix 2
provides a glossary of terms used.
Target condition being diagnosed
There are threemain forms of skin cancer.Melanoma has the high-
est skin cancer mortality (Cancer Research UK 2017); however,
themost common skin cancers in Caucasian populations are those
arising from keratinocytes: basal cell carcinoma (BCC) and cuta-
neous squamous cell carcinoma (cSCC) (Gordon 2013; Madan
2010). In 2003, the World Health Organization estimated that
between two and three million ’non-melanoma’ skin cancers (of
which BCC is estimated to account for around 80% and cSCC
around 16% of cases) and 132,000 melanoma skin cancers occur
globally each year (WHO 2003).
In this DTA review there are three target conditions of interest
melanoma, BCC and cSCC.
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes
- the epidermal cells that produce pigment or melanin. Cutaneous
melanoma refers to any skin lesion with malignant melanocytes
present in the dermis, primarily including superficial spreading,
nodular, acral lentiginous and lentigo maligna melanoma variants
(see Figure 1). Melanoma in situ refers to abnormal melanocytes
that are contained within the epidermis and have not yet invaded
the dermis, but are at risk of progression to melanoma if left un-
treated. Lentigo maligna, a subtype of melanoma in situ in chron-
ically sun-damaged skin, denotes another form of proliferation
of abnormal melanocytes. Melanoma in situ and lentigo maligna
are both atypical intraepidermal melanocytic variants. All forms
of melanoma in situ can progress to invasive melanoma if growth
breaches the dermo-epidermal junction during a vertical growth
phase; however,malignant transformation is both lower and slower
for lentigo maligna than for melanoma in situ (Kasprzak 2015).
Melanoma is one of the most dangerous forms of skin cancer,
with the potential to metastasise to other parts of the body via the
lymphatic system and bloodstream. It accounts for only a small
percentage of skin cancer cases but is responsible for up to 75%
of skin cancer deaths (Boring 1994; Cancer Research UK 2017).
Figure 1. Sample photograph of superficial spreading melanoma(left), basal cell carcinoma (centre) and
squamous cell carcinoma (right). Copyright © 2012 Dr Rubeta Matin: reproduced with permission.
The incidence of melanoma rose to over 200,000 newly diagnosed
cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an
estimated 55,000 deaths (Ferlay 2015). The highest incidence was
observed in Australia with 13,134 new cases of melanoma of the
skin in 2014 (ACIM 2017), and in New Zealand with 2341 reg-
istered cases in 2010 (HPA and MelNet NZ 2014). In the USA,
the predicted incidence in 2014 was 73,870 per annum and the
predicted number of deaths was 9940 (Siegel 2015). The highest
rates in Europe are in north-western Europe and the Scandina-
vian countries, with the highest incidence reported in Switzerland
of 25.8 per 100,000 people in 2012. Rates in the England have
tripled from 4.6 and 6.0 per 100,000 in men and women respec-
tively, in 1990, to 18.6 and 19.6 per 100,000 in 2012 (EUCAN
2012). Indeed, in the UK, melanoma has one of the fastest ris-
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ing incidence rates of any cancer, with the biggest projected in-
crease in incidence between 2007 and 2030 (Mistry 2011). In the
decade leading up to 2013, age-standardised incidence increased
by 46%, with 14,500 new cases in 2013 and 2459 deaths in 2014
(Cancer Research UK 2017). Rates are higher in women than in
men; however, the rate of incidence in men is increasing faster
than in women (Arnold 2014). The rising incidence in melanoma
is thought to be primarily related to an increase in recreational sun
exposure and tanning bed use and an increasingly ageing popula-
tion with higher lifetime recreational ultraviolet (UV) exposure, in
conjunction with possible earlier detection (Belbasis 2016; Linos
2009). Belbasis 2016 provides a detailed review of putative risk
factors, including eye and hair colour, skin type and density of
freckles, history of melanoma, sunburn and presence of particular
lesion types.
A database in the USA of over 40,000 patients from 1998 on-
wards, which assisted the development of the 8th American Joint
Committee on Cancer (AJCC) Staging System indicated a five-
year survival of 97% to 99% for stage I melanoma, which dropped
to 32% to 93% in stage III disease depending on tumour thick-
ness, the presence of ulceration and number of involved nodes
(Gershenwald 2017). While these are substantial increases rel-
ative to survival in 1975 (Cho 2014), increasing incidence be-
tween 1975 and 2010 means that mortality rates have remained
static during the same period. This observation, coupled with in-
creasing incidence of localised disease, suggests that improved sur-
vival rates may be due to earlier detection and heightened vig-
ilance (Cho 2014). New targeted therapies for advanced (stage
IV), melanoma (e.g. BRAF inhibitors), have improved survival,
and immunotherapies are evolving such that long-term survival is
being documented (Pasquali 2018; Rozeman 2017). No new data
regarding the survival prospects for patients with stage IV disease
were analysed for the AJCC 8 staging guidelines due to lack of
contemporary data (Gershenwald 2017).
Basal cell carcinoma
BCC can arise from multiple stem cell populations, including
from the bulge and interfollicular epidermis (Grachtchouk 2011).
BCC growth is usually localised, but it can infiltrate and damage
surrounding tissue, sometimes causing considerable destruction
and disfigurement, particularly when located on the face (Figure
1). The four main subtypes of BCC are superficial, nodular, mor-
phoeic or infiltrative, and pigmented. They typically present as
slow-growing asymptomatic papules, plaques or nodules which
may bleed or formulcers that do not heal (Firnhaber 2012). People
with a BCC often present to healthcare professionals with a non-
healing lesion rather than specific symptoms such as pain. Many
lesions are diagnosed incidentally (Gordon 2013).
BCC most commonly occurs on sun-exposed areas on the head
and neck (McCormack 1997), and they are more common inmen
and in people over the age of 40. Different authors have attributed
a rising incidence of BCC in younger people to increased recre-
ational sun exposure (Bath-Hextall 2007a; Gordon 2013; Musah
2013). Other risk factors include Fitzpatrick skin types I and II
(Fitzpatrick 1975; Lear 1997; Maia 1995); previous skin cancer
history; immunosuppression; arsenic exposure; and genetic predis-
position, such as in basal cell naevus (Gorlin’s) syndrome (Gorlin
2004; Zak-Prelich 2004). Annual incidence is rising worldwide;
Europe has experienced a mean increase of 5.5% per year since the
late 1970s, the USA 2% per year, while estimates for the UK show
incidence appears to be increasing more steeply at a rate of an ad-
ditional 6 per 100,000 people per year (Lomas 2012). The rising
incidence has been explained by an ageing population; changes in
the distribution of known risk factors, particularly UV radiation;
and improved detection due to the increased awareness among
both practitioners and the general population (Verkouteren 2017).
Hoorens 2016 points to evidence for a gradual increase in the size
of BCCs over time, with delays in diagnosis ranging from 19 to
25 months.
According to National Institute for Health and Care Excellence
(NICE) guidance (NICE 2010), low-risk BCCs are nodular le-
sions occurring in people older than 24 years who are not im-
munosuppressed and do not have Gorlin syndrome. Furthermore,
they should be located below the clavicle; should be small (diame-
ter of less than 1 cm) with well-definedmargins; not recurrent fol-
lowing incomplete excision; and not in awkward or highly visible
locations (NICE 2010). Superficial BCCs are also typically low
risk and may be amenable to medical treatments such as photody-
namic therapy (PDT) or topical chemotherapy (Kelleners-Smeets
2017). Assigning BCCs as low or high risk influences the man-
agement options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can be found on ’high-risk’
anatomical areas such as the eyebrow, eyelid, nose, ear and temple
(these are at higher risk of invisible spread and therefore are more
at risk of being incompletely excised (Baxter 2012; Lear 2014)),
and they can arise from long-standing untreated lesions or from
a recurrence of aggressive BCC after primary treatment (Lear
2012). Very rarely, BCC metastasises to regional and distant sites
resulting in death, especially cases of large neglected lesions in
people who are immunosuppressed or those withGorlin syndrome
(McCusker 2014). Rates of metastasis are reported at 0.0028% to
0.55%(Lo 1991), with very poor survival rates. It is recognised that
basosquamous carcinoma (more like a high-risk SCC in behaviour
and not considered a true BCC) is likely to have accounted for
many cases of apparent metastases of BCC hence the spuriously
high reported incidence in some studies of up to 0.55% which is
not seen in clinical practice (Garcia 2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinocytes of the outermost layer
(epidermis) of the skin. People with cSCC often present with an
ulcer or firm (indurated) papule, plaque or nodule (Firnhaber
2012; Griffin 2016), often with an adherent crust and poorly
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defined margins (Madan 2010). This type of carcinoma can arise
in the absence of a precursor lesion or it can develop from pre-
existing actinic keratosis or Bowen’s disease (considered by some
clinicians to be squamous cell carcinoma in situ); the estimated
annual risk of progression being less than 1% to 20% for newly
arising lesions (Alam 2001), and 5% for pre-existing lesions (Kao
1986). It remains locally invasive for a variable length of time, but
it has the potential to spread to the regional lymph nodes or via
the bloodstream to distant sites, especially in immunosuppressed
individuals (Lansbury 2010).High-risk lesions are those arising on
the lip or ear, recurrent cSCC, lesions arising on non-exposed sites,
scars or chronic ulcers, tumours more than 20mm in diameter and
with depth of invasion more than 4 mm, and poor differentiation
on pathological examination (Motley 2009). Perineural invasion
of nerves at least 0.1 mm in diameter is a further documented risk
factor for high-risk cSCC (Carter 2013).
Chronic ultraviolet light exposure through recreation or occupa-
tion is strongly linked to cSCC occurrence (Alam 2001). It is par-
ticularly common in people with fair skin and in less common ge-
netic disorders of pigmentation, such as albinism, xeroderma pig-
mentosum and recessive dystrophic epidermolysis bullosa (Alam
2001). Other recognised risk factors include immunosuppres-
sion; chronic wounds; arsenic or radiation exposure; certain drug
treatments, such as voriconazole and BRAF mutation inhibitors;
and previous skin cancer history (Baldursson 1993; Chowdri
1996; Dabski 1986; Fasching 1989; Lister 1997; Maloney 1996;
O’Gorman 2014). In solid organ transplant recipients, cSCC is
the most common form of skin cancer; the risk of developing
cSCC has been estimated at 65 to 253 times that of the general
population (Hartevelt 1990; Jensen 1999; Lansbury 2010). Over-
all, local and metastatic recurrence of cSCC at five years is esti-
mated at 8% and 5% respectively (Rowe 1992). The five-year sur-
vival rate of metastatic cSCC of the head and neck is around 60%
(Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is
wide local surgical excision of the lesion, to remove both the tu-
mour and any malignant cells that might have spread into the sur-
rounding skin (Garbe 2016; Marsden 2010; NICE 2015a; SIGN
2017; Sladden 2009). Recommended lateral surgical margins vary
according to tumour thickness (Garbe 2016), and to stage of dis-
ease at presentation (NICE 2015a).
Treatment options for BCC and cSCC include surgery, other
destructive techniques such as cryotherapy or electrodesiccation
and topical chemotherapy. A Cochrane Review of 27 randomised
controlled trials (RCTs) of interventions for BCC found very
little good-quality evidence for any of the interventions used
(Bath-Hextall 2007b).Complete surgical excision of primaryBCC
has a reported five-year recurrence rate of less than 2% (Griffiths
2005; Walker 2006), leading to significantly fewer recurrences
than treatment with radiotherapy (Bath-Hextall 2007b). After ap-
parent clear histopathological margins (serial vertical sections) af-
ter standard excision biopsy with 4mm surgical peripheral margins
taken there is a five-year reported recurrence rate of around 4%
(Drucker 2017). Mohs micrographic surgery , whereby surgeons
microscopically examine horizontal sections of the tumour peri-
operatively, undertaking re-excision until the margins are tumour-
free, are options for high-risk lesions on the face where standard
wider excision margins might lead to incomplete excision or con-
siderable functional impairment (Bath-Hextall 2007b; Lansbury
2010; Motley 2009; Stratigos 2015). Bath-Hextall 2007b found
one trial comparing Mohs micrographic surgery with a 3 mm
surgical margin excision in BCC (Smeets 2004); the update of
this study showed non-significantly lower recurrence at 10 years
with Mohs micrographic surgery (4.4% with Mohs micrographic
surgery compared to 12.2% after surgical excision; P = 0.10) (van
Loo 2014).
The main treatments for high-risk BCC are standard surgical exci-
sion, Mohs micrographic surgery or radiotherapy. For low-risk or
superficial subtypes of BCC, or for people with small or multiple
(or both) BCCs at low-risk sites (Marsden 2010), destructive tech-
niques other than excisional surgery may be used (e.g. electrodes-
iccation and curettage or cryotherapy (Alam 2001; Bath-Hextall
2007b)). Alternatively, non-surgical (’non-destructive’) treatments
may be considered (Bath-Hextall 2007b; Drew 2017; Kim 2014),
including topical chemotherapy such as imiquimod (Williams
2017), 5-fluorouracil (Arits 2013), ingenol mebutate (Nart 2015),
and photodynamic therapy (PDT) (Roozeboom 2016). Non-sur-
gical treatments are most frequently used for superficial forms of
BCC, with one head-to-head trial suggesting topical imiquimod
is superior to PDT and 5-fluorouracil (Jansen 2018). Although
non-surgical approaches are increasingly used, they do not allow
histological confirmation of tumour clearance, and their efficacy is
dependent on accurate characterisation of the histological subtype
and depth of tumour. The 2007 Cochrane review of BCC inter-
ventions found limited evidence from very small RCTs for these
approaches (Bath-Hextall 2007b), which have only partially been
addressed by subsequent studies (Bath-Hextall 2014; Kim 2014;
Roozeboom 2012). Most BCC trials have compared interventions
within the same treatment class, and few have compared medical
versus surgical treatments (Kim 2014).
Vismodegib, a first-in-class Hedgehog signalling pathway in-
hibitor is now available for the treatment of metastatic or lo-
cally advanced BCC based on the pivotal study ERIVANCE BCC
(Sekulic 2017). It is licensed for use in these patients where surgery
or radiotherapy is inappropriate, e.g. for treating locally advanced
periocular and orbital BCCs with orbital salvage of patients who
otherwise would have required exenteration (Wong 2017). How-
ever, NICE has recommended against the use of vismodegib based
on cost effectiveness and uncertainty of evidence (NICE 2017).
A systematic review of interventions for primary cSCC found only
one RCT eligible for inclusion (Lansbury 2010). Current practice
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therefore relies on evidence fromobservational studies, as reviewed
in Lansbury 2013, for example. Surgical excision with predeter-
mined margins is usually the first-line treatment (Motley 2009;
Stratigos 2015). Estimates of recurrence after Mohs micrographic
surgery, surgical excision or radiotherapy, which are likely to have
been evaluated in higher-risk populations, have shown pooled re-
currence rates of 3%, 5.4% and 6.4%, respectively, with overlap-
ping confidence intervals (CI); the review authors advised caution
when comparing results across treatments (Lansbury 2013).
Index test(s)
Teledermatology is a term used to describe the delivery of der-
matological care through information and communication tech-
nology (Bashshur 2015). It uses imaging modalities to provide
specialist dermatology services either to other healthcare profes-
sionals (such as general practitioners (GP)), or to patients directly
(Ndegwa 2010). It is considered a valuable tool in the diagnosis
and management of skin disease, because of the visual nature of
skin lesions and rashes (Warshaw 2011). Teledermatology allows
an increased information flow between primary care physicians
and dermatologists, which could lead to a reduction in waiting
times and limit unnecessary referrals (Ndegwa 2010; Warshaw
2011; Bashshur 2015). In rural areas, where access to speciality
services can have significant and potentially off-putting travel and
time implications for the patient, teledermatology has the poten-
tial to widen access to specialist opinion.
Teledermatology consultations can be conducted in two main
ways, store-and-forward or ’asynchronous,’ and live interactive or
’synchronous’ (Ndegwa 2010). With the store-and-forward ap-
proach, clinicians and patients are separated by both time and
space, as electronic digital images are taken and then transmitted
to a dermatologist for review at a later unspecified time (Warshaw
2011). The pictures can be digital photographic (or ’macroscopic’)
images, or can be magnified dermoscopic images taken using a
dermatoscope. Images are often accompanied by a summary of
the patient history and demographic information as part of a con-
sultation package (Ndegwa 2010). Furthermore, recent develop-
ments in smartphone technology have also introduced a new plat-
form for transferring lesion images from one setting to another
(Chuchu 2018). The store-and-forward approach is advantageous
as it requires less sophisticated technology and lower-cost equip-
ment (Warshaw 2011); however, it does not allow the specialist
to take a direct history, request additional views or communicate
in detail the purpose of management to the patient or referrer
(Ndegwa 2010).
Live interactive teledermatology uses videoconferencing and image
transmission to connect the patient, referrer and dermatologist
in real time (Ndegwa 2010). The dermatologist and patient can
interact verbally in a similar manner to a traditional clinic-based
encounter, but more extensive telecommunications infrastructure
and time are needed (Ndegwa 2010).
Clinical pathway
The diagnosis of melanoma can take place in primary, secondary
and tertiary care settings by both generalist and specialist health-
care providers. In the UK, people with concerns about a new or
changing skin lesion will usually present first to their GP or, less
commonly, directly to a specialist in secondary care, which could
include a dermatologist, plastic surgeon, other specialist surgeon
(such as an ear, nose and throat specialist or maxillofacial surgeon),
or ophthalmologist (Figure 2).CurrentUKguidelines recommend
that all suspicious pigmented lesions presenting in primary care
should be assessed by taking a clinical history and visual inspection
guided by the revised seven-point checklist (MacKie 1990). Clin-
icians should refer those with suspected melanoma or cSCC for
appropriate specialist assessment within two weeks (Chao 2014;
Marsden 2010; NICE 2015a). Evidence is emerging, however, to
suggest that excision ofmelanoma byGPs is not associatedwith in-
creased risk compared with outcomes in secondary care (Murchie
2017). In the UK, low-risk BCC are usually recommended for
routine referral, with urgent referral for those in whom a delay
could have a significant impact on outcomes, for example due to
large lesion size or critical site (NICE 2015b). Appropriately qual-
ified generalist care providers increasingly undertake management
of low-risk BCC in the UK such as by excision of low-risk lesions
(NICE 2010). Similar guidance is in place in Australia (CCAAC
Network 2008).
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Figure 2. Current clinical pathway for people with skin lesions.
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Teledermatology consultations can aid more appropriate triage of
lesions, providing reassurance for benign lesions and referral via
urgent or non-urgent routes to secondary care (e.g. for suspected
BCC. The distinction between setting and examiner qualifications
and experience is important, as specialist clinicians might work in
primary care settings (e.g. in the UK, GPs with a special interest
in dermatology and skin surgery who have undergone appropriate
training), and generalists might practice in secondary care settings
(e.g. GPs working alongside dermatologists in secondary care, or
plastic surgeons who do not specialise in skin cancer). The level of
skill and experience in skin cancer diagnosis varies for both gen-
eralist and specialist care providers and impacts on test accuracy.
For referred lesions, the specialist clinician will use history-taking,
visual inspection of the lesion (in comparison with other lesions
on the skin) usually in conjunction with dermoscopic examina-
tion, and palpation of the lesion and associated regional nodal
basins to inform a clinical decision. If melanoma is suspected,
then urgent 2 mm excision biopsy is recommended (Lederman
1985; Lees 1991); for cSCC, predetermined surgical margin exci-
sion or a diagnostic biopsy may be considered. BCC and prema-
lignant lesions potentially eligible for non-surgical treatment may
undergo a diagnostic biopsy before initiation of therapy. Equiv-
ocal melanocytic lesions for which a definitive clinical diagnosis
cannot be reached may undergo surveillance to identify any lesion
changes that would indicate excision biopsy or reassurance and
discharge for lesions that remain stable over a period of time.
Prior test(s)
Although smartphone applications and community- or high street
pharmacy-based teledermatology services (e.g. the Boots ’Mole
Scanning Service’ www.boots.com/health-pharmacy-advice/skin-
services/mole-scanning-service) can increasingly be accessed di-
rectly by people who have concerns about a skin lesion (Kjome
2017), the diagnosis of skin cancer is still based on history taking
and clinical examination by a suitably qualified clinician. In the
UK, this is typically undertaken at two decision points - first in
primary care where theGPmakes a decision to refer or not to refer,
and then a second time by a dermatologist or other secondary care
clinician where a decision is made to biopsy or excise or not.
Visual inspection of the skin is undertaken iteratively, using both
implicit pattern recognition (non-analytical reasoning) and more
explicit ’rules’ based on conscious analytical reasoning (Norman
2009), the balance of which will vary according to experience and
familiarity with the diagnostic question. Various attempts have
been made to formalise the “mental rules” involved in analytical
pattern recognition for melanoma (Friedman 1985; Grob 1998;
MacKie 1985; MacKie 1990; Sober 1979; Thomas 1998); how-
ever, visual inspection for keratinocyte skin cancers relies primarily
on pattern recognition. Accuracy has been shown to vary accord-
ing to the expertise of the clinician. Primary care physicians have
been reported to miss over 50% of BCCs (Offidani 2002) and to
misdiagnose around 33% of BCCs (Gerbert 2000). In contrast,
one Australian study found that trained dermatologists were able
to detect 98% of BCCs, but with a specificity of only 45% (Green
1988).
A range of technologies have emerged to aid diagnosis to reduce
the number of diagnostic biopsies or inappropriate surgical proce-
dures. Dermoscopy using a hand-held microscope has become the
most widely used tool used by clinicians to improve diagnostic ac-
curacy of pigmented lesions, in particular for melanoma (Dinnes
2018a); it is less well established for the diagnosis of BCC or
cSCC. Dermoscopy (also referred to as dermatoscopy or epilumi-
nescence microscopy) uses a hand-held microscope and incident
light (with orwithout oil immersion) to reveal subsurface images of
the skin at increased magnification of ×10 to ×100 (Kittler 2001).
Used alongside clinical examination, dermoscopy has been shown
in some studies to increase the sensitivity of clinical diagnosis of
melanoma fromaround60%to asmuch as 90%(Bono 2006;Carli
2002; Kittler 1999; Stanganelli 2000) with much smaller effects
in others (Benelli 1999; Bono 2002). The accuracy of dermoscopy
depends on the experience of the examiner (Kittler 2001), with
accuracy when used by untrained or less-experienced examiners
potentially no better than clinical inspection alone (Binder 1997;
Kittler 2002).
The diagnostic accuracy, and comparative accuracy, of visual in-
spection and dermoscopy have been evaluated in a further three re-
views in this series (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c).
Role of index test(s)
The use of teledermatology by primary care or by other generalist
clinicians has the potential to ensure that people with suspicious
lesions are appropriately referred for examination by a specialist
clinician, and people with non-suspicious lesions are appropriately
reassured and managed in primary care. If an accurate triage is
made, the proportion of people who are referred unnecessarily will
be minimised and lesions requiring urgent referral and treatment
correctly identified. By creating an environment where there is
facilitated access to more specialist services, selective dermatology
referral could ultimately reduce costs while enabling a faster, more
reliable and more efficient service (Piccolo 2002). Increased infor-
mation flow between primary care physicians and dermatologists
also has the potential effect of increasing knowledge and reducing
isolated decision-making (Bashshur 2015).
When diagnosing potentially life-threatening conditions such as
melanoma, the consequences of falsely reassuring a person that
they do not have skin cancer can be potentially fatal, as the delay
to diagnosis means that the window for successful early treatment
may be missed. To minimise these false-negative diagnoses, a good
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diagnostic test for melanoma demonstrates high sensitivity and
high negative predictive value (i.e. very few of those with a negative
test result will actually have a melanoma). Giving false-positive
test results (meaning the test has poor specificity and a high false-
positive rate) resulting in the removal of lesions that are benign, is
arguably less of an error thanmissing a potentially fatal melanoma,
but does have implications for patient welfare and costs. False-
positive diagnoses cause unnecessary scarring from the biopsy or
excision procedure, and increase patient anxiety while they await
the definite histology results and increase healthcare costs as the
number needed to remove to yield one melanoma diagnosis in-
creases.
Delay in diagnosis of a BCC as a result of a false-negative result
is not as serious as for melanoma because BCCs are usually slow
growing and unlikely to metastasise. However, delayed diagnosis
can result in a larger and more complex excision with consequent
greater morbidity. Very sensitive diagnostic tests for BCC may
compromise on lower specificity leading to a higher false-positive
rate, and an enormous burden of skin surgery, such that a bal-
ance between sensitivity and specificity is needed. The situation
for cSCC is more similar to melanoma in that the consequences
of falsely reassuring a person that they do not have skin cancer
can be serious and potentially fatal. Thus, a good diagnostic test
for cSCC should demonstrate high sensitivity and a correspond-
ing high negative predictive value. In summary, a test that can
reduce false-positive clinical diagnoses without missing true cases
of disease has patient and resource benefits. False-positive clinical
diagnoses cause unnecessary morbidity from the biopsy, and could
lead to initiation of inappropriate therapies and increase patient
anxiety.
Alternative test(s)
Teledermatology provides an alternative means for primary care
clinicians (and therefore patients) to access specialist opinion com-
pared to the standard referral process from primary to secondary
care. Although the general public can also seek advice on skin le-
sions, they may be concerned about doing so via smartphone ap-
plications or from services provided within community or ’high
street’ pharmacies. These are not considered direct alternatives to
teledermatology services.
Several other tests that may have a role in diagnosis of skin cancer
have been reviewed as part of our series of systematic reviews, in-
cluding visual inspection and dermoscopy (Dinnes 2018a; Dinnes
2018b; Dinnes 2018c), smartphone applications (Chuchu 2018).
Reflectance confocal microscopy (Dinnes 2018d; Dinnes 2018e),
optical coherence tomography (Ferrante di Ruffano 2018a), and
computer-assisted diagnosis techniques applied to various types
of images including those generated by dermoscopy, diffuse
reflectance spectrophotometry and electrical impedance spec-
troscopy (Ferrante di Ruffano 2018b), and high-frequency ul-
trasound (Dinnes 2018f). Evidence permitting, the accuracy of
available tests will be compared in an overview review, exploiting
within-study comparisons of tests and allowing the analysis and
comparison of commonly used diagnostic strategies where tests
may be used singly or in combination.
Rationale
Our series of reviews of diagnostic tests used to assist clinical diag-
nosis of melanoma aimed to identify themost accurate approaches
to diagnosis and provide clinical and policy decision-makers with
the highest possible standard of evidence on which to base deci-
sions. With increasing rates of skin cancer and the push towards
the use of dermoscopy and other high-resolution image analysis
in primary care, the anxiety around missing early cases needs to
be balanced against the risk of over referrals, to avoid sending too
many people with benign lesions for a specialist opinion. It is ques-
tionable whether all skin cancers detected by sophisticated tech-
niques, even in specialist settings, help to reduce morbidity and
mortality, or whether newer technologies run the risk of increasing
false-positive diagnoses. It is also possible that use of some tech-
nologies (e.g. widespread use of dermoscopy in primary care with
no training), could actually result in harm by missing melanomas
if they are used as replacement technologies for traditional history-
taking and clinical examination of the entire skin. Many branches
ofmedicine have noted the danger of such “gizmo idolatry” among
doctors (Leff 2008).
Although teledermatology is increasingly used, the accuracy of dif-
ferent approaches to providing teledermatology services (e.g. store-
and-forward versus live-link modalities, and use of clinical versus
dermoscopic images) has yet to be fully established. A review by
Warshaw 2011 suggested that both store-and-forward and live-
link teledermatology had acceptable diagnostic accuracy and con-
cordancewhen comparedwith clinical face-to-face diagnosis; how-
ever, clinic-based dermatology had superior diagnostic accuracy
(i.e. in comparison to store-and-forward teledermatology consul-
tations). As with any technology requiring significant investment,
a full understanding of the benefits including patient acceptability
and cost-effectiveness in comparison to usual practice should be
obtained before such an approach can be recommended; estab-
lishing the accuracy of diagnosis and referral accuracy is one of
the key components. Given the rapidly changing evidence base in
skin cancer diagnosis, there is a need for an up-to-date analysis of
the accuracy of teledermatology for skin cancer diagnosis.
This review followed a generic protocol which covered the full
series of Cochrane DTA reviews for the diagnosis of melanoma
(Dinnes 2015a); aspects of this reviewwhich relate to the diagnosis
of BCC and cSCC follow the generic protocol that was written
to cover the reviews in the series for the diagnosis of keratinocyte
skin cancers (Dinnes 2015b). The ’Background’ and ’Methods’
sections of this review therefore use some text that was originally
published in the protocols (Dinnes 2015a; Dinnes 2015b), and
text that overlaps some of our other reviews (Chuchu 2018;Dinnes
2018a; Dinnes 2018b).
13Teledermatology for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
O B J E C T I V E S
To determine the diagnostic accuracy of teledermatology for the
detection of any skin cancer (melanoma, BCC or cSCC) in adults,
and to compare its accuracy with that of in-person diagnosis.
Accuracy was estimated separately according to the type of teled-
ermatology images used:
• photographic images;
• dermoscopic images;
• photographic and dermoscopic images.
Secondary objectives
• To determine the diagnostic accuracy of teledermatology
for the detection of invasive melanoma or atypical
intraepidermal melanocytic variants in adults, and to compare its
accuracy with that of in-person diagnosis.
• To determine the diagnostic accuracy of teledermatology
for the detection of invasive melanoma only, in adults, and to
compare its accuracy with that of in-person diagnosis.
• To determine the diagnostic accuracy of teledermatology
for the detection of BCC in adults, and to compare its accuracy
with that of in-person diagnosis.
• To determine the diagnostic accuracy of teledermatology
for the detection of cSCC in adults, and to compare its accuracy
with that of in-person diagnosis.
• To determine the referral accuracy of teledermatology (i.e.
to compare diagnostic decision making based on
teledermatology images with that of an in-person consultation).
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity
for investigation across our series of reviews, as outlined in our
generic protocols (Dinnes 2015a; Dinnes 2015b), and described
in Appendix 4; however, our ability to investigate these was nec-
essarily limited by the available data on each individual test re-
viewed.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the
result of the index test with that of a reference standard, including
the following:
• studies where all participants receive a single index test and
a reference standard;
• studies where all participants receive more than one index
test(s) and reference standard;
• studies where participants are allocated (by any method) to
receive different index tests or combinations of index tests and all
receive a reference standard (between-person comparative (BPC)
studies);
• studies that recruit series of participants unselected by true
disease status;
• diagnostic case-control studies that separately recruit
diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant
lesions to those for healthy skin (i.e. with no lesion present);
• both prospective and retrospective studies; and
• studies where previously acquired clinical or dermoscopic
images were retrieved and prospectively interpreted for study
purposes.
We excluded studies from which we could not extract 2×2 contin-
gency data or if they included fewer than five cases of melanoma,
BCC or cSCC or fewer than five benign lesions. For studies of
referral accuracy where a lesion’s final diagnosis was not reported,
we required at least five ’positive’ cases as identified by the expert
diagnosis reference standard. The size threshold of five was arbi-
trary. However, such small studies are unlikely to add precision to
estimate of accuracy.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with lesions suspicious for skin can-
cer or adults at high risk of developing skin cancer. We excluded
studies that recruited only participants with malignant or benign
final diagnoses.
We excluded studies conducted in children, or which clearly re-
ported inclusion of more than 50% of participants aged 16 and
under.
Index tests
We included studies evaluating teledermatology alone, or teleder-
matology in comparison with face-to-face diagnosis.
The following index tests were eligible for inclusion:
• store-and-forward teledermatology;
• real-time ’live link’ teledermatology.
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Data for face-to-face clinical diagnosis against a histological refer-
ence standard was also included where reported, to allow a direct
comparison with teledermatology to be made.
Although primary care clinicians can in practice be specialists in
skin cancer, we considered primary care physicians as generalist
practitioners and dermatologists as specialists. Within each group,
we extracted any reporting of special interest or accreditation in
skin cancer.
Target conditions
We defined the primary target condition as the detection of any
skin cancer, primarily cutaneous melanoma, BCC or cSCC.
We considered four additional definitions of the target condition
in secondary analyses, namely, the detection of:
• invasive cutaneous melanoma alone;
• invasive cutaneous melanoma or atypical intraepidermal
melanocytic variants (including melanoma in situ, lentigo
maligna);
• BCC;
• cSCC.
We also considered referral accuracy, comparing decision making
from teledermatology comparedwith the face-to-face decisions for
the same lesions. These decisions could have included the decision
to excise a lesion, follow-up a lesion or refer a lesion for face-to-
face assessment.
Reference standards
Teledermatology can be assessed in terms of diagnostic accuracy
in comparison to the final lesion diagnosis and referral accuracy
in comparison to a face-to-face expert management decision.
To establish diagnostic accuracy, the ideal reference standard
was histopathological diagnosis in all eligible lesions. A quali-
fied pathologist or dermatopathologist should have performed
histopathology. Ideally, reporting should have been standardised
detailing a minimum dataset to include the histopathological fea-
tures of melanoma to determine the AJCC Staging System (e.g.
Slater 2014).We did not apply this minimum dataset requirement
as a necessary inclusion criterion, but extracted any pertinent in-
formation.
Partial verification (applying the reference test only to a subset
of those undergoing the index test) was of concern given that le-
sion excision or biopsy were unlikely to be carried out for all be-
nign-appearing lesions within a representative population sample.
Therefore, to reflect what happens in reality, we accepted clini-
cal follow-up of benign-appearing lesions as an eligible reference
standard, while recognising the risk of differential verification bias
(as misclassification rates of histopathology and follow-up will dif-
fer). Additional eligible reference standards included cancer reg-
istry follow-up and ’expert opinion’ with no histology or clinical
follow-up.
All of the above were considered eligible reference standards for
establishing lesion final diagnoses (diagnostic accuracy) with the
following caveats:
• all study participants with a final diagnosis of the target
disorder must have had a histological diagnosis, either
subsequent to the application of the index test or after a period
of clinical follow-up, and
• at least 50% of all participants with benign lesions must
have had either a histological diagnosis or clinical follow-up to
confirm benignity.
To establish referral accuracy of teledermatology (i.e. the ability of
the remote observer to approximate an in-person diagnosis), the
action recommended by the remote observer was compared with
an in-person ’expert opinion’ reference standard (i.e. the diagnosis
or management recommendation of an appropriately qualified
clinician made face-to-face with the study participant).
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 5). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed on MEDLINE. The Information Special-
ist devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies:
• MEDLINE via Ovid (from 1946);
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• MEDLINE In-Process & Other Non-Indexed Citations via
Ovid;
• Embase via Ovid (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) 2016, Issue 7, in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR)
2016, Issue 8, in the Cochrane Library;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE) 2015, Issue 2;
• CRD HTA (Health Technology Assessment) database
2016, Issue 3; and
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We screened relevant systematic reviews identified by the searches
for their included primary studies, and included any missed by
our searches. We checked the reference lists of all included papers,
and subject experts within the author team reviewed the final list
of included studies. There was no electronic citation searching.
Data collection and analysis
Selection of studies
At least one review author (JDi or NC) screened titles and ab-
stracts, and discussed and resolved any queries by consensus. A
pilot screen of 539MEDLINE references showed good agreement
(89% with a kappa of 0.77) between screeners. Primary test ac-
curacy studies and test accuracy reviews (for scanning of reference
lists) of any test used to investigate suspected melanoma, BCC or
cSCC were included at initial screening. Both a clinical reviewer
(from one of a team of 12 clinician reviewers) and a methodolo-
gist reviewer (JDi or NC) independently applied inclusion criteria
to all full-text articles (Appendix 6), and resolved disagreements
by consensus or by a third party (JDe, CD, HW and RM). We
contacted authors of eligible studies when insufficient data were
presented to allow for the construction of 2×2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodological reviewer
(JDi,NCor LFR) independently extracted data concerning details
of the study design, participants, index test(s) or test combinations,
and criteria for index test positivity, reference standards and data
required to complete a 2×2 diagnostic contingency table for each
index test using a piloted data extraction form.Datawere extracted
at all available index test thresholds. We resolved disagreements
by consensus or by a third party (JDe, CD, HW, and RM). We
entered data into Review Manager 5 (Review Manager 2014).
We contacted authors of included studies where information re-
lated to the target condition (in particular to allow the differen-
tiation of invasive cancers from ’in situ’ variants) or there were
missing diagnostic threshold. We contacted authors of conference
abstracts published from 2013 to 2015 to ask whether full data
were available. If there was no full paper, we marked conference
abstracts as ’pending’ and will revisit them in a future review up-
date.
Dealing with multiple publications and companion papers
Where we identified multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If this contact with authors was unsuccessful, we used
the most complete and up-to-date data source where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 7). We piloted the modified QUADAS-2
tool on five included full-text articles. One clinical reviewer (as
detailed above) and one methodological reviewer (JDi, NC or
LFR) independently assessed quality for the remaining studies; we
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resolved disagreements by consensus or by a third party (JDe, CD,
HW and RM).
Statistical analysis and data synthesis
Our unit of analysis was the lesion rather than the participant.
This is because firstly, in skin cancer initial treatment is directed
to the lesion rather than systemically (thus it is important to be
able to correctly identify cancerous lesions for each person), and
secondly, it is the most common way in which the primary studies
reported data. Although there is a theoretical possibility of correla-
tions of test errors when the same people contribute data for mul-
tiple lesions, most studies included very few people with multiple
lesions and any potential impact on findings was likely to be very
small, particularly in comparison with other concerns regarding
risk of bias and applicability. For each analysis, we included only
one dataset per study to avoid multiple counting of lesions.
For the diagnosis of melanoma, any BCCs or invasive cSCCs that
were correctly identified by teledermatology but that were identi-
fied as melanomas in the ’disease-negative’ group were considered
as true-negative test results rather than as false positives, on the
basis that excision of such lesions would be a positive outcome for
the participants concerned. However, for the diagnosis of BCC,
we considered any melanomas or cSCCs that were mistaken for
BCCs as false-positive results. This decision was taken on the basis
that the clinical management of a lesion considered to be a BCC
might be quite different to that for a melanoma or cSCC and
could potentially lead to a negative outcome for the participants
concerned, for example if a treatment other than excision was ini-
tiated.
For preliminary investigations of the data, we plotted estimates of
sensitivity and specificity on coupled forest plots and in receiver
operating characteristic (ROC) space for each index test, target
condition and reference standard combination. When meta-anal-
ysis was possible and there were at least four studies, we used a
bivariate model to obtain summary estimates of sensitivity and
specificity (Chu 2006; Reitsma 2005). When there were fewer
than four studies and little or no heterogeneity in ROC space, we
pooled sensitivity and specificity using fixed-effect logistic regres-
sion (Takwoingi 2017). We included data for face-to-face diag-
nosis only if reported in comparison to teledermatology diagno-
sis. Using these direct (head-to-head) comparisons, a comparative
meta-analysis to compare the accuracy of teledermatology with
face-to-face diagnosis was not possible because there were too few
studies. However, we tabulated results from the studies and esti-
mated differences in sensitivity and specificity. Since these com-
parative studies did not report the cross-classified results of the
two index tests in participants with and without a particular form
of skin cancer, we were unable to compute CIs for the differences
using methods that accounted for the paired nature of the data.
Therefore, we assumed independence between the sensitivities and
between the specificities of the two tests, and calculated 95% CIs
for the differences using the Newcombe-Wilson method without
continuity correction (Newcombe 1998). We performed analyses
using Stata version 15 (Stata 2017).
Investigations of heterogeneity
We examined heterogeneity by visually inspecting forest plots of
sensitivity and specificity, and summary ROC (SROC) plots. We
were unable to perform meta-regression to investigate potential
sources of heterogeneity due to insufficient numbers of studies.
Sensitivity analyses
There were too few data to perform sensitivity analyses.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for de-
tecting funnel plot asymmetry (Deeks 2005), we did not perform
tests to detect publication bias.
R E S U L T S
Results of the search
The search identified 34,517 unique references and screened them
for inclusion after reading the title and abstract. Of these, we
reviewed 1051 full-text papers for eligibility for any one of the
suite of reviews of tests to assist in the diagnosis of melanoma or
keratinocyte skin cancer; 203 publicationswere included in at least
one review in our series and 848 publications were excluded (see
Figure 3; PRISMA flow diagram of search and eligibility results).
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Figure 3. PRISMA flow diagram.
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Of the 125 studies tagged as potentially eligible for this review of
teledermatology, we included 22 publications. Exclusions from the
review were primarily due to: lack of test accuracy data to complete
a 2×2 contingency table (31 studies), ineligible populations (38
studies) or target conditions (19 studies), not accuracy studies (23
studies) and inadequate sample size (fewer than five cases of skin
cancer, fewer than five benign lesions, or for referral accuracy, fewer
than five ’positive’ cases identified by the expert diagnosis refer-
ence standard) (seven studies) or reference standards (11 studies).
Of the 31 studies for which a 2×2 table could not be constructed,
11 reported only agreement between observers or between teleder-
matology and the reference standard and 14 had at least one piece
of missing data. A list of the 103 studies with reasons for exclusion
is provided in the Characteristics of excluded studies table, with a
list of all studies excluded from the full series of reviews available
as a separate pdf (please contact skin.cochrane.org for a copy of
the pdf ).
We contacted the corresponding authors of 12 studies and asked
them to supply further information to allow study inclusion or
to clarify diagnostic thresholds or target condition definition. We
received responses from four authors allowing inclusion of all four
studies in this review (Borve 2015; Mahendran 2005; Warshaw
2010b;Wolf 2013). One of the four authors was unable to provide
all of the information requested such that the data presented in
the paper could only be partially included in this review (Warshaw
2010b).
The 22 included study publications reported on 22 cohorts of
lesions and provided 96 datasets (individual 2×2 contingency ta-
bles). Sixteen studies (73%) including 4057 lesions and 879 ma-
lignant cases reported data for the diagnostic accuracy of teleder-
matology (Arzberger 2016; Borve 2015; Bowns 2006; Congalton
2015; Coras 2003; Ferrara 2004; Grimaldi 2009; Jolliffe 2001a;
Kroemer 2011; Massone 2014; Moreno Ramirez 2005; Piccolo
2000; Piccolo 2004; Silveira 2014; Warshaw 2010b; Wolf 2013),
five of which also reported data for the diagnostic accuracy of
expert face-to-face clinical diagnosis (Coras 2003; Jolliffe 2001a;
Kroemer 2011; Piccolo 2000;Warshaw 2010b). Six studies (27%)
including 1449 lesions reported data for the referral accuracy of
teledermatology (i.e. teledermatology diagnosis or management
action as the index test versus expert face-to-face diagnosis or
management action as the reference standard) (Jolliffe 2001b;
Mahendran 2005; Manahan 2015; Oliveira 2002; Phillips 1998;
Shapiro 2004); these studies included 270 ’positive’ cases as de-
termined by the reference standard face-to-face decision. A cross-
tabulation of studies by reported comparisons, target conditions
and types of image used is provided in Table 1 and summary study
details is presented in Appendix 8.
Studies were primarily prospective case series (18 studies; 82%),
with two retrospective case series (9%) (Moreno Ramirez 2005;
Piccolo 2004), and two case-control studies (9%) (Ferrara 2004;
Wolf 2013), three of which retrospectively selected previously ac-
quired images for prospective evaluation in the study (Ferrara
2004; Piccolo 2004; Wolf 2013). Studies were conducted in:
Europe (14 (64%) studies), including five studies from Austria
(Arzberger 2016; Kroemer 2011; Massone 2014; Piccolo 2000;
Piccolo 2004), and four from the UK (Bowns 2006; Jolliffe
2001a; Jolliffe 2001b; Mahendran 2005); North America (four
(18%) studies; Phillips 1998; Shapiro 2004; Warshaw 2010b;
Wolf 2013); or South America (two studies; 9%; Oliveira 2002;
Shapiro 2004); or in Australia (Manahan 2015); or New Zealand
(Congalton 2015) (9%). Eight (36.4%) studies included only
pigmented (Coras 2003; Grimaldi 2009; Jolliffe 2001a; Moreno
Ramirez 2005; Piccolo 2000; Wolf 2013) or melanocytic (Ferrara
2004; Piccolo 2004) lesions (Piccolo 2004 restricting to acral le-
sions only); the remainder included any suspicious lesion.
Ten studies were based in primary care or community-based set-
tings. Seven studies acquired lesion images in primary care (Borve
2015; Grimaldi 2009; Mahendran 2005; Massone 2014; Moreno
Ramirez 2005; Oliveira 2002; Shapiro 2004), two studies were
in a community skin cancer screening outreach programme with
image acquisition for ’remote’ assessment by specialists in a sec-
ondary care setting (Silveira 2014) or using live transmission video-
conferencing (Phillips 1998), and one study recruited participants
at high risk of melanoma who took images of their own lesions
that they ’did not like the look of ’ using a smartphone (Manahan
2015). There were no studies conducted in high street pharmacy-
type settings. Five of the 10 studies reported the diagnostic accu-
racy of the teledermatology image-based assessment (Borve 2015;
Grimaldi 2009; Massone 2014; Moreno Ramirez 2005; Silveira
2014), and five examined referral accuracy, comparing the tele-
dermatology assessment against specialist in-person assessment
(Mahendran 2005; Manahan 2015; Oliveira 2002; Phillips 1998;
Shapiro 2004). Of these studies, nine were prospective in design
and one was retrospective (Moreno Ramirez 2005).
Twelve studies acquired lesion images at a secondary care der-
matology or pigmented lesion clinic (Arzberger 2016; Congalton
2015; Ferrara 2004; Jolliffe 2001a; Jolliffe 2001b; Kroemer 2011;
Piccolo 2000; Piccolo 2004; Warshaw 2010b; Wolf 2013), from a
private dermatology practice (Coras 2003), or in a medical imag-
ing unit (Bowns 2006), at the time of the patient consultation, and
a second dermatologist made remote image-based diagnoses. Of
these studies, nine were prospective in design, two studies retrieved
routinely collected lesion images for prospective ’teledermatology’
examination (Piccolo 2004; Wolf 2013), and one did not clearly
report how lesion images were acquired (Ferrara 2004). Six studies
reported data only for the diagnostic accuracy of specialist image-
based assessment (Arzberger 2016; Bowns 2006; Congalton 2015;
Ferrara 2004; Piccolo 2004; Wolf 2013), five compared the diag-
nostic accuracy of image-based diagnosis to that of a dermatolo-
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gist’s face-to-face diagnosis (Coras 2003; Jolliffe 2001a; Kroemer
2011; Piccolo 2000; Warshaw 2010b), and one examined refer-
ral accuracy, comparing specialist image-based assessment against
specialist in-person assessment (Jolliffe 2001b).
Ten evaluations reported data using photographic images for teled-
ermatology consultations (Jolliffe 2001a; Jolliffe 2001b; Kroemer
2011; Mahendran 2005; Moreno Ramirez 2005; Oliveira 2002;
Shapiro 2004; Silveira 2014; Warshaw 2010b; Wolf 2013), nine
for a combination of clinical and dermoscopic images (Arzberger
2016; Borve 2015; Bowns 2006; Congalton 2015; Coras 2003;
Grimaldi 2009; Manahan 2015; Massone 2014; Piccolo 2000),
and three reported data for diagnosis using dermoscopic images
only (Ferrara 2004; Kroemer 2011; Piccolo 2004). The final study
reported referral accuracy data for live-link teledermatology using
three cameras: a full-body camera, a lens for close-up views and a
magnifying lens to allow magnified examination and examination
with polarised light (Phillips 1998). The Warshaw 2010b paper
also reported accuracy data for diagnosis using a combination of
photographic and dermoscopic images; however, we were unable
to obtain underlying 2×2 data to allow the inclusion of this aspect
of the study.
Images for store and forward teledermatology were obtained using
a mobile phone camera alone (Kroemer 2011) or coupled with a
dermatoscope (Borve 2015; Kroemer 2011; Manahan 2015); us-
ing still images from a video camera (Jolliffe 2001a; Jolliffe 2001b);
using a combination of film and digital images (Ferrara 2004);
or using a digital camera (13 studies) to acquire photographs
(Mahendran 2005;MorenoRamirez 2005;Oliveira 2002; Shapiro
2004; Silveira 2014; Warshaw 2010b; Wolf 2013), dermoscopic
images (Ferrara 2004; Piccolo 2004), or both (Arzberger 2016;
Congalton 2015; Coras 2003; Grimaldi 2009; Massone 2014;
Piccolo 2000). Bowns 2006 acquired photographic and dermo-
scopic images in a medical photography unit (equipment not de-
scribed). See the Characteristics of included studies table for de-
tails of the digital cameras and mobile phones used. Eighteen
(82%) studies provided observers with additional clinical infor-
mation along with the digital image of the lesion, three did not
clearly report whether additional clinical information was pro-
vided (Arzberger 2016; Grimaldi 2009; Manahan 2015), and one
did not provide any further participant-related information (Wolf
2013). The remote observers were dermatologists in 19 (86%)
studies, oncologists in one, and a mixture of dermatologists and
other healthcare professionals (e.g. oncologists, plastic surgeons)
in two (9%).
The five studies providing a direct comparison of teledermatol-
ogy with in-person evaluation by a dermatologist based diagnosis
on visual inspection of the lesion with dermoscopy used for some
(proportions not reported) (Coras 2003; Jolliffe 2001a; Kroemer
2011; Warshaw 2010b), or for all lesions (Piccolo 2000). One
study reported using pattern analysis (Coras 2003), and the re-
maining three (50%) studies did not specify any algorithm used
to aid diagnosis. The direct comparison of teledermatology with
in-person evaluation by a GP provided in Grimaldi 2009 was not
included in this review as it is not directly relevant to telederma-
tology in this context.
For the 16 studies reporting diagnostic accuracy,11 (69%) used
histology alone as the reference standard (Arzberger 2016;
Congalton 2015; Coras 2003; Ferrara 2004; Jolliffe 2001a;
Kroemer 2011; Piccolo 2000; Piccolo 2004; Silveira 2014;
Warshaw 2010b; Wolf 2013), three (19%) used both histology
and expert opinion for some benign lesions (Borve 2015; Bowns
2006; Massone 2014), and two (12%) used histology and follow-
up of clinically benign-appearing lesions (Grimaldi 2009;Moreno
Ramirez 2005). The median number of study participants was 77
(interquartile range (IQR) 4p to 182) (reported in 10 studies), and
median number of lesions was 116 (IQR 45 to 240). The median
prevalence of skin cancer was 30% (IQR 21% to 45%) and me-
dian percentage of men was 46% (IQR 35% to 47%) (reported
in nine studies). Where reported (eight studies), the median age
was 52 years (IQR 43 to 65) (reported in eight studies). Four
of the 16 diagnostic accuracy studies did not report the range in
age of included participants (Bowns 2006; Coras 2003; Grimaldi
2009; Wolf 2013), four restricted inclusion to adults only (Borve
2015; Massone 2014; Silveira 2014; Warshaw 2010b), and eight
included participants under the age of 16 years (Arzberger 2016;
Congalton 2015; Ferrara 2004; Jolliffe 2001a; Kroemer 2011;
Moreno Ramirez 2005; Piccolo 2002; Piccolo 2004); however,
data were not presented to allow data to be extracted excluding
children.
For the six studies reporting referral accuracy, the same dermatolo-
gist undertaking the teledermatology assessment made the face-to-
face reference standard diagnosis, either within one to two weeks
(Mahendran 2005;Oliveira 2002), or with a gap of several months
between assessments (Jolliffe 2001b), by a dermatology trainee un-
der the supervision of the teledermatologist (Manahan 2015), or
a different dermatologist (Phillips 1998; Shapiro 2004). The me-
diannumber of study participantswas 50 (IQR49 to 72) (reported
in all six studies), and median number of lesions was 107 (IQR
94 to 253). The reported decisions of the face-to-face expert in-
cluded diagnosis ofmalignancy (Oliveira 2002; Phillips 1998), de-
cision to excise (Mahendran 2005; Phillips 1998; Shapiro 2004),
or decision to see face-to-face (Jolliffe 2001b; Manahan 2015);
the median overall percentage of ’positive’ expert diagnoses was
15% (IQR 10% to 41%). One study reported the median age of
included participants was 46.7 years (Phillips 1998); two studies
reported age ranges of 8 to 94 years (Jolliffe 2001b), and 50 to 64
years (Manahan 2015); and four did not report the range in ages
(Mahendran 2005; Oliveira 2002; Phillips 1998; Shapiro 2004).
The percentage of men ranged from 15.7% (Phillips 1998) to
49% (Manahan 2015) (reported in three studies).
Methodological quality of included studies
The overall methodological quality of included studies is sum-
marised in Figure 4 and Figure 5. At least half of studies were
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at high or unclear risk of bias for participant selection, reference
standard, and flow and timing domains, while the majority were
at low risk for the index test. The applicability of study findings
were of high or unclear concern for the majority of studies in all
domains assessed.
Figure 4. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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For participant selection, seven (32%) studies were at low risk of
bias (Borve 2015; Bowns 2006; Grimaldi 2009; Jolliffe 2001b;
Mahendran 2005; Oliveira 2002; Warshaw 2010b), and five
(23%) studies were at high risk (Congalton 2015; Ferrara 2004;
Massone 2014; Moreno Ramirez 2005; Wolf 2013). Four stud-
ies applied inappropriate participant exclusions (such as excluding
poor-quality images, or difficult to diagnose lesions) (Congalton
2015; Massone 2014; Moreno Ramirez 2005; Wolf 2013); and
two studies used a case-control type study design with separate
selection of malignant cases and lesions with benign diagnosis
(Ferrara 2004; Wolf 2013). Fourteen studies were at high concern
for applicability of participants due to recruitment from secondary
care or specialist clinics rather than from the primary setting in
which teledermatology is more likely to be used (12/22; Arzberger
2016; Bowns 2006; Congalton 2015; Coras 2003; Jolliffe 2001a;
Jolliffe 2001b; Kroemer 2011; Moreno Ramirez 2005; Piccolo
2000; Piccolo 2004; Warshaw 2010b; Wolf 2013), and/or due
to inclusion of multiple lesions per participant (6/22; Congalton
2015; Grimaldi 2009; Jolliffe 2001b; Kroemer 2011; Manahan
2015; Warshaw 2010b). Two studies were at low concern for par-
ticipant applicability (Oliveira 2002; Phillips 1998).
For the index test, all of the teledermatology assessments were at
low risk of bias for the index test apart from Phillips 1998, in
which it was unclear whether the teledermatology diagnoses were
made blinded to the decision to the face-to-face clinician (refer-
ence standard). One study was judged of low concern for applica-
bility of teledermatology (Massone 2014), and 12 (45%) studies
were of high concern (Arzberger 2016; Bowns 2006; Congalton
2015; Coras 2003; Ferrara 2004; Jolliffe 2001a; Jolliffe 2001b;
Kroemer 2011; Piccolo 2000; Piccolo 2004; Warshaw 2010b;
Wolf 2013), due to images acquired by dermatologists based in
secondary care settings or from pigmented lesion clinic databases
rather than images acquired in primary care. For the five studies
reporting direct comparisons of teledermatology with face-to-face
expert clinical diagnoses, two (40%) were at low risk of bias (Coras
2003; Warshaw 2010b) and three (60%) were judged unclear, as
the thresholds used were not clearly prespecified (Jolliffe 2001a;
Kroemer 2011; Piccolo 2000). For the comparison between tests,
there was no blinding between store-and-forward teledermatology
and face-to-face clinical diagnosis in Jolliffe 2001a; the remain-
ing four comparative studies did not describe any blinding (Coras
2003; Kroemer2011; Piccolo 2000;Warshaw 2010b).One (20%)
study was of low concern for applicability of the face-to face di-
agnosis (Coras 2003), and four of unclear concern of applicabil-
ity as the thresholds used for diagnosis were not clearly reported
to allow replication of methods (Jolliffe 2001a; Kroemer 2011;
Piccolo 2000; Warshaw 2010b).
For the reference standard domain, 10 (45%) studies were at low
risk of bias (Arzberger 2016; Congalton 2015; Coras 2003; Ferrara
2004; Jolliffe 2001a; Piccolo 2000; Piccolo 2004; Silveira 2014;
Warshaw 2010b; Wolf 2013), and 12 (55%) were at high risk ei-
ther because they were referral accuracy studies using only expert
face-to-face diagnosis as the reference standard (Jolliffe 2001b;
Mahendran 2005; Manahan 2015; Oliveira 2002; Phillips 1998;
Shapiro 2004), or because they were diagnostic accuracy stud-
ies that did not meet our criteria for an adequate reference stan-
dard (i.e. greater than 80% of lesions with histology and up to
20%with clinical follow-up; see Appendix 7) (Borve 2015; Bowns
2006; Grimaldi 2009; Kroemer 2011; Massone 2014; Moreno
Ramirez 2005). Only two studies clearly reported blinding of the
reference standard diagnosis to the teledermatology assessment
(Phillips 1998; Shapiro 2004), and two did not implement any
blinding (Mahendran 2005; Oliveira 2002); these were all referral
accuracy studies. Six studies were of low concern for the applicabil-
ity of the reference standard, including three of the 16 diagnostic
accuracy studies that clearly reported the level of experience of the
histopathologist (Ferrara 2004; Piccolo 2004; Warshaw 2010b),
and three of the six referral accuracy studies that reported the
expertise of the face-to-face reference standard diagnosis (Jolliffe
2001b; Mahendran 2005; Shapiro 2004).
For flow and timing of participants, two referral accuracy studies
were at low risk of bias (Jolliffe 2001b; Phillips 1998), and 17
(77%) were at high risk of bias; either because they did not use the
same reference standard for all participants (Borve 2015; Bowns
2006; Grimaldi 2009; Massone 2014; Moreno Ramirez 2005),
or they did not include all study participants in the final analy-
sis (Arzberger 2016; Congalton 2015; Coras 2003; Jolliffe 2001a;
Kroemer2011;Mahendran 2005;Manahan 2015;Massone 2014;
Moreno Ramirez 2005; Oliveira 2002; Shapiro 2004; Silveira
2014; Warshaw 2010b; Wolf 2013). Fourteen (64%) studies did
not clearly report the interval between reference standard and in-
dex test (Arzberger 2016; Congalton 2015; Coras 2003; Ferrara
2004; Grimaldi 2009; Jolliffe 2001a; Kroemer 2011; Manahan
2015; Massone 2014; Moreno Ramirez 2005; Piccolo 2000;
Piccolo 2004; Warshaw 2010b; Wolf 2013).
Findings
Study results are summarised below according to target condition
with results of meta-analyses in Table 2 with summary details in
Appendix 8. Lack of data and between-study variation in popula-
tions, approaches to teledermatology and target conditions con-
sidered, limited the pooled analyses that could be undertaken.
1. Target condition: detection of any skin cancer
Seven studies with 1588 lesions and 638 cases of skin cancer re-
ported the diagnostic accuracy of teledermatology assessment for
the detection of the primary target condition of any skin cancer.
Forest plots of study data are provided in Figure 6 with results of
meta-analysis in Figure 7.
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Figure 6. Forest plot of tests for the detection of any skin cancer (any). CI: confidence interval; FN: false
negative; FP: false positive; TN: true negative; TP: true positive.
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Figure 7. Summary receiver operating characteristic plot of teledermatology using photographic images
versus histology for the detection of any skin cancer (any).
Four studies compared diagnosis based on photographic images
to histology (Figure 6). In three studies, sensitivities for the cor-
rect diagnosis of malignancy ranged from 93% (95% CI 77% to
99%) to 100% (95% CI 75% to 100%) and specificities from
88% (95% CI 77% to 95%) to 96% (95% CI 82% to 100%)
(Jolliffe 2001a; Kroemer 2011; Moreno Ramirez 2005). All three
studies reported a cross-tabulation of lesion final diagnoses against
the diagnosis on teledermatology such that data could be extracted
for the detection of any malignancy, regardless of any misclassi-
fication of one skin cancer for another (e.g. a BCC diagnosed as
a melanoma or vice versa). Similarly there was high sensitivity in
Silveira 2014 (96%, 95% CI 94% to 98%) but specificity was
outlying at 25% (95% CI 14% to 39%); data here were presented
for the detection of ’malignant’ versus benign cases with no break-
down of individual lesion diagnoses given. The low specificity in
Silveira 2014 result was likely due to the recruitment of partici-
pants with lesions deemed to be highly clinically suspicious after
visual inspection of the lesion during a community screening pro-
gramme; the prevalence of malignancy was 87.5% with only 52
benign cases in a sample of 416 lesions.
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The pooled result across the four studies indicated a summary
sensitivity of 94.9% (95% CI 90.1% to 97.4%) and summary
specificity of 84.3% (95% CI 48.5% to 96.8%) based on 717
lesions and 452 cases of skin cancer (Table 2; Figure 7).
One study also reported diagnosis based on dermoscopic images
only versus histology (Kroemer 2011). Sensitivity was lower than
for assessment using photographic images (85%, 95% CI 71%
to 94% with histology versus 93%, 95% CI 82% to 99% with
dermoscopic images) with similar specificities (Figure 6).
Three studies with 928 lesions and 215 cases of skin cancer com-
pared image-based diagnosis based on both clinical and dermo-
scopic images to histology (Figure 6). Each study used a slightly
different threshold to decide test positivity: the correct classifica-
tion of lesions as malignant versus benign (Massone 2014), le-
sions considered malignant or possibly malignant (Borve 2015),
or lesion recommended for excision (Arzberger 2016). Sensitivi-
ties were 100% in all three studies. Specificities ranged from 25%
(95% CI 5% to 57%) (Arzberger 2016) to 92% (95% CI 74% to
99%) (Massone 2014). Massone 2014 was a primary care-based
study for which accuracy data could only be estimated for a sub-
group of 32 of the original 962 lesions. Arzberger 2016 included
participants at particularly high risk for melanoma, while Borve
2015 included large proportions of seborrhoeic keratosis (19%)
and actinic keratosis (9%) in the disease-negative group. These
factors may have made differentiating a malignant case from a be-
nign one more challenging.
We undertook no statistical pooling for these studies due to vari-
ation in threshold and heterogeneity in specificities.
Two studies compared remote image-based assessment with in-
person diagnosis by a dermatologist for the detection of any skin
cancer using the same diagnostic thresholds as for the teleder-
matology decision (Jolliffe 2001a; Kroemer 2011). Jolliffe 2001a
reported 100% (95% CI 75% to 100%) sensitivity for both as-
sessments, while Kroemer 2011 reported 100% (95% CI 92% to
100%) sensitivity for in-person diagnosis compared to 93% (95%
CI 82% to 99%) for diagnosis using photographic images and
85% (95% CI 71% to 94%) for dermoscopic image-based assess-
ment (Table 3; Figure 6). Both studies reported only marginal dif-
ferences in specificity between approaches.
2. Target condition: invasive melanoma or atypical
intraepidermal melanocytic variants
Nine studies with 2510 lesions and 206 melanoma reported the
diagnostic accuracy of teledermatology assessment for the detec-
tion of invasive cutaneous melanoma or atypical intraepidermal
variants (Figure 8), only two of which also reported data for the
detection of any skin cancer (Table 2).
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Figure 8. Forest plot of tests for the detection of invasive melanoma or atypical intraepidermal melanocytic
variants. CI: confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive; VI:
visual inspection.
In four studies with 1834 lesions and 106 melanomas comparing
diagnosis based on photographic images to histology, sensitivities
ranged from 59% (95% CI 42% to 74%) to 100% (95% CI 48%
to 100%) and specificities from 30% (95% CI 22% to 40%) to
100% (95% CI 93% to 100%) (Kroemer 2011; Moreno Ramirez
2005; Warshaw 2010b; Wolf 2013). In three studies, the data ex-
tractedwere for the correct diagnosis ofmelanomawhereas inWolf
2013, lesions were classified as ’atypical’ or ’typical’ as opposed to
reporting the correct diagnosis of melanoma. The difference in the
diagnostic decision recorded in Wolf 2013 is likely to account for
the low specificity observed.
The relatively low sensitivity and specificity observed in Warshaw
2010b is difficult to explain but may be related to differences in
population characteristics between studies. Two studies restricted
inclusion to pigmented lesions considered clinically atypical by at
least one dermatologist (Wolf 2013), or meeting explicit criteria
that might suggest a higher risk for melanoma (Moreno Ramirez
2005). Wolf 2013 selecting specific lesion types and excluding
those with an equivocal diagnosis. Kroemer 2011 included partic-
ipants with any lesion type who were either self-referred or referred
by a local doctor to a general dermatology clinic. Warshaw 2010b
also included any lesion type (pigmented or non-pigmented) from
participants who required or requested removal of one or more
skin lesions (denoted ’high risk’ by the study authors) or from peo-
ple who were referred by non-dermatology healthcare providers
for specialist assessment (denoted as ’lower risk’); furthermore, le-
sions in 30 histopathological categories with fewer than 25 lesions
were excluded (171 lesions).
Two studies compared dermoscopic image-based diagnosis to his-
tology (Ferrara 2004; Kroemer 2011). Sensitivities were 71%
(95% CI 29% to 96%; Ferrara 2004) and 100% (95% CI 48% to
100%; Kroemer 2011) and specificities were 60% (95% CI 15%
to 95%; Ferrara 2004) to 97% (95% CI 91% to 99%; Kroemer
2011). Ferrara 2004 reported sensitivity of 71% (95% CI 29%
to 96%) and specificity 60% (95% CI 15% to 95%) for the cor-
rect differentiation of seven melanomas from five benign lesions.
Kroemer 2011 reported very similar sensitivity and specificity for
the correct diagnosis of melanoma using only dermoscopic images
to their result using non-magnified photographic images: sensitiv-
ities with both approaches were 100% (95% CI 48% to 100%)
while specificities were 98% (95%CI 96% to 100%) using photo-
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graphic images compared to 97% (95% CI 91% to 99%) for der-
moscopic images.Datawere not presented for diagnosis using both
clinical and dermoscopic images; however, the study reported that
“re-evaluation of both image types in (discordant cases) did not
improve the diagnostic accuracy of teleconsultations” (Kroemer
2011).
Four studies with 664 lesions and 93 cases of melanoma or atyp-
ical intraepidermal melanocytic variants compared teledermatol-
ogy based on both clinical and dermoscopic images to histology
(Bowns 2006; Congalton 2015; Coras 2003; Grimaldi 2009).
Summary estimates of sensitivity were 85.4% (95% CI 68.3% to
94.1%) and specificity 91.6% (95% CI 81.1% to 96.5%) (Table
2; Figure 9).
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Figure 9. Summary receiver operating characteristic plot of teledermatology using clinical and
dermoscopic images for the detection of invasive melanoma or atypical intraepidermal melanocytic variants.
29Teledermatology for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Across the 10 teledermatology datasets, the number of melanomas
missed ranged from 0 (two datasets, both from Kroemer 2011) to
17 (Warshaw 2010b).
Three studies in this group compared teledermatology assessment
of images to face-to-face diagnosis by a dermatologist (Coras 2003;
Kroemer 2011; Warshaw 2010b) (Table 3). In Warshaw 2010b,
the diagnostic accuracy of teledermatology diagnosis of melanoma
using photographic images and patient history was considerably
lower compared to an in-person dermatologist diagnosis (using
visual inspection with or without the use of dermoscopy as deter-
mined by the individual clinician); data from the author showed
that sensitivity was 15% lower for teledermatology assessment
(95% CI -33% to 6%) and specificity was 22% lower (95% CI -
26% to -19%) (Table 3). The accuracy of the expert face-to-face
diagnosis was nevertheless relatively low, with sensitivity of 73%
(95% CI 57% to 86%) and specificity of 63% (95% CI 61% to
66%) (Figure 8). The two studies comparing teledermatology di-
agnosis using both macro and dermoscopic images demonstrated
only marginal differences between the two approaches (Coras
2003; Kroemer 2011) (Table 3).
3. Target condition: invasive cutaneous melanoma
Piccolo 2000 with 43 lesions reported the diagnostic accu-
racy of teledermatology assessment for the detection of invasive
melanoma selected for their ’diagnostic difficulty (11 cases of
melanoma) and Piccolo 2004 for the differentiation of six acral
melanoma from 71 benign acral lesions (Figure 10). In Piccolo
2000, the sensitivity for store-and-forward teledermatology assess-
ment was 82% (95% CI 48% to 98%) and specificity was 100%
(95%CI 89% to 100%) in comparison to in-person dermatologist
assessment of the same lesions where sensitivity was 73% (95%
CI 39% to 94%) and specificity 97% (95% CI 84% to 100%)
(one invasive melanoma missed in the face-to-face encounter was
identified using teledermatology). Similar teledermatology accu-
racy (based on a consensus’ of six out of 11 observers) was obtained
for acral lesions in Piccolo 2004 using only dermoscopic images:
observed sensitivity was 83% (95% CI 36% to 100%) and speci-
ficity was 96% (95% CI 88% to 99%).
Figure 10. Forest plot of tests for the detection of invasive melanoma. CI: confidence interval; FN: false
negative; FP: false positive; MM: malignant melanoma; TN: true negative; TP: true positive; VI: visual
inspection.
4. Target condition: BCC
Four studies reported the diagnostic accuracy of teledermatology
assessment for the detection BCC (Figure 11; Figure 12).
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Figure 11. Forest plot of tests for the detection of basal cell carcinoma (BCC). CI: confidence interval; FN:
false negative; FP: false positive; TN: true negative; TP: true positive.
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Figure 12. Receiver operating characteristic plot teledermatology using photographic images alone versus
histology for the detection of basal cell carcinoma.
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Three evaluations of photographic images for 301 lesions with 62
cases of BCC (Jolliffe 2001a; Kroemer 2011; Moreno Ramirez
2005), produced summary estimates of sensitivity of 93.5% (95%
CI 84.0% to 97.6%) and specificity 95.8% (95% CI 92.4% to
97.7%) (Table 2; Figure 12). Four BCCs were missed in two stud-
ies (Kroemer 2011; Moreno Ramirez 2005).
One study reported lower sensitivity using dermoscopic images
(80%, 95% CI 61% to 92%) compared to photographic images
(90%, 95% CI 73% to 98%), due to an additional two BCCs be-
ing mistaken for actinic keratosis (Kroemer 2011). A further study
reporting data only for teledermatology using clinical and dermo-
scopic images also reported low sensitivity for BCC of 66% (95%
CI 46% to 82%) (Bowns 2006). Both studies reported specificities
of 93% and over (Figure 11).
Two studies provided a comparison with expert face-to-face as-
sessment (Table 3). Kroemer 2011 reported higher sensitivity and
specificity in the face-to-face assessments and Jolliffe 2001a re-
ported almost identical sensitivity and specificity estimates from
the two approaches.
5. Target condition: cutaneous squamous cell
carcinoma
Kroemer 2011 reported accuracy for the detection of cSCC in
104 lesions with 10 cases of cSCC. There was a sensitivity of 90%
(95% CI 55% to 100%) (one cSCC missed) for diagnosis based
on photographic images and for the face-to-face assessments, with
a sensitivity of 60% (95% CI 26% to 88%) (four cSCCs missed)
for remote assessment based on dermoscopic images (Figure 13).
Specificities were over 98% for all three approaches to diagnosis.
Figure 13. Forest plot of tests for the detection of cutaneous squamous cell carcinoma (cSCC). CI:
confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive; VI: visual
inspection.
6. Referral accuracy
Six studies gave information on diagnostic decision making by
teledermatology consultants compared to expert face-to-face de-
cisions (as the reference standard) (Figure 14).
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Figure 14. Forest plot of tests for referral accuracy (expert in-person diagnosis as reference standard). CI:
confidence interval; FN: false negative; FP: false positive; TN: true negative; TP: true positive.
Four studies reported data for store-and-forward teledermatol-
ogy using photographic images, for the diagnosis of malignancy
(Oliveira 2002), for the decision to excise a lesion (Mahendran
2005; Shapiro 2004), for the decision to refer versus not re-
fer (Jolliffe 2001b), or to excise or follow-up at a later date
(Mahendran 2005). Jolliffe 2001b reported data both for teled-
ermatology by a dermatologist and by a dermatology registrar. It
was not possible to pool results across these studies due to hetero-
geneity in the teledermatology.
Two studies found perfect or almost perfect agreement between
teledermatology and face-to-face consultation (sensitivities 100%
and specificities 98% to 100%; Oliveira 2002; Shapiro 2004),
while Mahendran 2005 also reported 100% sensitivity both for
the decision to excise a lesion and the decision to excise or follow-
up (Figure 14). In Jolliffe 2001b, the sensitivity of teledermatol-
ogy by the dermatologist was 69% (95% CI 61% to 77%), with
44 lesions recommended for face-to-face consultation ’missed’ by
the remote observer, compared to 92% for the registrar’s teleder-
matology assessment (12 lesions ’missed’).
Specificities were more variable with 69% (95% CI 55% to 81%)
and 57% (95%CI 39% to 73%) reported inMahendran 2005 for
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the decision to excise a lesion and the decision to excise or follow-
up a lesion and 85% (95% CI 82% to 87%) and 67% (95% CI
63% to 70%) reported in Jolliffe 2001b for the dermatologist and
dermatology registrar for the decision to refer a lesion.The number
of lesions recommended for some action by the teledermatologist
that were not recommended for action by the face-to-face expert
in these studies ranged from 16 (Mahendran 2005) to 217 (Jolliffe
2001b).
Manahan 2015 reported the sensitivity and specificity of the tele-
dermatologist’s decision to recommend a lesion for face-to-face
consultation based on macro and dermoscopic images compared
to the same recommendation by the face-to-face dermatologist
(301 lesions; 35 recommended for face-to-face consultation): the
resulting sensitivity was 91% (95% CI 77% to 98%) with three
lesions ’missed’ and specificity was 89% (95% CI 85% to 93%)
with 28 lesions recommended for a face-to-face visit that were not
selected by the in-person dermatologist.
Finally, Phillips 1998 reported data for the accuracy of live-link
teledermatology using videoconferencing compared to a derma-
tologist’s face-to-face decision (as the reference standard) for 107
lesions. Data were reported at three different thresholds: for the
correct diagnosis of a skin cancer (melanoma, BCC or cSCC), for
the classification of a lesion as definitely or probablymalignant and
for the decision to biopsy a lesion. Sensitivities were 67% (95%CI
22% to 96%) for correct diagnosis, 60% (95% CI 15 to 95%) for
definitely or probably malignant and 82% (95% CI 48 to 98%)
for decision to biopsy a lesion Specificities were 96% (95% CI 90
to 99%) for both the correct diagnosis of a skin cancer and lesions
definitely or probably malignant and 86% (95% CI 78 to 93%)
for decision to biopsy a lesion.
Investigations of heterogeneity
We were unable to undertake planned formal investigations of
heterogeneity due to insufficient number of studies.
D I S C U S S I O N
Although in some countries teledermatology services may provide
recommendations to allow skin cancer management (including
biopsy or excision) in a primary care setting, in the UK teleder-
matology consultations for the most part ensure that people with
potentially malignant skin lesions are appropriately referred from
a generalist (usually primary care) setting for specialist assessment
and treatment. Therefore, the primary objective of this review was
to assess the accuracy of teledermatology for the detection of any
skin cancer in adults, comparing its accuracy with that of an in-
person specialist diagnosis.
Summary of main results
We included 22 studies: 16 considering the diagnostic accuracy of
image-based teledermatology (five in comparison to an in-person
assessment), and six examining the referral accuracy of telederma-
tology assessment. Key results are presented in the Summary of
findings. The overall risk of bias was rated as high or unclear for
participant selection, reference standard, and participant flow and
timing in at least half of all studies; the majority were considered
at low risk of bias for the index test. The applicability of study
findings were of high or unclear concern for most studies in all do-
mains assessed due to the recruitment of study participants from
secondary care settings or specialist clinics rather than from the
primary or community-based settings in which teledermatology
is more likely to be used and due to the acquisition of lesion im-
ages by dermatologists or in specialist imaging units rather than
by primary care clinicians.
Seven studies addressed our primary objective of the detection of
any skin cancer. For the correct diagnosis of lesions as malignant,
summary sensitivity from four studies using photographic images
was 94.9% (95% CI 90.1% to 97.4%) and summary specificity
84.3% (95% CI 48.5% to 96.8%). Individual study estimates us-
ing dermoscopic images or a combination of photographic and
dermoscopic images generally suggested similarly high sensitivities
with highly variable specificities. Limited comparative data sug-
gested similar diagnostic accuracy between teledermatology assess-
ment and in-person diagnosis by a dermatologist; however, data
were too scarce to draw firm conclusions.
For the detection of invasive melanoma or atypical intraepidermal
melanocytic variants, both sensitivities and specificities were very
variable, with reported diagnostic thresholds including the cor-
rect diagnosis of melanoma, classification of lesions as ’atypical’ or
’typical’, and the decision to refer or to excise a lesion. For teled-
ermatology using photographic images, sensitivities ranged from
59% (95% CI 42% to 74%) to 100% (95% CI 48% to 100%)
and specificities from 30% (95% CI 22% to 40%) to 100% (95%
CI 93% to 100%) in four studies. For teledermatology using both
photographic and dermoscopic images summary estimates for an-
other four studies were 85.4% (95% CI 68.3% to 94.1%) for sen-
sitivity and 91.6% (95% CI 81.1% to 96.5%) for specificity. The
number of melanomas missed ranged from 0 to 17.
Referral accuracy data comparing teledermatology against a face-
to-face reference standard was based on a number of different di-
agnostic decisions including the diagnosis of malignancy, the de-
cision to excise a lesion, the decision to refer versus not refer, or to
excise or follow-up at a later date. Agreement was generally good
for lesions considered to require some positive action by face-to-
face assessment (sensitivities of over 90%). For lesions considered
of less concernwhen assessed face-to-face (e.g. for those not recom-
mended for excision or referral), agreement was more variable with
teledermatology specificities ranging from 57% (95% CI 39% to
73%) to 100% (95% CI 86% to 100%), suggesting that remote
assessment is more likely recommend excision, referral or follow-
up compared to in-person decisions.
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Across all studies, there were wide variations in sensitivity and
specificity for all definitions of the target condition. Studies were
generally small with varying approaches to teledermatology as-
sessment, including the use of clinical or dermoscopic images (or
both); use of mobile phone cameras, digital cameras or video im-
ages; and varying thresholds for deciding test positivity. The defi-
nition of the target condition also varied such that data for the pri-
mary objective could only be extracted from seven of the 16 studies
assessing diagnostic accuracy, nine studies reporting data only for
the detection of individual skin cancers. These factors somewhat
limited our ability to pool results across studies and further, to
draw conclusions regarding the accuracy of teledermatology.
Overall, there were four key limitations of the studies.
• The spectrum (or case mix) of different lesion types varied
across studies, with a relatively high prevalence of malignant
lesions.
Study participants were largely recruited from secondary care set-
tings or from pigmented lesion clinic databases rather than from
primary care or other limited prior testing settings and 50% of
the studies assessing diagnostic accuracy relied on a histological
reference standard (i.e. all included participants underwent lesion
excision). In others, accuracy data could be extracted for less than
25% of lesions assessed at a virtual lesion clinic (Congalton 2015),
or as part of a preventive medical screening programme (Massone
2014). Therefore, recruited participants were more likely to have
lesions with a higher index of suspicion of malignancy compared
to those for whom a GP might have considered a teledermatol-
ogy assessment in practice, thereby limiting the generalisability of
study results. These ’spectrum effects’ are an increasingly recog-
nised concept for medical tests, often leading to lower sensitivity
and higher specificity when applied in settings with participants
with limited prior testing compared to participants further down
the referral pathway (Usher-Smith 2016). However, the direction
of effect is not consistent across tests and diseases (Leeflang 2013),
the mechanisms in action often being complex and sometimes
difficult to identify.
• Study definitions of ’malignancy’ varied and
teledermatology results were often not provided according to
lesion type.
In four included studies, the reported definition of malignancy
did not accord with our protocol-defined definition, with studies
including melanomametastases, Bowens disease or ’in situ cSCC’,
actinic keratosis or severely dysplastic naevi as ’malignant.’ In some
cases, data were reported to allow reclassification of these lesions
as disease negative for at least some of the reported thresholds for
test positivity (Borve 2015; Massone 2014); however, for others,
reclassification of these lesions as disease positive was not possible
and these studies could only be included in our analyses for the
detection of individual skin cancers (melanoma or BCC) (Bowns
2006; Congalton 2015). Other studies had to be excluded from
the review altogether due to varying definitions of ’malignant’ (e.g.
Borve 2013; Tandjung 2015). The lack of teledermatology results
according to lesion type further limited our ability to comment on
the implications of missed malignancies; the failure to pick up a
melanoma or cSCCpotentially carryingmore severe consequences
in comparison to a missed BCC.
• The definition of a positive teledermatology result varied
and was not always relevant to decision making in practice.
Of the 16 diagnostic accuracy studies, only three studies reported
data for the decision to excise a lesion (one for any skin cancer and
two for the detection of melanoma), and five reported data for
teledermatologists’ classification of lesions as malignant (or prob-
ably malignant). Nine of the 16 studies focused on teledermatol-
ogists’ ability to correctly diagnose lesions as melanomas (eight le-
sions) or as BCCs (four lesions) which, although of interest, is not
the primary factor driving teledermatology decisions in practice
where the key judgement in most circumstances is whether or not
a lesion should be referred for a face-to-face consultation.
• Insufficient comparisons were available for the diagnostic
accuracy of teledermatology-based diagnosis and diagnosis based
on a face-to-face dermatology clinic visit.
Only five of the 16 studies assessing diagnostic accuracy included
a comparison of teledermatology-based diagnosis with diagnosis
based on in-person diagnosis by a dermatologist; two for the detec-
tion of any skin cancer (Jolliffe 2001a; Kroemer 2011), and three
for the detection of melanoma (Jolliffe 2001a; Kroemer 2011;
Piccolo 2000). Therefore, we were unable to adequately assess
whether a teledermatology diagnosis of malignancy accurately re-
flects a diagnosis made in-person. The six studies of referral ac-
curacy suggested that diagnosis of individual lesions using store-
and-forward teledermatology could miss around 10% of lesions
recommended for clinical action (e.g. surgical excision) during a
face-to-face consultation (even up to 31% in one study) and is
also likely to recommend an action is required for lesions that are
considered of less or no concern when seen in-person. In practice,
a face-to-face consultation also allows a total body skin examina-
tion which may lead to incidental skin cancers being picked up
which could also be missed by the teledermatology referral of only
one or two lesions (Hanson 2016).
Our systematic review of dermoscopy as an addition to visual in-
spection of a lesion for the diagnosis of melanoma found in-person
dermoscopy (including 26 studies) to be substantially more accu-
rate compared to diagnosis based on dermoscopic images (includ-
ing 60 studies) (relative diagnostic odds ratio 4.6, 95% CI 2.4 to
9.0; P < 0.001) (Dinnes 2018a). Despite a number of contribut-
ing factors, including differences in study populations, different
algorithms to assist test interpretation and differences in observer
experience, we concluded that remote test interpretation cannot
approximate a physical, face-to-face patient-to-clinician interac-
tion. In particular, total body skin examination is likely to have a
significant impact on the decision to excise a lesion suspected to be
melanoma (Aldridge 2013; Argenziano 2012; Grob 1998). Only
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two of the 22 included teledermatology studies mentioned the
use of total body photography (Arzberger 2016; Phillips 1998). It
is notable also, that across the 60 image-based evaluations in the
review of dermoscopy, 30 (50%) were blinded to all other partici-
pant information and only 17 (28%) provided observers with the
photographic image of the same lesion to assist test interpretation
(Dinnes 2018a). It is conceivable that an image-based assessment
with full patient information provided in the context of a proper
teledermatology consultation would provide a closer approxima-
tion of the diagnostic decision that would be made with the pa-
tient present.
Strengths and weaknesses of the review
The strengths of this review include an indepth and comprehensive
electronic literature search, systematic review methods including
double extraction of papers by both clinicians andmethodologists,
and contact with authors to allow study inclusion or clarify data.
A clear analysis structure was planned to allow test accuracy to be
estimated according to varying definitions of the target condition
and a detailed and replicable analysis of methodological quality
was undertaken.
The main concerns for the review were the lack of studies, small
sample sizes, heterogeneity in teledermatology assessments, inad-
equate reporting of primary studies to allow quality to be fully
judged and importantly, the lack of clinical applicability of the
findings due to participant recruitment from, and image acquisi-
tion in, referral settings.
In comparison to other available systematic (Ndegwa 2010;
Warshaw 2011) and non-systematic (Bashshur 2015; Whited
2006; Whited 2016) reviews, our review provides a focus on the
triaging or diagnosis of skin cancer as opposed to the evaluation
of teledermatology for any dermatological disorder. The two most
recently published reviews either found evidence generally in sup-
port of teledermatology (Bashshur 2015), or suggesting inferior
accuracy compared to in-person assessments for pigmented lesions
(Whited 2016). In contrast we were unable to identify sufficient
evidence to establish the diagnostic accuracy of teledermatology
in comparison to a face-to-face clinical assessment. Our reviews
of the diagnostic accuracy of visual inspection of suspicious skin
lesions for the detection of melanoma (Dinnes 2018b), and of
dermoscopy in comparison to visual inspection of a suspicious
skin lesion (Dinnes 2018a), suggest that image-based assessment
may not be equivalent to a face-to-face patient:clinician interac-
tion. However, both reviews focused on the correct diagnosis of
melanoma as opposed to any skin cancer, neither included studies
that were specifically designed to evaluate teledermatology pro-
grammes and did not examine any effect on accuracy from poten-
tial improvements in image quality over time.
Our a priori decision to exclude studies with fewer than five ma-
lignant cases could be construed as a weakness of the review; how-
ever, of the seven studies excluded on this basis, five were also
excluded due other reasons such as inability to construct a 2×2
contingency table or ineligible study populations and one used
multiple images of only four lesions to examine the effect of the
positioning of a lesion within an image on clinicians ability to de-
tect it (Chen 2002). The final study which was excluded only on
the basis of sample size reported the effect of adding dermoscopic
images to an existing teledermatology consultation system for 63
lesions fulfilling the criteria for teleconsultation (Moreno-Ramirez
2006); all three malignant lesions were correctly picked up using
both photographic images and with the addition of dermoscopic
images (100% sensitivities) while specificities were 65%with pho-
tographic images and 78% with photographic and dermoscopic
images.
We were also unsuccessful in our attempts to contact the authors
of eight of 12 studies which could have been eligible for inclu-
sion in the review, especially those studies which reported only
agreement between observers or agreement with final lesion di-
agnoses rather than providing results in a 2×2 contingency table
format. Furthermore, only partial data were provided to allow the
inclusion of one study in the review (Warshaw 2010b); the review
would be considerably strengthened if data for teledermatology
using dermoscopic images could have been included. Finally, the
review was limited to the identification of skin cancer rather than
assessing the potential additional benefits of teledermatology such
as positive identification of benign lesions such as actinic keratosis
(Janda 2015).
Ongoing technological advances are continually improving the
quality, clarity and colour-rendition of digital images taken with
cameras and mobile phones. The ability to zoom in on new larger
image files potentially provides even more detailed information
compared to observation of a lesionwith the naked eye alone. Such
advances could be of particular help in the triage of lesions with
no distinguishing features (e.g. for the identification of amelan-
otic melanomas), the additional magnification potentially giving
subtle clues to aid diagnosis. Although we have documented the
equipment used to obtain images in the included studies, we were
unable to identify any clear effects from changes in technology.
Our review of the diagnostic accuracy of teledermatology was also
unable to evaluate a number of other pertinent factors.
• The archiving and auditable trail provided by a
teledermatology consultation. With conventional face-to-face
consultations, much of the interchange is verbal and unrecorded;
for teleconsultation however, every aspect of the referral and
diagnostic opinion are recorded such that it can be reviewed and
audited at a later date.
• The possibility of ’crowd-review’ of lesion images. In-
person clinical assessment is often conducted by a single
clinician, consultation with other qualified clinicians reserved for
more difficult lesions or to support more junior clinicians. The
nature of teledermatology diagnosis lends itself to lesion review
by multiple clinicians and to have virtual multidisciplinary
review of cases if necessary.
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• Changing the referral behaviour of primary care clinicians.
The availability of a teledermatology service could result in a
specialist opinion being sought for much earlier presentations of
conditions than would normally be the case, which not only
changes the spectrum of lesion types observed by
teledermatologists, potentially impacting on their accuracy, but
could ultimately result in overdiagnosis and treatment. For
example, some lesions identified and either excised or treated
non-surgically following a teleconsultation might have resolved
spontaneously if monitored for longer in primary care, or if
referred for a standard face-to-face consultation. The effect on
referral behaviour is likely to be exacerbated where ease of access
to a teledermatology service for a specialist opinion may be
preferred by GP trainees to seeking the opinion of a more
experienced GP.
• Possible over-reliance by GPs and reassurance for patients
on a benign diagnosis from a teledermatology consultation. As
with all clinical consultations, a diagnostic opinion from a
teledermatology consultation is limited to the quality of the
clinical information provided and the circumstances at the time
of consultation. If those circumstances change, for example if a
pigmented lesion diagnosed as ’benign’ evolves or changes its
nature in some way, then that lesion should be reviewed. ’Safety-
netting’ such lesions is an important part of management and
monitoring in primary care.
Applicability of findings to the review question
The data included in this review are unlikely to be generally appli-
cable to the intended setting. Most studies recruited participants
from secondary care or referral settings rather than from primary
care settings where patients are far less likely to have skin cancer,
and potentially suspicious lesions are likely to be earlier in their
development and evolution. Lesion images were often acquired
in secondary care rather than being acquired in primary care and
transmitted for a specialist opinion using teledermatology. Con-
siderable heterogeneity in approaches to teledermatologywere also
observed limiting generalisability.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Studies were generally small and heterogeneous and methodolog-
ical quality was difficult to judge due to poor reporting. Consider-
ing concerns regarding the applicability of study participants and
of lesion image acquisition in specialist settings, our results suggest
that teledermatology can be relied upon to correctly identify most
malignant lesions. Using a more widely defined threshold to iden-
tify ’possibly’ malignant cases or lesions that should be considered
for excision is likely to appropriately triage those lesions requiring
face-to-face assessment by a specialist.
Implications for research
Despite the increasing use of teledermatology on a national and
international level, the evidence base to support its ability to accu-
rately triage lesions from primary to secondary care is lacking and
further prospective and pragmatic evaluation is needed. Consec-
utive series of participants with suspicious skin lesions judged to
require a specialist opinion by general practitioners should be re-
cruited (i.e. excluding those clearly judged to be malignant or be-
nign) and referred for store-and-forward teledermatology in com-
parison to routine referral to a dermatologist. The reason for re-
ferral (e.g. exclusion of melanoma to avoid an urgent or ’two-week
wait’ referral, exclusion of cSCC or basal cell carcinoma, or ex-
clusion of ’any skin cancer’) should be clearly recorded. ’State-of-
the-art’ digital photography should be used (potentially utilising
mobile phone cameras) to allow the full benefit of current technol-
ogy to be exploited, and compared with smart phone applications,
and systematic follow-up of non-excised lesions implemented to
avoid over-reliance on a histological reference standard. The level
of training and experience of both the referring and specialist clin-
icians should be explicit to allow the generalisability of results to
be judged. Any future research study needs to be clear about the
diagnostic pathway followed by study participants, and should
conform to the updated Standards for Reporting of Diagnostic
Accuracy (STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arzberger 2016
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: May to October 2009
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: study participants with at least 1 of the following factors associated with mod-
erate-to-high risk of melanoma: personal or first-degree relative history of melanoma; history of
dysplastic naevi; > 5 atypical naevi; > 100 naevi; lesion suspicious for melanoma
Setting: specialist clinic (Pigmented Skin Lesion Clinic Medical University of Graz)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): number eligible: 70; number included: 20
Sample size (lesions): number eligible: 1922; number included: 23
Participant characteristics:
Age: range: 11-81 years
Gender: male: 35, female 35
Lesion characteristics: none reported
Index tests TD
Acquisition and transmission of images: after clinical examination participants had total body
photography performed by an experienced dermatology nurse or dermatology resident (took on
the role of a “melanographer”), images were taken using the MoleMap program, without regard
of the decision made at the FTF examination. Without regard to the medical decision resulting
from the F2F evaluation, the melanographer acquired body-sector photographs (Nikon D40 and
D50 digital SLR, Nikon Corporation Tokyo, Japan) and photographs of selected skin lesions were
those that were: “(i) highly suspicious; (ii) concerning; (iii) changing and/or different; (iv) > 3 mm;
(v) itching, bleeding, inflamed; or (vi) suspicious for basal cell carcinoma (BCC) or squamous cell
carcinoma.” Selected lesions had a close-upmacroscopic and dermoscopic image taken. Images were
then uploaded to a centralised server in New Zealand, which was accessible to the participating
teledermoscopy experts
Nature of images used: clinical and dermoscopic
Any additional participant information provided: total body images
Observer qualifications (remote diagnosis): dermatologists (experts in dermoscopy)
Diagnosis based on: single observer
Number: 4
Method of diagnosis: 4 remote teledermoscopy experts evaluated the total body images and der-
moscopic images, and gave a recommendation for each lesion
Management options (diagnostic threshold): recommendations for management included: “self-
monitoring,” “short-term monitoring” and “excision”
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Arzberger 2016 (Continued)
Target condition and reference
standard(s)
Reference standard: histology
Details: histology (excision)
Lesions were selected for excision after conventional FTF total body and dermoscopic examination
of all lesions, performed by individual dermatologists with expertise in the assessment of pigmented
lesions. Histopathological examination of excised lesions was performed at the Dermatopathology
Laboratory at the Medical University Graz, Graz, Austria
• Number participant/lesions: 23
• Disease positive: 9
• Disease negative: 14
Target condition (final diagnoses)
• Melanoma (invasive): 8
• Melanoma (in situ): 1
• BCC: 2
• Other: 12 melanocytic nevi
Flow and timing 50 participants were excluded from the final analysis (48 participants were discharged with the
recommendation to do monthly self-skin examination and 2 participants were followed up)
20 participants had their lesions excised (included in the final analysis)
The interval between index test and reference standard was not clearly reported; however, it appeared
to be simultaneously
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
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Arzberger 2016 (Continued)
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Unclear
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Arzberger 2016 (Continued)
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
Borve 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: January 2011 to December 2012
Country: Sweden
Patient characteristics and set-
ting
Inclusion criteria: adults > 18 years of age with ≥ 1 skin lesions of concern requiring referral to a
dermatologist using the TD referral system
Setting: primary (20 primary healthcare centres in western Sweden)
Prior testing: N/A
Setting for prior testing: N/A
Exclusion criteria: did not attend FTF visit(s), did not comply or skin lesions were located on a
body part that could not be photographed
Sample size (participants): number eligible: 902; number included: 816
Participant characteristics:
Age: mean 54; range: 18-93 years
Gender: 474 (61.3%) women
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: GPs used the smartphone TD referral system. The GP
took 1 clinical and 1 dermoscopic image using an iPhone 4 with a FotoFinder Handyscope app, and
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Borve 2015 (Continued)
completed a standardised query form including all the relevant clinical information. This was then
sent through a secure web-based TD platform (Tele-Dermis) with a secure socket layer encryption.
Simultaneously the participating dermatologists received an email that a new referral was ready for
assessment
Nature of images used: clinical photographs and dermoscopic images
Any additional participant information provided: clinical information
Diagnosis based on: single; number of examiners: 4
Observer qualifications (remote diagnosis): 3 specialists in dermatology and 1 resident in derma-
tology
Method of diagnosis: dermatologists logged onto the Tele-Dermis platform to review the referrals
on a 17- or 19-inch liquid crystal display monitor. They chose from standardised triage responses
including an assessment of the nature of the lesion (benign, malignant or unclear), ≥ 1 possible
diagnoses, the priority given (high, within 2 weeks; medium, within 4 weeks or low, within 8-12
weeks), suggested management (none, medical therapy, destructive therapy or surgery) and, finally,
a dermoscopic description
Target condition and reference
standard(s)
Histological plus expert diagnosis
Histology: 551
Details:AllMMs and SCCs (keratoacanthomaswere classified as SCCs) were confirmed histopatho-
logically. Final diagnosis confirmed histopathologically in 292 TD referrals (36%) and 259 paper
referrals (35%)
Expert diagnosis (FTF diagnosis at dermatology clinic): 265
Method of diagnosis: dermatologists used dermoscopy to evaluate the study lesions and carried
out full body skin examination
Prior test data: all relevant clinical information (FTF visits were not blinded to the results of the
teledermoscopists)
Diagnostic threshold: NR
Diagnosis based on: single
Number of examiners: NR
Observer qualifications: dermatologists (specialists in dermoscopy)
Experience in practice: high
Experience with index test: high
Target condition (final diagnoses)
Malignant:MM: 19 (2.3%); MiS: 16 (2.0%); SCC: 17 (2.1%); SCC in situ: 7 (0.9%); BCC: 109
(13.4%); AK: 61 (7.5%); other malignant: 0
Benign: dysplastic nevi: 89 (10.9%); BN: 236 (28.9%); SK: 125 (15.3%); other benign: 137 (16.
8%)
Flow and timing • Excluded participants: none reported
• Time interval to reference test: all participants were called to attend an FTF visit at the
corresponding department of dermatology. A suspicion of MM or SCC was triaged within 2
weeks. After the triage process, all participants were managed according to standard protocols at
the hospitals independently of the referral method.
Comparative
Notes -
Methodological quality
57Teledermatology for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Borve 2015 (Continued)
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low Unclear
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
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Borve 2015 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Yes
High
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Bowns 2006
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: people either referred to the 2-week wait or ’target’ clinics, or those initially
referred to the normal outpatient service but who were diverted by the consultant on the basis of
the referral form
Setting: specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: clinical or dermatoscopic (or both) suspicion (not clearly described, but all referred
with certain degree of concern based on referral to 2-week wait or urgency graded by consultant
based on referral letter)
Setting for prior testing: primary
Exclusion criteria: NR
Sample size (participants): NR but < 256 as a number of participants were referred for > 1 lesion,
all treated as independent
Sample size (lesions): number eligible: 267; number included: 256
Participant characteristics: NR
Age: classified by age band; 61% were aged > 55 years
Gender: male: 46.9%
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: lesion images were taken at the Medical Photography
Unit (equipment not described) before an outpatient appointment with a dermatologist using both
normal photographic methods and a dermatoscope
Nature of images used: clinical and dermoscopic
Any additional participant information provided: initial referral forms or letter provided
Method of diagnosis: independent dermatologist assessed photographs and gave their most likely
diagnosis and level of confidence in the diagnosis. They also gave an opinion on whether the lesion
was malignant and a recommendation on whether they would wish to see the participant
Diagnosis based on: single observer
Number of examiners: 3 consultants
Observer qualifications (remote diagnosis): dermatologist (experience NR)
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus other
Details: histology undertaken in 164 cases, including 78/85 malignant cases and 86/171 benign
cases (50.3%)
FTF diagnosis/expert opinion
Details: final diagnoses for 92 lesions reached by FTF decision only (VI ± use of dermoscopy (not
specified)), including 7/85 malignant (’mainly with diagnoses of BCC or Bowen’s disease’) and 85/
171 benign cases
Number of examiners: 7 consultant dermatologists
Experience in practice: NR
Experience with index test: NR
Target condition (final diagnoses as per expert clinical diagnosis and histology)
• Malignant: melanoma (invasive): 19; MiS: 5; BCC: 29; cSCC: 16; other malignant: 1
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Bowns 2006 (Continued)
• Benign: severe dysplasia: 3; SK: 70; BN: 64; ’Benign’ diagnoses: BD/in situ SCC: 9; solar
keratosis: 15; other benign: 25
Flow and timing • Excluded participants: 11 excluded; 7 wrong lesion imaged, 3 histology already undertaken,
3 image file lost.
• Time interval to reference test: medical photographs were taken immediately prior to FTF
consultation. Reference diagnosis was based on FTF with or without histology. Time to histology
NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Bowns 2006 (Continued)
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
No
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Bowns 2006 (Continued)
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
Congalton 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 1 April 2012 to 31 March 2013
Country: New Zealand
Patient characteristics and set-
ting
Inclusion criteria: people referred from primary care with skin lesions suspicious for melanoma
triaged via a VLC instead of being seen FTF at a hospital clinic. Referrals that indicated 1-6 lesions
of concern were included
Setting: secondary (general dermatology) and private care
Prior testing: clinical or dermatoscopic (or both) suspicion
Setting for prior testing: primary
Exclusion criteria: difficult to diagnose lesions - location/site of lesion skin lesions on scalp and
genitals were generally excluded, as were those where body site was not clearly identified in the
referral
Sample size (participants): number eligible: 345; number included: 310
Sample size (lesions): number included: 613
Participant characteristics:
Age: median: 58 (range: 15-92) years
Gender: male: 142; female 168
Race/ethnicity (%): white: 242 (78%); black or African American: 12 (4%); Hispanic or Latino:
3 (< 1%); Asian: 16 (5%); other: Maori 16 (5%), Pacific islanders 12 (3%); missing: 12 (4%)
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: participants attended 2 imaging clinics run by a private
TD company (MoleMap NZ). Total body photography not offered. Macroscopic and dermoscopic
images captured using a Canon G6 camera or MoleCam; regional anatomic views captured using
Nikon D3100. Information on the referred lesions such as whether the person had noticed any
changes in size, colour, bleeding and itching was recorded. Hair and eye colour, skin type, previous
history of sun exposure and family/personal history of skin cancers were also captured. Files were
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Congalton 2015 (Continued)
archived using proprietary software (MoleMap NZ) and uploaded to a secure server via a virtual
private network
Nature of images used: clinical and dermoscopic images
Any additional participant information provided: participant details
Diagnosis based on: single observer
Number of examiners: 2
Observer qualifications (remote diagnosis): dermatologist
Methodof diagnosis:using theMoleMapDiagnose software, 2 experienceddermatologists reviewed
participant details and images remotely, making a diagnosis and suggesting management
Management options (diagnostic threshold): options included: “(i) specialist assessment or exci-
sion of the lesion; (ii) re-imaging in 3-months’ time to detect change (e.g., atypical naevus without
criteria for immediate excision); (iii) discharge to care of general practitioner (GP) e.g., for cryother-
apy or topical therapy; (iv) self-monitoring and (v) lesion of no concern.”
Target condition and reference
standard(s)
Reference standard - histology alone; 129 lesions excised; 123 considered suspicious for malig-
nancy on TD, 5 considered benign and 1 ’undiagnosable’
Target condition (final diagnoses as per expert clinical diagnosis and histology)
• Melanoma (in situ and invasive, or NR): 48
• Other malignant: NMSC 45
• ’Benign’ diagnoses: 32
Flow and timing • Excluded participants: 1 participant excluded from further analysis because he attended the
VLC after the referred lesion had been excised; further 484 lesions assessed at the VLC but, with
no final diagnoses reported, could not be included.
• Time interval to reference test: medical photographs were taken immediately prior to FTF
consultation.
Comparative -
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
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Congalton 2015 (Continued)
Did the study avoid including
participants with multiple le-
sions?
No
High High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test FTF diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Was the test applied and inter-
preted in a clinically applicable
manner?
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
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Congalton 2015 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
Unclear
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Congalton 2015 (Continued)
for melanoma or cSCC or 6
months for BCC?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Was the interval between ap-
plication of the index tests less
than 1 month?
Were all tests applied and inter-
preted in a clinically applicable
manner?
Coras 2003
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 16-month period. Did not say the date
Country: Germany
Patient characteristics and set-
ting
Inclusion criteria: PSLs undergoing excision due to diagnosis of melanoma or atypical nevus, to
rule out melanoma or at the participant’s request
Setting: secondary (general dermatology) (teledermoscopy diagnosis); private care FTF diagnosis
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
Sample size (lesions): number eligible: 90; number included: 45
Participant characteristics: none reported
Lesion characteristics: none reported
Index tests In-person assessment (for those comparing FTF vs histology)
Method of diagnosis: participating dermatologists with experience in dermoscopy established a
clinical diagnosis based on pattern analysis after personal consultation with the participant in their
private practice clinics
Prior test data: NR
Diagnostic threshold: NR
Diagnosis based on: single
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Coras 2003 (Continued)
Number of examiners: 3
Observer qualifications: dermatologist (experts with great experience in dermoscopy)
Experience in practice: high
Experience with index test: high
TD
Acquisition and transmission of images: each of the participating dermatologists acquired digital
images after FTF consultation using the same technical equipment (Dermogenius ultra - hand-held
CCD camera with pixel size 512×512), and sent them via an email attachment with corresponding
participant data and medical history
Nature of images used: clinical photographs and dermoscopic images
Any additional participant information provided: clinical examination or case notes (or both)
Observer qualifications (remote diagnosis): physician experienced in dermoscopy
Diagnosis based on: single observer
Method of diagnosis: a physician evaluated the images and made a diagnosis based on the images
and history of the participant
Other detail: the participating dermatologists used the same technical equipment for the acquisition
of digital images
Target condition and reference
standard(s)
Reference standard: histology
Details: the histological diagnosis of majority of cases was performed at the Department of Der-
matology Regensburg
Target condition (final diagnoses)
• Melanoma (in situ and invasive, or NR): 16
• ’Benign’ diagnoses: 29
Flow and timing • Excluded participants: they reported that many images were of poor quality (10) and that
only 45 biopsies were done 50 people who did not have histology excluded
• Time interval to reference test: unclear
• Time interval between index test(s): most likely days (email transmission of images for
remote assessment)
Comparative Each of the participating dermatologists who conducted a FTF clinical diagnosis acquired digital
images of the lesion, and send them via an email attachment with corresponding participant data
and medical history
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
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Coras 2003 (Continued)
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test FTF diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
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Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than 1 month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Unclear Low
Ferrara 2004
Study characteristics
Patient sampling Study design: case control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: NR; likely Italy
Patient characteristics and set-
ting
Inclusion criteria: pigmented melanocytic lesions with dermoscopic images (a single image per
case) and accompanying histological material were retrieved; approach to lesion selection was not
described
Setting: unspecified
Prior testing: clinical or dermatoscopic (or both) suspicion
Setting for prior testing: NR
Exclusion criteria: none reported
Sample size (participants): NR
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Sample size (lesions): number included: 12
Participant characteristics: 10 males and 2 females, aged 14-79 (median 41) years.
Lesion characteristics: 7 lesions removed from the trunk, 4 from the limbs and 1 from the face.
Lesions ranged in size from 4 mm to 14 mm in diameter (median 6 mm)
Index tests TD
Acquisition and transmission of images: dermoscopic images were either acquired on film
(Dermaphot) and then digitised (8) or were acquired directly from a digital camera (4); (MoleMax
or Videocap) photographic images were also available in 9/12 cases
Nature of images used: dermoscopic images
Any additional participant information provided: clinical examination or case notes (or both)
Observer qualifications (remote diagnosis): dermatologist
Diagnosis based on: single observer
Number of examiners: 3
Method of diagnosis: stored images were viewed on a standard-resolution colour monitor by 3
remote consultants in a single session; the teledermoscopy diagnosis (melanoma or other lesion
type) was recorded by a single consultant, followed by a teledermatopathology diagnosis (based on
histological image). The original histological diagnosis from the consultation file was then presented
(apparently along with the original clinical diagnosis). “Dermoscopic-pathological remarks” were
made and finally a consensus diagnosis was reached by 2 consultants; the latter was taken as the
’gold standard’ for the study
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details:12 caseswith dermoscopic images (1 image per case) and accompanyinghistologicalmaterial
were retrieved from consultation files. The conventional histopathology diagnosis was regarded as
the gold standard: a consensus diagnosis between 2 consultants was requested in order to minimise
any influence of the
previous dermatopathology diagnosis
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 7. Invasive melanoma: 4; MiS: 3
’Benign’ diagnoses: 5. Junctional nevus: 1; Reed naevus: 1; blue naevus: 1; actinic lentigo: 1; SN: 1
Flow and timing • Excluded participants: NR
• Time interval to reference test: images taken at time of FTF consultation; interval to excision
NR
• Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
Unclear
High Unclear
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
Unclear
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of the results of the index tests?
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Yes
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Unclear
Grimaldi 2009
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: October 2005 to March 2006
Country: Italy
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Patient characteristics and set-
ting
Inclusion criteria: cutaneous pigmented lesions with digital images forwarded by primary care
physicians to a referral centre for confirmation of diagnosis
Setting: primary (lesions selected for referral by GPs; accuracy of GP diagnosis assessed); secondary
(general dermatology); telediagnosis by expert observer also assessed
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: lesions whose removal had been explicitly demanded by the patients for aesthetic
reasons, and those irritated or subjected to trauma
Sample size (participants): number included: 197
Sample size (lesions): number included: 235
Participant characteristics: NR
Lesion characteristics: NR
Index tests In-person FTF clinical assessment by GP: not included in this review
TD
Acquisition and transmission of images: images acquired by PCPs using Konica Minolta
Dimage Z10 digital cameras (zoom 0, automatic setting, macro off, flash off ) coupled with 3Gen
37 mm dermoscopes (with annular white LED lamp). All PCPs involved in the programme were
asked not to start any therapy, but to send the images acquired to the reference centre first. All
photographed lesions were uploaded from the peripheral units to the central research unit for
telediagnosis with only a 2-step judgement (before and after dermoscopy) formulated by the sending
physician
Nature of images used: clinical photographs; dermoscopic images
Any additional participant information provided: unclear
Observer qualifications (remote diagnosis): dermatologist; plastic surgeons
Number of observers: unclear
Experience in practice: high experience or ’Expert’
Experience with index test: not described
Method of diagnosis: unclear but telediagnosis may also have followed ABCD, study stated, “after
second appraisal of the images received made by the reference unit) the appropriate guidelines for
every case, established in relation to the formulated and controlled diagnosis... When the diagnosed
lesion was considered as ’needing control’ by the medical staff of the reference centre, the patient
was included in a periodic observation programme, according to which images of the lesions were
recorded and compared at set intervals, according to a protocol if the cutaneous lesion was judged
as ’needing surgery’ the therapeutic programme (radical removal, sentinel lymph node biopsy,
reconstructive surgery, other therapies) was carried out at the Plastic Surgery Unit of the University
of Siena in all cases, after verification of the digital images and checks on the patient.”
Target condition and reference
standard(s)
Reference standard: histological diagnosis + FU
Details: 219 benign lesions were investigated by dermoscopic follow-up (after 2, 4 and 6 months)
in the peripheral centres, and in all cases the diagnosis was confirmed (no clinical change) by
telediagnosis from the main centre. These cases were subsequently controlled at regular 6 month
FU checks. 16 lesions were labelled as ’to be removed’ at the final check
Histology (not further described) number participants/lesions: 16; disease positive: 5; disease negative:
11
Clinical FU + histology of suspicious lesions: length of FU: 6 months
• number participants: 219; disease positive: 0; disease negative: 208
Target condition (final diagnoses)
• Melanoma (in situ and invasive, or NR): 5
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• Other: 230 benign
Flow and timing • Excluded participants: NR
• Time interval to reference test: NR
• Time interval between index test(s): all the digital images from the peripheral centres (235
lesions) were forwarded to the reference centre in real time
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
Yes
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If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Yes
High
Jolliffe 2001a
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: people referred by their GP for dermatological assessment of a pigmented lesion
at the PLC
Setting: specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: not explicitly mention but most likely clinical examination
Setting for prior testing: primary
Sample size (participants): number eligible: 138; number included: 138
Sample size (lesions): number eligible: 144; number included: 144; clinical diagnosis 140; teled-
ermoscopy
Participant characteristics:
Age: range 15-94 years
Gender: male: 48 (34%); female 90 (66%)
Lesion characteristics: NR
Index tests In-person FTF clinical assessment
Method of diagnosis: at the PLC a clinical diagnosis (± the use of dermoscopy) based upon
information in the referral letter and examination findings was made and recorded by the examining
doctor
Prior test data: clinical examination or case notes (or both)
Diagnostic threshold: NR
Diagnosis based on: single
Number of examiners: 1
Observer qualifications: dermatologist
Experience in practice: unclear
Experience with index test: unclear
TD
Acquisition and transmission of images: the examining doctor using a single chip video camera,
obtained an image of the pigmented lesion. The image was then archived using proprietary software
and images were transmitted through a Fast Screen Machine 2 video overlay card and viewed on a
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15 inch monitor
Nature of images used: clinical
Any additional participant information provided: clinical examination or case notes (or both)
Observer qualifications (remote diagnosis): dermatologist
Diagnosis based on: single observer
Number of observers: 1
Method of diagnosis: the anonymous video images and the GP’s referral letter were then viewed
several months later by the same doctor who performed the in-person assessment and a diagnosis
made
Management options: NR
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Lesions had been excised either to confirm or refute clinical suspicion of malignancy or atypia. No
participant had a lesion removed on account of the study
Target condition (final diagnoses)
Malignant: melanoma (in situ and invasive, or NR): 2; Lentigo maligna: 2; BCC: 9
Benign diagnoses: atypical naevus: 5; benign melanocytic naevus: 89; SK: 9; solar lentigo: 7;
blue naevus: 4; freckle: 2; SN: 2; dermoid cyst: 2; pyogenic granuloma: 2; congenital naevus: 1;
naevus sebaceous: 1; DF: 1; haemangioma: 1; abscess: 1; nodular hidradenoma: 1; non-caseating
granuloma: 1; apocrine hidrocystoma: 1; angiokeratoma circumscriptum: 1
Flow and timing • Excluded participants: in 4 cases it was impossible to make a diagnosis from the image, due
to poor image quality.
• Time interval to reference test: NR
• Time interval between index test(s): the same doctor viewed the images several months after
examining the participant in clinic.
Comparative The anonymous video images and the GP’s referral letter were then viewed several months later by
the same doctor and a diagnosis made. The same doctor who performed the clinical examination
viewed the images. The doctor’s potential memory of a lesion may, therefore, be perceived to be
a source of bias. In reality, > 800 pigmented lesions had been seen by this doctor between the in-
person and video examinations, making memory of a specific lesion less likely
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low High
DOMAIN 2: Index Test FTF diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than 1 month?
No
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
High High
Jolliffe 2001b
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: people referred to the dermatology departments of the Royal Free Hospital or
theWhittington Hospital during the study period by their GPs for assessment of a pigmented lesion
Setting: specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: GP referral for dermatological assessment at a PLC
Setting for prior testing: primary
Exclusion criteria: none reported
Sample size (participants): number included: 611
Sample size (lesions): number included: 819
Participant characteristics:
Age: range 8-94 years
Gender: male: 196 (24%); female: 90 (66%)
82Teledermatology for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jolliffe 2001b (Continued)
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: lesion images were taken by the examining doctor using
a single-chip video camera; images were viewed on a 15-inch monitor and stored as JPEG files with
minimum compression; overhead artificial illumination was used throughout and the best image
used if a series were taken
Nature of images used: clinical
Any additional participant information provided: clinical examination or case notes (or both)
Observer qualifications (remote diagnosis): dermatologist
Diagnosis based on: single observer
Number of observers: 3
Method of diagnosis: images were viewed several months later alongside GP referral information
independently by all 3 doctors
Management options: the clinician made a decision whether a lesion warranted a referral or not
on the basis of the image and referral information
Target condition and reference
standard(s)
Reference standard: expert diagnosis (FTF diagnosis at dermatology clinic)
Details: participants were seen in clinic by a registrar or 1 of 2 consultant dermatologists. Following
history taking and clinical examination, a treatment plan was formed (reassure, review with photo-
graph or biopsy lesion) and clinical diagnosis recorded. Clinical diagnoses were then grouped into
lesions ’not to be missed’ (i.e. reference standard positive) including “malignant melanoma, basal
cell carcinoma (BCC), atypical naevus, keratoacanthoma and pyogenic granuloma (owing to the
potential clinical confusion with amelanotic melanoma)” and benign lesions (i.e. reference standard
negative), including benign melanocytic naevus, SK, congenital naevus, DF, solar lentigo and AK
Target condition (final diagnoses as per expert clinical diagnosis)
Disease positive: melanoma (invasive): 9; BCC: 19; lentigo maligna: 1
Disease negative: SK: 152; benignmelanocytic naevus: 361; postinflammatory hyperpigmentation:
2; blue naevus: 2; atypical naevus: 112; nail infection: 2; congenital naevus: 27; haematoma: 2;
DF: 25; eczema: 2; solar lentigo: 23; keratoacanthoma: 1; foreign body: 1; angioma: 18; abscess: 1;
AK: 13; SN: 1; fibroepithelial polyp: 11; dermoid cyst: 1; viral wart: 10; apocrine hidradenoma: 1;
chloasma: 1; comedone: 5; cutaneous horn: 1; dermatosis papulosis nigrans: 4; congenital arteriove-
nous malformation: 1; naevus sebaceous: 4; psoriasis: 1; scar/fibrosis: 3; spider naevus: 1; pyogenic
granuloma: 2
Flow and timing Participants had the FTF consultation first before having their lesions images. The images were
then viewed several months later in conjunction with the GP’s referral information by all 3 doctors
independently
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Yes
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Low
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Study characteristics
Patient sampling Study design: NR
Data collection: prospective
Period of data collection: reported “a 3 month period” - no dates mentioned
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: people self-referred or referred by a local doctor for evaluation of a skin tumour.
Men or womenwith benign ormalignant (or both) skin tumours ofmelanocytic or non-melanocytic
origin
Setting: secondary (general dermatology) Department of Dermatology, Medical University of Graz,
Austria
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion; patient request
for evaluation/excision physician or self-referral
Setting for prior testing: primary; all participants were self-referred or referred by a local doctor
Exclusion criteria: none reported
Sample size (participants): number eligible: 88; number included: 80/88
Sample size (lesions): number eligible: 113 lesions; number included: they reported 104/113
tumours of 80/88 participants were tele-evaluated. However, adding all in table 1 gives > 113 (there
were up to 3 (total 322) clinical and 3 dermoscopic (total 278) images)
Participant characteristics:
Age: mean: missing; median: 69; range: 3-93 years
Gender: male: 41/88 available. Not stated who withdrew; female 47/88 available. Not clear who
remained
Race/ethnicity (%): missing: not stated, but they were Austrian
Lesion characteristics: NR
Index tests In-person FTF clinical assessment
Method of diagnosis: not clear from paper how in-person assessment was conducted but most
likely VI of the skin (± use of dermoscopy) no algorithm described
Prior test data: unclear
Diagnostic threshold: unclear
Diagnosis based on: single
Number of examiners: unclear
Observer qualifications: NR
Experience in practice: NR
Experience with index test: NR
TD
Acquisition and transmission of images: lesions were selected during the outpatient visit and up
to 3 clinical (autofocus mode) and dermoscopic images (macro mode) images were obtained by
the clinician using a mobile phone with a built in mega-pixel camera (for clinical photos) (Nokia
N73 with a built-in 3.2-megapixel camera; Nokia, Helsinki, Finland) with the addition of a pocket
dermoscopy device attached to the camera lens for dermoscopic images (DermLite II PROHR; 3Gen
LLC, Dana Point, CA, USA). Images were stored in JPEG format and saved on a computer USB
port. Clinical and dermoscopic datasets of each lesion together with relevant clinical information
(age, sex, tumour onset, location and participant history) were separately transmitted via a virtual
private network for online consultation
Nature of images used: clinical photographs and dermoscopic images
Any additional participant information provided: clinical examination or case notes (or both)
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relevant clinical information
Observer qualifications (remote diagnosis): dermatologist (board certified with clinical expertise
in TD and dermoscopy)
Diagnosis based on: single observe
Method of diagnosis: a board-certified dermatologist with clinical expertise in TD and dermoscopy
reviewed each set of clinical and dermoscopic images separately. The lesions were grouped into
4 diagnostic categories (benign melanocytic, benign non-melanocytic, malignant melanocytic and
malignant non-melanocytic skin tumours). The teleconsultant based on this then recorded 1primary
and 1 differential diagnosis
Target condition and reference
standard(s)
Reference standard: histological diagnosis and expert diagnosis
Details: histopathology was used as the gold standard in 78/104 (75%), including for 32/58 benign
lesions (55%). According to ethical principles and to the standards of routine practice, the clinical
and dermoscopic FTF diagnoses were considered adequate in those participants with clinically
and dermoscopically benign and non-suspicious lesions (i.e. 44% of benign group), and no biopsy
procedure was performed
Target condition (final diagnoses)
Malignant: melanoma (invasive): 2; melanoma (in situ): 1; BCC: 30; cSCC:10; lentigo maligna: 3
Benign: SK: 6; AK: 17; BD: 1; benign naevus: 15; other: soft tissue tumour: 4; angioma: 4; solar
lentigo: 3; virus-induced tumour: 1; trichilemmoma: 0; other: 7
Flow and timing • Excluded participants: 3 declined participation. In 33% of cases, no history could be
obtained. Clinical and 18 dermoscopic pictures were inadequate, so 104 tumours from 80
participants were included.
• Time interval to reference test: it does not state
• Time interval between index test(s): it reported there was a 1-month delay between clinical
and dermoscopic telederm picture evaluation
Comparative 1-month delay between FTF assessment and clinical and dermoscopic telederm evaluation
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
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Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test FTF diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than 1 month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Mahendran 2005
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: no dates, but over 18 months
Country: UK
Patient characteristics and set-
ting
Inclusion criteria: people with a suspicious skin lesion seen by their local GP, had a lesion worthy
of dermatologist assessment, willing to have photographic images taken of lesion, willing to see a
dermatologist outpatient
Setting: primary where participants were recruited; secondary (general dermatology): where final
diagnosis was made
Prior testing: clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: primary
Exclusion criteria: 15% poor-quality index test image
Sample size (participants): number included: unclear
Sample size (lesions): number included: 106
Participant characteristics: none reported
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Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images:GPs took images of suspicious skin lesions using a digital
camera (Nikon Coolpix 950 digital camera (1200 × 1600 pixel resolution), the photograph together
with all the relevant history and details about the skin lesion were sent via email to the dermatology
department
Nature of images used: clinical photographs
Any additional participant information provided: past history; dermographics, site of lesion
Observer qualifications (remote diagnosis): dermatologist (consultant dermatologists)
Diagnosis based on: single observer (diagnosis made by 1 of 2 consultants)
Method of diagnosis: the remote observer gave a diagnosis or differential diagnosis plus a hypo-
thetical management plan where possible
Management options:management options included reassuring the participant, minor operation,
no action but further review appointment required
Target condition and reference
standard(s)
Reference standard: expert diagnosis (FTF diagnosis at dermatology clinic)
Details: all participants were subsequently seen in dermatology outpatient clinic by 1 of the same 2
consultants within 2 weeks and the clinical diagnosis and actual management plan were recorded;
lesions also seen FTF by a trainee dermatologist (specialist registrar year 3) ’blinded’ to the consul-
tants’ reports but the 2×2 data appeared to be for the consultant FTF assessment
Target condition (final diagnoses)
Malignant: melanoma (invasive): 4; BCC: 37; cSCC 4
Benign diagnoses: AK: 10; BD: 7; lentigo maligna: 1; atypical dysplastic nevi: 6; SK: 27; BN: 20;
other: DF: 11; inflammatory dermatoses: 8; haemangioma: 3; scar: 3; viral wart: 3; cellular naevus:
2; chondrodermatitis nodularis helices: 2; congenital naevus: 2; dilated pore of Winer: 2; lesion
resolved: 2; squamous papilloma: 2; blue naevus: 1; halo naevus: 1; lichenoid keratosis: 1; myxoid
cyst: 1; pressure sore: 1; pyogenic granuloma: 1; sebaceous gland hyperplasia: 1
Flow and timing • Excluded participants: 57 ’excluded’ as could not be managed by TD and no FTF decision
given; either insufficient quality for assessment (24) or need to see in clinic to make a decision
• Time interval to reference test: within 2 weeks
• Time interval between index test(s): not stated
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Low Unclear
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
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For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Yes
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Yes
High
Manahan 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: Australia
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Manahan 2015 (Continued)
Patient characteristics and set-
ting
Inclusion criteria: participants aged 50-64 years at high risk of melanoma (fair skin type, previous
skin excisions, personal or family history) recruited via the ’QSkin’ study (500/43,794 participants
weremailed an invitation toparticipate; plus 59 volunteerswho requested participation after learning
about the study via university websites or in the local news. Only those with a suitable smartphone
could participate. Participants instructed to submit “photos of moles or spots that they ’did not
like the look of ’,” and were given instructions about how to select lesions based on asymmetry and
colour
Setting: community
Prior testing: none
Setting for prior testing: N/A
Exclusion criteria: no smartphone
Sample size (participants): 500 (invited) plus 58 volunteers; of the 230 who completed the ques-
tionnaire, the first 58 who expressed interest and had a suitable smartphone were enrolled. 50 at-
tended for FTF skin examination, 1 of whom was later excluded
Sample size (lesions): 341 lesions included; 309 with a primary TD diagnosis
Participant characteristics:
Age: 50-64 years
Gender: 49% male
Other: 31% with first-degree family member with melanoma and 90% self-reported a fair skin type
Lesion characteristics: back: 106 (34%); chest/abdomen: 57 (18%); legs: 56 (18%); arms: 46
(15%); head/neck: 44 (14%)
Index tests TD
Acquisition and transmission of images: study primarily aimed to evaluate skin self-examination
(participants randomised to receive 10-step guide to skin self-examination) and mobile TD. All
participants usedHandyscope FotoFinder dermoscope smartphone attachment (FotoFinder Systems
GmbH, Bad Birnbach, Germany) and Handyscope app, to obtain and send magnified lesion image
along with a second clinical (macro) image to verify the anatomical site of each skin lesion
Nature of images used: clinical and dermoscopic
Any additional participant information provided:
Diagnosis based on: single observer
Number of examiners: 1
Observer qualifications (remote diagnosis): board-certified dermatologist, experienced in TD
Method of diagnosis: unclear; method of viewing images NR. Dermatologist indicated whether
the photograph was suitable to provide a diagnosis before making management recommendation
Management options: primary diagnosis, with up to 2 differential diagnoses (cannot extract 2×2)
, and whether clinical skin examination (FTF) was required (action)
Target condition and reference
standard(s)
Reference standard: FTF expert diagnosis (referral accuracy)
Details: clinical skin examination performed by a dermatology registrar under supervision of the
dermatologist who undertook the telediagnosis. The samemanagement options were recommended
in the FTF consultation
Target condition (clinical diagnoses FTF)
Malignant: BCC: 13; SCC/IEC: 1
Benign: atypical naevus: 4; benign naevus: 165; solar lentigo: 22; SK: 81. Non-pigmented: AK: 34;
DF: 2; other: 18
Recommendation to see FTF (reference standard): 35
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Flow and timing Excluded participants: 8/58 participants did not attend for FTF examination; 1/58 without age
restriction; 32/341 lesions did not appear to have a primary TD diagnosis
Time interval to reference test: NR
Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
Massone 2014
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: February 2008 to February 2010
Country: Austria
Patient characteristics and set-
ting
Inclusion criteria: people undergoing health screening for a health insurance company at 3 pre-
ventive healthcare centres in Austria selected by GP for second-opinion teleconsulting as part of a
preventive medical screening programme
Setting: private care
Prior testing: clinical or dermatoscopic suspicion (or both)
Setting for prior testing: private care
Exclusion criteria: poor-quality index test image
Sample size (participants): number eligible: 112; number included: 30
Sample size (lesions): number eligible: 121; number included: 32
Participant characteristics:
Age: mean: 47; median: 47; range: 18-84 years
Gender: male: NR for the number of participants for whom data were presented only given the
overall number from eligible participants (642; 93%). Female: NR for the number of participants
for whom data were presented only given the overall number from eligible participants (48; 7%)
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: GPs screened patients and if they noted a suspicious
skin lesion then they acquired dermoscopic and if needed photographic images of the same skin
lesion. Photographic images were taken using a digital camera, with the addition of a polarised light
contact dermatoscope for the dermoscopic images (Canon Powershot digital camera (Canon Inc.
, Tokyo, Japan) and DermLite Photo; 3Gen LLC, San Juan Capistrano, CA, USA) adjusted from
MoleMax System (Derma Medical Systems, Vienna, Austria)). Images correlated by only age, sex
and location of the lesion were transmitted via a virtual private network for teleconsultation. No
personal participants’ data were transmitted
Nature of images used: clinical photographs and dermoscopic images
Any additional participant information provided: age, sex and location of the lesion
Diagnosis based on: single observer
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Number of examiners: 2
Observer qualifications (remote diagnosis): dermatologist (with high experience of dermoscopy)
Method of diagnosis: 1 of 2 dermatologists reviewed the images within 48 hours. First, they
reviewed the quality of images on a 3-point scale, ranging from excellent (1) to low quality (3).
Second, they assessed the lesion and grouped them into 1 of 4 groups: (1) benign melanocytic, (2)
malignant melanocytic, (3) benign non-melanocytic and (4) malignant NMLs and defined them
according to WHO guidelines
Management options: they also recorded management of the participant as follows, “(i) no further
treatment or FU in 3, 6 or 12 months interval in case of benign skin lesions, (ii) referral to a local
dermatologist for FTF examination in case of suspicious skin lesions and (iii) excision in case of
suspected malignancy.”
Target condition and reference
standard(s)
Reference standard: histological diagnosis plus FTF diagnosis/expert opinion
Details: people visiting the healthcare centres were coming from different towns of Austria therefore
no institutions were specifically recommended but the patients were free to select a dermatologist
of their choice for further assessment. No feedback was requested, it was possible to collect FU data
only for the participants referred to the department or who responded to a phone call or a letter.
Of these cases, only 19 had histology and 13 had an FTF expert assessment
Histology (not further described):number participants/lesions: 19; disease positive: 7; disease negative:
12
Expert opinion: number participants: 13; disease positive: 0; disease negative: 13
Target condition (final diagnoses)
Malignant: melanoma: 2, BCC: 5
Benign: dysplastic nevi: 11, SK: 4; other: angioma: porokeratosis: 1; AK: 1
Flow and timing • Excluded participants: it was possible to collect FU data only for the participants referred to
the department or who responded to a phone call or a letter. 112 participants were eligible as
attending the department of dermatology but of these 82 participants were lost to FU
• Time interval to reference test: NR
• Time interval between index test(s): NR
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
No
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Are the included patients and
chosen study setting appropri-
ate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
Yes
High Unclear
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
Unclear
99Teledermatology for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Massone 2014 (Continued)
enced histopathologist or by a
dermatopathologist?
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
Moreno Ramirez 2005
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective
Period of data collection: January to April 2004
Country: Spain
Patient characteristics and set-
ting
Inclusion criteria: people with pigmented, circumscribed lesions fulfilling ≥ 1 of the following
criteria: changing lesion (’ABCD changes’), recent lesion (< 3-year history), multiple lesions (> 20
MN counted by the GP), symptomatic lesion (pain, itching, bleeding) or concerned about moles.
Accuracy data reported only for those subsequently referred to the PLC and for whom pathology
results were available
Setting: specialist unit (skin cancer/pigmented lesions clinic)
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Prior testing:most likely clinical examination (the reasons for teleconsultationwere listed as concern
about moles; recent pigmented lesion; changing lesions; symptoms; multiple lesions)
Setting for prior testing: unspecified
Exclusion criteria: Excluded difficult to diagnose
Sample size (participants): number eligible: 219; number included: 108 referred to PLC, 57
participants included in the final analysis
Participant characteristics:
Age: mean: 43; range: 2-84 years
Gender: male: 77 (35%); female 142 (65%)
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: 2 digital pictures were taken by the GP using a digital
camera at a resolution of 1600×1200 pixels (Coolpix 4300, Nikon). A panoramic view of the lesion
area and a close up of the lesion were taken. Images were inserted into a word document with
relevant clinical information. This was transmitted via the intranet to an email account at the PLC
Nature of images used: clinical photographs
Any additional participant information provided: clinical examination or case notes (or both)
Diagnosis based on: unclear how many remote observers
Number of examiners: NR
Observer qualifications (remote diagnosis): dermatologist
Method of diagnosis: at the teleconsultation, observers classified the lesions as being, “benign
melanocytic naevus, multiple MN (>20 naevi as seen on teleconsultation), atypical naevus,7 con-
genital naevus, blue naevus, solar lentigo, lentigo maligna, melanoma, special melanocytic lesion
(genital naevus, acral naevus, recurrent naevus), seborrhoeic keratoses, basal cell carcinoma (BCC)
, DF, vascular lesion, non-pigmented lesion, or a ’difficult to diagnose’ lesion.” After evaluation of
the pictures and clinical information, a report was returned to the GP at the primary care centre,
with suggestions regarding the diagnosis and management of the case
Management options: limited to ’referral’ or ’non-referral’ of the participant to the FTF clinic.
Participants who had readily identifiable benign lesions such as benign melanocytic naevus, solar
lentigo, SK, DF, vascular lesions and non-pigmented lesions were not referred to the PLC. All other
remaining categories were routinely referred to the PLC for FTF assessment
Target condition and reference
standard(s)
Reference standard: histological diagnosis
Details: at the PLC, physical and dermoscopic examinations were carried out, as well as excisional
biopsy in suspicious or malignant cases, and FU of participants with risk factors for melanoma (16/
25 benign underwent histology)
Target condition (final diagnoses)
Melanoma (in situ): 1, BCC: 23; lentigo maligna: 3; dysplastic nevi: 16, common: nevi 8; blue nevi:
4
Flow and timing • Excluded participants: 13 difficult to diagnosis cases, plus 28 with ’malignant or suspicious
lesions’ were excluded from 2x2 tables
• Time interval to reference test: unclear - only mentioned, “Teleconsultation reports were sent
to the GP in a mean time of 44 h [hours] (range 2-96 h). Patients referred to the face-to-face clinic
were seen within the following two weeks (mean of 8 days, range 5-14). Dermatologists at the
PLC spent an average of 2.3 h per week in evaluating the teleconsultations received.”
• Time interval between index test(s): N/A
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Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
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Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
No
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
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for melanoma or cSCC or 6
months for BCC?
High
Oliveira 2002
Study characteristics
Patient sampling Study design: case series
Data collection: unclear but appeared prospective
Period of data collection: NR
Country: Brazil
Patient characteristics and set-
ting
Inclusion criteria: participants with suspect dermatological identified by an assistant nurse who
had undergone training to identify potentially malignant skin lesions. Only those who attended for
FTF assessment were included
Setting: primary care; Centro de Saúde Escola Geraldo de Paula Souza (primary care public health
service)
Prior testing: none
Setting for prior testing: N/A
Exclusion criteria: none reported
Sample size (participants): 103 eligible; 90 included
Sample size (lesions): 90
Participant characteristics: NR
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: lesions photographed in primary care by an assistant
nurse using a Kodak DC265 Zoom digital camera. 2 hours’ training in the use of the camera was
provided and included instruction on the installation of the camera’s software and transferring the
images to the computer. Images were sent by nurse with an electronic case report form and included
her diagnostic impression whether the lesion was non-malignant or malignant
Nature of images used: clinical
Any additional participant information provided: participant record
Diagnosis based on: single observer
Number of examiners: 1
Observer qualifications (remote diagnosis): dermatologist from the Department of Dermatology
of the Faculty of Medicine of the University of São Paulo
Method of diagnosis: not clearly described. All cases were assessed remotely by a dermatologist
prior to the in-person evaluation
Management options: malignant or benign; malignant diagnosis indicated biopsy needed
Target condition and reference
standard(s)
Reference standard: expert diagnosis (referral accuracy)
Details: within 1 week the same dermatologist saw the participant in-person. Participants were
referred for biopsy when skin cancer was the suspected diagnosis. The in-person assessments by the
dermatologist (and the biopsy results in a few cases) were used as reference
Target condition (FTF diagnoses)
Malignant: 8
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Benign: 82
Flow and timing Excluded participants: 2 lesions without a TD diagnosis
Time interval to reference test: 1 week from photographs being taken
Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Yes
Low Low
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
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Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Unclear
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
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If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
Phillips 1998
Study characteristics
Patient sampling Study design: case series
Data collection: NR but appeared prospective
Period of data collection: 1996
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: participants attending 4 skin cancer screenings at community hospitals in rural
eastern North Carolina, USA
Setting: community
Prior testing: none
Setting for prior testing: N/A
Exclusion criteria: none reported
Sample size (participants): 51
Sample size (lesions): 107
Participant characteristics:
Age: mean: 46.7 years
Gender: male: 8 (15.7%)
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: all sites were on a 1/2 T-1 link (786 kbs). All sites had
3 cameras available, each of which was used in evaluating the participants: a full-body camera, a
lens for viewing the lesions close up, and a magnifying lens that allowed even closer views as well as
examination with polarised light (CLI CODEC (Panasonic 3-chip or Canon 1-chip)). All monitors
offered 620 lines of resolution. It was not clear who operated the cameras during the teleconsul-
tations. The in-person evaluation was conducted first so that if a complete skin examination was
performed, representative lesions were selected by the on-site physician for evaluation by the remote
physician
Nature of images used: live link
Any additional participant information provided: physicians could communicate directly with
the participant
Diagnosis based on: single observer
Number of examiners: 2; each examiner was the on-site physician at 2 screenings and the “remote
physician” at 2 screenings
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Phillips 1998 (Continued)
Observer qualifications (remote diagnosis): dermatologist
Method of diagnosis: live link consultation; physicians could communicate directly with the study
participant
Management options:most likely diagnosis for a given lesion; the degree of concern that a specific
lesion was malignant; and recommendation as to whether to do a biopsy of the lesion
Target condition and reference
standard(s)
Reference standard: expert diagnosis (referral accuracy)
Details: all participants were first evaluated by the on-site physician. Participants were given a choice
of having a total body examination, only the sun-exposed skin, or a specific lesion(s) evaluated by the
on-site physician. This physician recorded specific lesions on an image of the human body and the
most likely diagnosis for a given lesion; the degree of concern that a specific lesion was malignant;
and recommendation as to whether to do a biopsy of the lesion. If a complete skin examination was
performed, representative lesions were selected by the on-site physician for evaluation by the remote
physician. The participant was subsequently seen by the remote dermatologist, and the same data
were recorded
Target condition (FTF diagnoses)
Malignant: BCC: 2; SCC: 3; lentigo maligna: 1
Benign: SK: 27; BN: 32; AK: 14; lentigo: 10; other: 30
Flow and timing Excluded participants: none described
Time interval to reference test: consecutive
Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Yes
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Phillips 1998 (Continued)
Unclear Low
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Unclear
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Phillips 1998 (Continued)
High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Low
Piccolo 2000
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: states 3 months but no specific dates given
Country: Austria (Graz)
Patient characteristics and set-
ting
Inclusion criteria: people with PSL selected because of their diagnostic difficulty and subsequently
excised for a histopathological evaluation
Setting: unspecified described as a multicentre study
Prior testing: lesions included in the study were selected because of their diagnostic difficulty; did
not specify what prior tests were done
Setting for prior testing: unspecified
Exclusion criteria: poor-quality index test image (all images scoring 4 were excluded from the
study)
Sample size (participants): number included: 40
Sample size (lesions): number included: 43
Participant characteristics:
Age: median: 39.5 years; range: 3-91 years
Gender: male: 21 (53%); female 19 (47%)
Lesion characteristics: site: face: 2; head: 1; neck: 1; trunk: 8; arms: 3; legs: 7; back: 20; buttocks:
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Piccolo 2000 (Continued)
1
Index tests In-person FTF clinical assessment
Method of diagnosis: all lesions were examined with a dermatoscope during the FTF clinical
diagnosis. Diagnosis wasmade by an expert dermatologist based on clinical features and dermoscopic
findings. No specific algorithm (e.g. the Stolz index) was used for dermoscopic diagnosis
Prior test data: unclear
Diagnostic threshold: NR
Diagnosis based on: single
Number of examiners: 1
Observer qualifications: dermatologist (an expert in the diagnosis of PSL)
Experience in practice: high
Experience with index test: high
TD
Acquisition and transmission of images: each image was acquired following the in-person consul-
tation with the digital camera at a fixed 10-fold magnification. 2 different lenses were used to capture
clinical and dermoscopic images (DCS 460, Kodak, Rochester, NY, USA), which used a Nikon
body (N90, Nikon, Tokyo, Japan); original image size 2036×3060 pixels in RGB colour mode (32
bit/pixel), then compressed to 511×768 pixels (24 bit/pixel). These were stored on a prototype TD
workstation and distributed to remote centres via email together with basic participant data (initials,
age, sex and site of the lesion)
Nature of images used: clinical photographs and dermoscopic images
Any additional participant information provided: participant data (initials, age, sex and site of
the lesion)
Diagnosis based on: single observer
Number of examiners: 11
Observer qualifications (remote diagnosis): dermatologists (6), residents in dermatology (2),
internist (1), GP (1), oncologist (1)
Experience in practice: not described
Experience with index test: mixed experience (low and high experience combined)
Method of diagnosis: NR
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: all lesions were excised for a histopathological evaluation
Target condition (final diagnoses)
Melanoma (in situ and invasive, or NR): 11; BCC: 3; SK: 2; benign naevus: melanocytic naevus:
23; ’benign’ diagnoses: angiokeratoma: 1; lentigines: 3
Flow and timing • Excluded participants: NR
• Time interval to reference test: NR
• Time interval between index test(s): NR
Comparative Remote observers received images via email
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test FTF diagnosis
112Teledermatology for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Piccolo 2000 (Continued)
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Unclear Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Unclear
DOMAIN 4: Flow and Timing
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Piccolo 2000 (Continued)
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Unclear
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Yes
Was the interval between ap-
plication of the index tests less
than 1 month?
Unclear
Were all tests applied and inter-
preted in a clinically applicable
manner?
No
Unclear High
Piccolo 2004
Study characteristics
Patient sampling Study design: case series
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: multicentre study participating centres were in Italy, Japan, Austria and Slovenia
Images used were from University of Graz, Austria and University of L’Aquila, Italy
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Piccolo 2004 (Continued)
Patient characteristics and set-
ting
Inclusion criteria: people with melanocytic acral lesions (71 commonMN and 6melanomas) from
73 people at the Department of Dermatology, University of Graz and Department of Dermatology,
University of L’Aquila
Setting: secondary
Prior testing: selected for excision (no further detail)
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (participants): number included: 73
Sample size (lesions): number included: 77
Participant characteristics:
Age: mean: 28 years; range: 4-77 years
Gender: male: 34; female 39
Lesion characteristics: site: 67 lesions located on lower extremities (58 on plantar surface, 4 on
external part of foot, 3 on toe, and 2 on dorsal aspect of foot) and 10 on upper extremities (8 on
palm and 2 on finger)
Index tests TD
Acquisition and transmission of images: dermoscopic images of 48 melanocytic acral lesions were
acquired at the Department of Dermatology, University of Graz, using the MoleMax II System
at 30× magnification. Dermoscopic photographs acquired with Heine Dermaphot equipment at
10× magnification were retrieved from the database of the Department of Dermatology, University
of L’Aquila images. All images in the study were compressed (to facilitate email transmission) at
the Department of Dermatology, University of L’Aquila. The images selected represented all the
acral lesions included in the databases of the 2 dermatology departments. photographic images
were not included. The dermoscopic images, together with the essential clinical data (age and sex
of participant and site of the lesion), were transmitted individually by email to 11 colleagues in 8
remote centres
Nature of images used: dermoscopic images
Any additional participant information provided: case notes
Diagnosis based on: single observer
Number of examiners: 11 dermatologists
Observer qualifications (remote diagnosis): dermatologist (varying experience from high to low
dependant on numbers of years of specialisation in PSL)
Method of diagnosis: images were analysed the images on a computer monitor by each observer,
first to diagnose acral melanoma or atypical lesions, and second to categorise the lesions according to
the Saida classification. An acral naevus was considered to be atypical when≥ 6 of the 11 observers
made this diagnosis
Management options: observers made a management recommendation of digital dermoscopy FU
or surgical excision
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: all lesions were surgically excised and histopathologically diagnosed by 2 dermatopatholo-
gists
Target condition (final diagnoses)
• Melanoma: 6 acral melanomas
• Benign naevus: 71 acral MN
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Piccolo 2004 (Continued)
Flow and timing • Excluded participants: none reported
• Time interval to reference test: NR
• Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
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Piccolo 2004 (Continued)
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Yes
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
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Piccolo 2004 (Continued)
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
Unclear
Shapiro 2004
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: 10 July 1998 to 4 August 2000
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: PCP referred only those people with skin growths that posed a true diagnostic
challenge
Setting: primary, recruitment of study participants from PCP (estimated 50% of PCP participants
had dermatological lesions that were encountered during routine evaluation and 3% present exclu-
sively for dermatological reasons). Private (FTF consultation with the local dermatologist in private
practice). Secondary care (images sent from PCP to academic dermatologist for SAF dermatological
consultation)
Prior testing: a network community PCP-recruited participants whom he judged to require der-
matological consultation for evaluation of a cutaneous growth
Setting for prior testing: primary
Exclusion criteria: people who underwent previous evaluation by a dermatologist
Sample size (participants): number eligible: 61; number included: 49
Sample size (lesions): NR
Participant characteristics: NR
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: images were acquired by the PCP using an Olympus D-
600L digital camera. The first image captured the head and upper trunk. This was followed by an
image of the affected body part. The image and a clinical history were downloaded to a personal
computer using a serial port interface and accompanying software. The image transmission was
performed via e-mail using HUPNet, a private encrypted University of Pennsylvania Health System
area network
Nature of images used: clinical photographs
Any additional participant information provided: clinical history
Observer qualifications (remote diagnosis): dermatologist (1) (academic dermatologist with over
20 years’ experience in clinical dermatology)
Diagnosis based on: single observer
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Shapiro 2004 (Continued)
Number of observers: 1
Method of diagnosis: the images were reviewed by the PCP immediately before they were sent
to a board certified academic dermatologist for teledermatological consultation. After assessing the
case, the teledermatologist notified the PCP of the diagnosis or differential diagnosis and indicate
on a standard data collection sheet whether a sampling biopsy was necessary. The reason for recom-
mending biopsy was specified as well
Management options: asked to choose a management plan from 15 entries including 3 biopsy
plans (to rule out malignancy, to establish a diagnosis or to remove a benign lesion for cosmetic
purposes)
Target condition and reference
standard(s)
FTF diagnosis as reference standard
Method of diagnosis: the participants were simultaneously scheduled for an FTF visit with the
local dermatologist, who is in private practice, within 1 month. The FTF dermatologist completed a
standardised consultation formnotifying the PCPof his decision regarding the diagnosis, differential
diagnosis and whether a biopsy was indicated. A biopsy was performed at that visit by the FTF
dermatologist if the FTF dermatologist or the SAF teledermatologist favoured biopsy of the lesion
Prior test data: the telediagnosis triage decision was contained in a sealed envelope which was
opened by the FTF dermatologist after making his decision. Biopsy was then carried out by the
FTF dermatologists if recommended by either dermatologist
Diagnostic threshold: not described
Diagnosis based on: single
Number of examiners: 1
Observer qualifications: dermatologist
Experience in practice: > 20 years of experience in clinical dermatology
Experience with index test: high
Target condition (for 26 lesions undergoing biopsy; 23 on dermatologist recommendation and 3
at participant request)
Malignant: BCC: 5; cSCC: 4
Benign: benign neoplasms: 17
Assumed benign (no biopsy): 23 (including 1 participant who refused biopsy)
Flow and timing • Excluded participants: 11 breached the study protocol and were not included in the analysis.
Of the latter 11, 4 failed to present to the FTF dermatologist, 4 saw a different FTF
dermatologist, 1 died of unrelated causes before seeing the FTF dermatologist, and 2 underwent
evaluation of different lesions by the SAF teledermatologist and FTF dermatologist.
• Time interval to reference test: participants were simultaneously scheduled for an FTF visit
with the local dermatologist, who was in private practice, within 1 month.
• Time interval between index test(s): N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Shapiro 2004 (Continued)
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
No
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Shapiro 2004 (Continued)
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Yes
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Yes
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
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Silveira 2014
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: April 2010 and July 2011
Country: Brazil
Patient characteristics and set-
ting
Inclusion criteria: people with skin lesions that were determined to be suspicious after a direct VI
by a physician. All of the patients examined at the MPU were previously screened by a nurse from
the local municipality who was trained at Barretos Cancer Hospital
Setting: community MPU
Prior testing: not described
Setting for prior testing: unspecified
Exclusion criteria: none reported
Sample size (lesions): number included: 416
Participant characteristics:
Age: mean: 63.5, range: 19-93 years
Gender: NR
Lesion characteristics: site: head and neck: 273 (75.0); trunk: 28 (7.6); upper limbs: 61 (16.7);
lower limbs: 2 (0.5); skin type scale: 1-2: 295 (81); 3-4: 69 (19); 5-6: 0 (0)
Index tests TD
Acquisition and transmission of images: community (participants were evaluated in the MPU,
and their lesions were photographed by the MPU physician using a digital camera, Sony Cybershot
DSC-5780 digital camera with 8.1-megapixel resolution)
Nature of images used: clinical photographs
Any additional participant information provided: information such as age, skin complexion,
location of the lesion, stage and pathology results were collected
Observer qualifications (remote diagnosis): oncologists at the Barretos Cancer Hospital; both the
oncologists and the MPU physician had more than 10 years of experience in skin cancer screening
Number of observers: 2
Diagnosis based on: single observer
Method of diagnosis: all digital images were coded, stored and submitted at random to 2 oncolo-
gists at Barretos Cancer Hospital, they were blinded to the MPU physician’s diagnosis and pathol-
ogy reports, and classified the images using the following options: malignant lesion, oncological
treatment is indicated; benign lesion, no treatment required; unknown or a low-quality image
Target condition and reference
standard(s)
Reference standard: histological diagnosis
Details: lesions classified as possibly malignant at the mobile unit were excised or biopsied
Target condition (final diagnoses)
• Melanoma: 5; BCC: 286; cSCC: 59; malignant other: 14
• Benign diagnosis: 52
Flow and timing Excluded participants: 21 (4.6%) were excluded from the study because of poor-quality pho-
tographs, leaving 439 participants with pathological results. 23/439 (5.2%) were excluded because
of incomplete data preventing the identification of the participant
Interval between reference standard and index test: appeared consecutive “lesions were imaged,
biopsied/removed and submitted for histopathological examination.” 364 (87.5%) were confirmed
to be malignant by the biopsy, 52 were diagnosed by expert opinion
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Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Are the included patients and
chosen study setting appropri-
ate?
Yes
Did the study avoid including
participants with multiple le-
sions?
Unclear
Unclear Unclear
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
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Silveira 2014 (Continued)
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Unclear
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
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for melanoma or cSCC or 6
months for BCC?
High
Warshaw 2010b
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: November 2002 to August 2005
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: people enrolled at the Department of VA dermatology clinic who required (or
requested) removal of ≥ 1 skin neoplasms (’high-risk group’) and participants who were referred
to general dermatology clinic by non-dermatology healthcare providers for evaluation of a skin
neoplasm (lower-risk group). Biopsied lesions only were included. Warshaw 2009 and Warshaw
2009a included data for participants primary lesions only whereas Warshaw 2010 includes all
biopsied lesions, pigmented or non-pigmented, from histopathologic lesion categories with ≥ 5
lesions
Setting: secondary (general dermatology)
Prior testing: selected for excision (no further detail)
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: individuals requesting or referred for skin tag removal only or with papulosqua-
mous or eczematous conditions (non-neoplastic), previous biopsy of the lesion and inability to
comprehend and give informed consent
Sample size (participants): number eligible: 2152; number included: NR
Sample size (lesions): number eligible: 3021 enrolled; 1685 biopsied and eligible for inclusion;
number included: 1514
Age: mean: pigmented: 66; non-pigmented: 71; range: pigmented: 23-94; non-pigmented: 21-94
years
Gender: male: pigmented: 519 (95.8%); non-pigmented: 712 (97.8%)
Race/ethnicity: white: pigmented: 97.1%; non-pigmented: 98.9%; black or African-American:
pigmented: 1.3%; non-pigmented: 0.7%; other: pigmented: 1.5%; non-pigmented: 0.4%
High-risk characteristics
• History of melanoma: pigmented: 34 (6.3%); non-pigmented: 16 (2.2%)
• History of non-melanoma skin cancer: pigmented: 147 (27.1%); non-pigmented: 260 (35.
7%)
Lesion characteristics
• Clinical characteristics (appearance)
• Non-pigmented (%): for index lesions only (1270): 728 (57.3%)
• Other: pigmented: 19.4% size change, 16.6% itching, 9.6% bleeding; non-pigmented: 32.
1% size change, 23.9% itching, 26.6% bleeding
Lesion site
• Head/neck: pigmented: 38.2%; non-pigmented: 70.1%
• Trunk: pigmented: 24.2%; non-pigmented: 13.9%
• Upper limbs/shoulder: pigmented: 31.2%; non-pigmented: 12.0%
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Warshaw 2010b (Continued)
• Lower limbs/hip: pigmented: 5.7%; non-pigmented: 3.0%
• Buttock/groin: pigmented: 0.7%; non-pigmented: 1.1%
Index tests In-person assessment
Method of diagnosis: VI ± use of dermoscopy (“the clinical examination could include all options
normally available in the clinical setting (e.g., palpation, diascopy, dermatoscopy”)
Prior test data: selected for excision (no further detail)
Diagnostic threshold: qualitative (recorded primary diagnosis and up to 2 differential diagnoses,
plus a choice of 4 basic management plans (remove/biopsy/destroy, observe/reassure, antifungal
treatment, antibiotic treatment, anti-inflammatory treatment)
Primary diagnosis: clinicians had a choice of 17 common diagnoses for 1 primary and 1 or 2
differential diagnoses
Diagnosis based on: single observer
Number of examiners: 11 staff dermatologists
Observer qualifications: dermatologist
Experience in practice: not described
Experience with index test: not described
TD
Acquisition and transmission of images: the standard method used in most TD settings at the
onset of the study, and PLD images were obtained for each lesion following in-person consultation.
2 macro images (distance and close-up; digital Nikon Coolpix 4500 with a Nikon SL-1 ring flash
(Nikon, Melville, NY)) were obtained of each lesion. In addition, for lesions > 2 mm in height,
a macro angle (approximately 908 from the skin surface) was also taken. 1 PLD (digital Nikon
Coolpix 4500 with a 3Gen DermLite lens attachment) was also obtained. Dermoscopy images
taken and accuracy reported but insufficient data obtained from authors to allow their inclusion in
this review. Dermoscopy images unlikely to have influenced macro image interpretation as macro
images (photographs) alone and macro images plus dermoscopic images were interpreted two weeks
apart
Nature of images used: clinical photographs
Any additional participant information provided: clinical examination or case notes (the stan-
dardised participant and lesion history collected by the research assistants), or both
Observer qualifications (remote diagnosis): dermatologist (with > 5 years’ experience and recog-
nised PSL expert)
Diagnosis based on: single observer
Number of observers: 3
Method of diagnosis: using the same diagnostic and management categories as used by clinic
dermatologists, the teledermatologists recorded 1 primary diagnosis, up to 2 differential diagnoses,
and a management plan for each lesion
Target condition and reference
standard(s)
Histological reference standard: a board-certified dermatopathologist who was not involved with
any clinic assessments coded all histopathological diagnoses based on the pathology report
Number of participants/lesions: 1514
Target condition
Malignant: melanoma: 41; BCC: 410; cSCC: 240
Benign: ’benign’ diagnoses: benign keratoses: 223; dysplastic nevi: 154; actinic keratoses: 145; be-
nign nevi: 138; cysts: 73; benign appendageal tumours: 35; lentigines: 29; benign vascular neo-
plasms: 26
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Flow and timing Excluded participants: histopathologic categories with < 25 lesions (171)
Time interval to reference test: participants (from the VA clinic) were scheduled for a research
appointment before, but on the same day as, their dermatology clinic consult appointment. But
timing to histology NR. Participants from the general dermatology clinic undergoing a biopsy for
a skin neoplasm (because of physician recommendation or participant request) were also invited to
participate. Likely that photographs taken on same day as excision but again NR as such
Time interval between index test(s): immediate; photographs taken on day of FTF appointment
Comparative -
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 2: Index Test FTF diagnosis
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Unclear
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
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For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Yes
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
Unclear
Was the interval between ap-
plication of the index tests less
than 1 month?
Unclear
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Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Unclear Low
Wolf 2013
Study characteristics
Patient sampling Study design: case control
Data collection: retrospective image selection/prospective interpretation
Period of data collection: NR
Country: USA
Patient characteristics and set-
ting
Inclusion criteria: people with pigmented lesions that were considered atypical in clinical appear-
ance by ≥ 1 dermatologist and for which a clear histological diagnosis had been rendered by a
board-certified dermatopathologist. Images selected from image database in following categories:
categories: invasive melanoma, MiS, lentigo, benign nevus (including compound, junctional and
low-grade dysplastic nevi), DF, SK and haemangioma. Sampling not described
Setting: unspecified
Prior testing: selected for excision (no further detail)
Setting for prior testing: unspecified
Exclusion criteria: poor-quality index test image. Images that contained any identifiable features,
such as facial features, tattoos or labels with participant information were excluded or cropped to
remove the identifiable features or information. Lesionswith equivocal diagnoses, such as “melanoma
cannot be ruled out” or “atypical melanocytic proliferation,” were excluded, as were SN, pigmented
spindle cell nevus of Reed, other uncommon or equivocal lesions, and lesions with moderate- or
high-grade atypia
Sample size (participants): NR
Sample size (lesions): 188
Participant characteristics: NR
Lesion characteristics: NR
Index tests TD
Acquisition and transmission of images: the images of skin lesions were selected from a database
of images that are captured routinely before skin lesion removal to allow clinicopathological corre-
lation in making medical management decisions. Only used close-up images of lesions and those
that contained any identifiable features, such as facial features, tattoos or labels with participant
information, were excluded or cropped to remove the identifiable features or information
Nature of images used: photographic images
Any additional participant information provided: no further information used
Method of diagnosis: application run on a smartphone sent each image to a board-certified derma-
tologist for evaluation, and assessment that was returned to the user within 24 hours. The identity
of the dermatologist was not given, and it was unclear whether all the images were read by the same
dermatologist or by several different dermatologists. The output given was “atypical,” which was
considered to be a positive test result, or “typical,” which was considered to be a negative test result
Diagnosis based on: unclear how many observers
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Number of examiners: unclear
Observer qualifications (remote diagnosis): board-certified dermatologist
Experience in practice: unclear
Experience with index test: unclear
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: histology (not further described)
Target condition (final diagnoses)
Malignant: melanoma (in situ and invasive): 60
Benign: ’benign’ diagnoses: 128
Flow and timing • Excluded participants: authors reviewed 390 images for possible inclusion in this study.
Excluded 202 as being of poor image quality, containing identifiable participant information or
features, or lacking sufficient clinical or histological information.
• Time interval to reference test: N/A
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
Are the included patients and
chosen study setting appropri-
ate?
No
Did the study avoid including
participants with multiple le-
sions?
Unclear
High High
DOMAIN 2: Index Test Teledermatology
Were the index test results in-
terpreted without knowledge of
Yes
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the results of the reference stan-
dard?
If a threshold was used, was it
pre-specified?
Yes
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low High
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
For studies comparing TD/
FTF clinical diagnosis to his-
tology, was histology interpre-
tation carried out by an experi-
enced histopathologist or by a
dermatopathologist?
Unclear
For studies comparing TD to
FTF diagnosis, was the clinical
diagnosis carried out by an ex-
perienced observer?
Low Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
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Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical FU of border-
line/benign appearing lesions,
was there a minimum FU fol-
lowing application of index
test(s) of at least: 3 months
for melanoma or cSCC or 6
months for BCC?
High
ABCD(E): asymmetry, border, colour, differential structures (enlargement); AK: actinic keratosis; AMN: atypical melanocytic naevi;
BCC: basal cell carcinoma; BD: Bowen’s disease; BN: benign naevi; cSCC: cutaneous squamous cell carcinoma; DF: dermatofi-
broma; FTF: face-to-face; FU: follow-up; GP: general practitioner; IEC: intraepithelial carcinoma; MM: malignant melanoma; MiS:
melanoma in situ (or lentigo maligna); MN: melanocytic naevi; MPU: Mobile Prevention Unit; N/A: not applicable; NML: non-
melanocytic lesion; NMSC: non-melanoma skin cancer; NR: not reported; PCP: primary care provider; PLC: pigmented lesion
clinic; PLD: polarised light dermoscopy; PSL: pigmented skin lesion; SAF: safe-and-forward; SCC: squamous cell carcinoma; SK:
seborrhoeic keratosis; SN: Spitz nevi; TD: teledermatology; VA: Veteran Affairs; VI: visual inspection; VLC: virtual lesion clinic;
WHO: World Health Organization; WPC: within-person comparison (of tests).
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Armstrong 2007 Exclude not a primary study
Baba 2005 Exclude on study population
Badertscher 2015 Exclude on 2×2 data; for VI/Derm - only gave number of correct diagnoses (not broken down by TP/TN)
and gives GP ’score’ between T0 and T1
Exclude on index test - not a teledermatology study
Barnard 2000 Exclude on target condition; the primary target condition was not relevant to our reviews
Bashshur 2015 Exclude not a primary study; narrative review
Bataille 2011 Exclude conference abstract
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Bergmo 2000 Exclude not a primary study
Borve 2013 Exclude on target condition; included 1 melanoma metastases and 1 in situ SCC as D+ (these made up
5% of malignant group); author contacted (“Table 2 provided estimates of the diagnostic accuracy of the
face-to-face dermatologist and the two teledermoscopists, however in order to include the results in our
review we would need the underlying 2×2 contingency tables for these statistics. Is it at all possible for you
to provide us with them for each observer, particularly in regard to the ’Primary diagnosis’ and the ’Benign
vs malignant”’)
Boyce 2011 Exclude on study population; no breakdown given, just 7 suspicious lesions
Exclude on reference standard; no data given but only 7 referred on for formal assessment. Definitely <
50% histology rate
Braun 2000 Exclude on 2×2 data
Exclude but contacted authors. Sensitivty was reported in Table II but specificity unclear. Study reports %
of correct identification of each lesion type rather than FPs and does not provide numbers misclassified as
melanoma, or other malignancy. Also possibility of overlap with later publications, e.g. Coras 2003
Brown 2000 Exclude not a primary study
Burgiss 1997 Exclude on reference standard reports actions on telediagnosis (primarily for cost purposes) and did not
give final diagnoses (histo) or FTF diagnosis for all lesions
Chen 2002 Exclude on sample size
Study was based on individual participant images (< 5 cases). Only 4 lesions in total used in study (1 non-
BCC, 1 SK, 1 KA, 1 AK)
D’Elia 2007 Exclude on study population; not focused on suspected skin cancer
Exclude on 2×2 data; looked at agreement between diagnoses only
Di Stefani 2007 Exclude on sample size; < 5malignant: of 7 excised: 1melanoma (MiS associated with a nevus), 1 pigmented
BCC and 5 melanocytic nevi. Both tele-dx recommended the 2 malignancies for excision but no further
breakdown of agreement/disagreement given
Exclude on 2×2 data 7 ’D+’ according to FTF decision to excise but only reports kappa values for agreement
with tele-dx
Du Moulin 2003 Exclude on study population
Exclude on target condition
Edison 2008 Exclude on study population
Eminovic 2009 Exclude, not a primary study
Exclude on study population
Exclude on target condition
Fabbrocini 2008 Exclude on 2×2 data; there was insufficient data provided for each index test to populate 2×2 table
Exclude but contacted authors: “As we can only include DTA studies - do you have a cross tabulation of
each clinician’s diagnosis (e.g. at threshold of >=3 on 7 point checklist) against the histological diagnosis
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and/or a cross tabulation of the remote diagnosis against the Face to Face diagnoses?”
Ferrandiz 2007 Exclude on study population; all had a strong clinical diagnosis of NMSC or fast-growing tumour, the
purpose of the test was primarily to inform treatment plans
Exclude on 2×2 data; 4 of the original 134 appeared to have missing histology and did not know what the
additional clinical cases of each lesion were classed as on histology, e.g. the 14 extra BCCs and 5 KAs
Ferrandiz 2012 Exclude on target condition; on included CM
Gilmour 1998 Exclude on study population
Exclude on target condition
Granlund 2003 Exclude on study population
Griffiths 2010 Exclude on reference standard
Harrison 1998 Exclude on target condition, no breakdown of final diagnoses (histo) or of recommendations from FTF
consultation
Exclude on sample size; could not determine how many D+ for either reference standard
Exclude on 2×2 data; no underlying data provided; diagnostic ’accuracy’ of teleconsultation reported as
71% for 210 participants compared to 49% for the referring GPs (49%). Also stated that “telemedicine was
able to detect malignancies in 94% of cases compared with only 70% detected by general practitioners.”
Heffner 2009 Exclude on target condition
Hicks 2003 Exclude not a primary study
High 2000 Exclude on study population; not all suspected of skin cancer ’dermatological conditions’ including der-
matitis, acne, verruca, etc
Exclude on 2×2 data; reported agreement only; no breakdown of diagnoses/management decisions
Exclude on reference standard; table of final diagnoses appeared to be based on FTF diagnoses with histology
obtained for 69/106 (65%), so was ineligible for a tele-dx vs histo comparison (diagnostic accuracy) and is
not tele-dx vs FTF (referral accuracy) either
Hue 2016 Exclude on reference standard; final diagnoses/FTF decisions given only for 17 recommended for rapid
referral on tele-dx; no data for remaining 395 with non-urgent derm referral/annual FU recommendation/
discharge
Exclude on sample size; for tele-dx vs histo, only 5 excised included 1 melanoma
Exclude on 2×2; no data for tele-dx vs FTF
Hwang 2014 Exclude on study population
Ishioka 2009 Exclude on target condition
No breakdown of disease positive ’malignant’ provided
Kahn 2013 Exclude on target condition
Knol 2006 Exclude on study population
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Krupinski 1999 Exclude on 2×2 data; reported only diagnostic concordance/agreement
Lamel 2012 Exclude on 2×2 data; reported only summary concordance in diagnosis and management decisions between
decisions based on mobile phone image and in person; insufficient detail to work out referral accuracy
Exclude but contacted authors,“Study presents data on diagnostic and management concordance between
in person and remote (via mobile phone app) diagnoses, are any diagnostic accuracy data available, e.g.
observers diagnosis of malignant lesion when assessed remotely versus FtF diagnosis of malignancy?”
Lamminen 2000 Exclude not a primary study
Lesher 1998 Exclude on study population; included people with ’skin problems’ (included wide range of diagnoses)
Exclude on sample size; could extract referral accuracy (tele-dx vs FTF) but only 4 lesions with malignant
diagnosis on FTF (4 BCCs)
Lewis 1999 Exclude on 2×2 data; study appeared tomeet all eligibility criteria but disease prevalence not given alongside
sensitivity/specificity
Exclude but contacted authors: “(Sensitivity and specificity of remote diagnosis in comparison to FtF
diagnosis are provided but we would need number D+ in order to complete 2×2 table).”
Loane 1998a Exclude on study population
Loane 1998b Exclude not a primary study
Loane 2000 Exclude on study population; not focused on potentially malignant skin lesions; could not derive any
comparative data for detection of ’tumours’
Loane 2001a Exclude not a primary study
Loane 2001b Exclude on study population
Lowitt 1998 Exclude on study population
Lyon 1997 Exclude on 2×2 data: for operative referrals, only histo diagnosis given with overall number of disagreements
by FTF and tele-dx; no clear breakdown of index test results to derive 2×2
Exclude on study population; not all suspected of skin cancer
Martinez-Garcia 2007 Exclude on 2×2 data; not test accuracy
Exclude on reference standard; no reference standard reported; describes only tele-dx
Massone 2007 Exclude on reference standard; did not meet our criteria for diagnostic accuracy reference standard (only
12/25 (48%) of benign group with histo, including 1 AK as benign instead of malignant); and data not
presented to allow extraction of referral accuracy (tele-dx vs FTF) (included 955 lesions and reported tele-
dx recommendations for all 955; 121 were recommended for excision or for FTF consult but FU data only
available for 32 of these (19 with histo dx and 13 with FTF diagnosis))
Exclude on 2×2 data; data not clearly presented to allow extraction of referral accuracy (tele-dx vs FTF
alone); could only extract tele-dx vs FTF diagnosis of malignancy if we assume that all 7 malignant lesions
were diagnosed as such by FTF; from table 2 we only know that all 7 were excised presumably following
FTF consult
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May 2008 Exclude on 2×2 data: no data for a 2×2 table
Exclude on index test; effect on consultant priority of GP referral with photograph vs referral with no
accompanying photograph
McGraw 2009 Exclude on study population
McManus 2008 Exclude on study population
Moreno-Ramirez 2006 Exclude on sample size; comparison is tele-dx vs final diagnosis (58/61 were biopsied); only 1 melanoma
and 2 BCC
Moreno-Ramirez 2007 Exclude on reference standard: did not meet either criteria for eligible reference standard. Table 1 cross-
tabulates the telediagnosis (refer/not refer) against a gold standard which appeared to be a combination of
the FTF diagnosis (for those with clinically and dermoscopically benign and non-suspicious lesions, and
with a diagnostic confidence level of 3 after the FTF diagnosis) and histology (those with higher concern
at FTF evaluation were excised)
Moreno-Ramirez 2009 Exclude on study population
Exclude on reference standard
Ndegwa 2010 Exclude not a primary study; technology report
Nordal 2001 Exclude on study population
Exclude on target condition
Oakley 1997 Exclude on study population
Exclude on target condition
Oakley 2006 Exclude on 2×2 data; insufficient data presented
Exclude but contacted authors, “We are looking to compare telederm dx with FtF diagnosis within a
diagnostic accuracy framework (i.e. in a 2×2 contingency table) but in order to include your paper we would
need information on the misdiagnoses. Using the FtF diagnosis as the gold standard, we can use the data
in Table 2 to derive the ’sensitivity’ of the tele-Dx agreement for diagnosis of melanoma, BCC and SCC
(%agreement), but we would need to know the % of tele-dx reports that ’misdiagnosed’ the other lesion
types as malignant in order to derive ’specificity’. Would you be at all able to supply this data?
We could use the data in Table 6 to cross-tabulate the management decisions between the two approaches, if we
collapse the tele-Dx cat3 and cat4 groups together. However the % agreement for the teledermatology classification
adds to greater than 100.”
Oztas 2004 Exclude on study population
Exclude on target condition
Pak 1999 Exclude not a primary study; review of service
Pak 2002 Exclude conference abstract; no full text paper found
Pak 2003a Exclude on study population
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Pak 2003b Exclude on study population
Pak 2007 Exclude on reference standard; reference standard not clear
Pak 2009 Exclude not a primary study
Patro 2015 Exclude on target condition
Perednia 1998 Exclude on study population; not all suspected of skin cancer
Exclude on index test; not an evaluation of accuracy of teledermatology but of effect of access to telemedicine
on GP confidence and referral decisions
Phillips 1997 Exclude on sample size; 68 lesions; FTF diagnosis of 4 skin cancers (tele- and FTF diagnoses concordant for
1 melanoma and 2 BCC; FTF dx of 1 additional SCC in 1 further participant); no final diagnoses (histo)
recorded
Exclude on 2×2 data; presents agreement between observers only
Exclude on study population; not all suspected of skin cancer
Piccolo 1999 Exclude on 2×2 data; reports data for tele-dx, FTF and histo; breakdown of discordant results between tele-
dx vs FTF and tele-dx vs histo is given but only gives number (%) concordant; did not give number TP
and TN to allow 2×2 to be estimated for either comparison
Piccolo 2002 Exclude not a primary study; review article
Rashid 2003 Exclude on study population
Ribas 2010 Exclude on study population
Romero 2010 Exclude on study population
Romero 2014 Exclude on study population
Seidenari 2004 Exclude on 2×2 data; no data to populate 2×2 table just ROC curve values given
Exclude but contacted authors, “TABLE 5 provides AUC values for each diagnosis for both formats and
observers; requested data in 2×2 format, e.g. formelanoma ’certain’ against final diagnosis and formelanoma
’certain or fairly certain’ against final diagnosis?”
Senel 2013 Exclude on 2×2 data; no accuracy data available. For teledermatology it looks like they only gave the % of
correct diagnoses (Table 6) per dermatologist but give no breakdown by disease positive/negative so could
not work out 2×2 data
Shin 2014 Exclude on target condition
Tait 1999 Exclude on study population; not all suspected of skin cancer ’people with visible skin lesion or lesions’
(wide range in diagnoses recorded)
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Tan 2010a Exclude on reference standard; no reference standard described
Exclude on 2×2 data; not test accuracy; reported agreement between 5 dermatologists’ telediagnosis, not
against histology or FTF diagnosis
Tan 2010b Exclude on 2×2 data; study appeared tomeet eligibility criteria; however, although sensitivity and specificity
values were provided in Table 4 per dermatologist, it was not possible to work back to the underlying
2×2 (final diagnoses by histopath not given and FTF diagnoses for the same 491 lesions differ in Table 1
according to dermatologist A and dermatologist B)
Tandjung 2015 Exclude on target condition; ’malignant’ included: AK, BD, dysplastic nevus, lentigo maligna, SCC, BCC,
MM and KA
Exclude on index test; GPs sent images for teledermatology opinion; then free to send for biopsy or not;
results shown were only for those that were biopsied, according to teledermatology advice
Taylor 2001 Exclude on study population; not all suspected of skin cancer; wide variety of conditions included
Exclude on 2×2 data; reported % agreement only
Tucker 2005 Exclude on target condition; no breakdown of either final diagnoses or tele-dx
Exclude on 2×2 data; reports agreement only
Exclude on study population; not all suspected of skin cancer
van der Heijden 2013 Exclude on 2×2 data; only reported Kappa values for histology vs FTF and histology vs tele-dx (for each of
4 teledermatologists) but no underlying data given
Vano-Galvan 2011 Exclude on study population: not specific to skin cancer, population included infectious disease and in-
flammatory disease
Exclude on 2×2 data; only gives % agreement between tele-dx and FTF (gold standard)
Warshaw 2009a Exclude on 2×2 data; only reports accuracy
Exclude duplicate or related publication; author contacted in regard to 2010 paper
Exclude but contact author. Study presented diagnostic accuracy of teledermatology and clinic diagnosis in
comparison to histopathology; in order to include in our review, data would need to be presented as a 2×2
contingency table, either per type of malignancy e.g. tele-dx classification of melanoma vs not melanoma
against histological diagnosis of melanoma/not melanoma, or with malignant diagnoses grouped together,
i.e. tele-dx of malignancy vs not malignant against same histological breakdown. Requested these data for
the clinic diagnosis and for each method of telediagnosis for this study and for Warshaw 2009b.
**Author provided some data for detection of melanoma only and for use of macro images only for 2010
paper (pigmented and non-pigmented lesion combined)
Warshaw 2009b Exclude on 2×2 data; only reports accuracy
Exclude duplicate or related publication
Exclude but contact author. See Warshaw 2009a
Warshaw 2010a Exclude on 2×2 data; not test accuracy; interobserver agreement for subsample ofWarshaw 2009a/Warshaw
2010b trial
Warshaw 2015 Exclude on 2×2 data; only gives agreement between teledermatology diagnosis and FTF diagnosis
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Watson 2010 Exclude on target condition
Weingast 2013 Exclude on study population
Weinstock 2002 Exclude not a primary study
Weinstock 2009 Exclude not a primary study
Whited 1999 Exclude on 2×2 data; only gave % agreement between tele-dx and FTF and % correct diagnoses of tele-dx
vs histo
Whited 2002 Exclude not a primary study
Whited 2003 Exclude not a primary study
Whited 2004 Exclude not a primary study
Whited 2006 Exclude not a primary study; review article
Whited 2010 Exclude not a primary study
Whited 2016 Exclude not a primary study
Williams 2001 Exclude not a primary study
Williams 2007 Exclude not a primary study
Wootton 2000 Exclude on study population
Exclude on target condition
Zelickson 1997 Exclude on study population
AK: actinic keratosis; AUC: area under curve; BCC: basal cell carcinoma; BD: Bowen’s disease; CM: cutaneous melanoma; D+:
disease positive; Derm: dermoscopy; DTA: Diagnostic Test Accuracy; Dx: diagnosis; FP: false positives; FTF: face-to-face; FU:
follow-up; GP: general practitioner; histo: histology; KA: keratoacanthoma; MM: malignant melanoma; MiS: melanoma in situ (or
lentigo maligna); NMSC: non-melanoma skin cancer; ROC: receiver operating characteristic; SCC: squamous cell carcinoma; SK:
seborrhoeic keratosis; tele-Dx: teledermatology diagnosis; TP: true positive; TN: true negative; VI: visual inspection.
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Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Teledermatology - photographic
image vs histology (any)
4 717
2 Teledermatology - dermoscopic
image vs histology (any)
1 104
3 Teledermatology - photographic
+ dermoscopic image vs
histology (any)
3 871
4 Expert face-to-face (visual
inspection (VI) + dermoscopy)
vs histology (any)
2 248
5 Teledermatology - photographic
image vs histology (invasive
melanoma or atypical
intraepidermal melanocytic
variantsi)
4 1834
6 Teledermatology - dermoscopic
image vs histology (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
2 116
7 Teledermatology photographic +
dermoscopic image vs histology
(invasive melanoma or atypical
intraepidermal melanocytic
variants)
4 664
8 Expert face-to-face (VI +
dermoscopy) (invasive
melanoma or atypical
intraepidermal melanocytic
variants)
3 1663
9 Teledermatology - photographic
+ dermoscopic image vs
histology (invasive melanoma)
1 43
10 Expert face-to-face (VI +
dermoscopy) vs histology
(invasive melanoma)
1 43
11 Teledermatology - dermoscopic
image vs histology (acral
melanoma)
1 77
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12Teledermatology - photographic
image vs histology (basal cell
carcinoma (BCC))
3 301
13 Teledermatology - dermoscopic
image vs histology (BCC)
1 104
14Teledermatology - photographic
+ dermoscopic image vs
histology (BCC)
1 256
15 Expert face-to-face (VI +
dermoscopy) vs histology
(BCC)
2 248
16Teledermatology - photographic
image vs histology (cutaneous
squamous cell carcinoma
(cSCC))
1 104
17 Teledermatology - dermoscopic
image vs histology (cSCC)
1 104
18 Expert face-to-face (VI +
dermoscopy) vs histology
(cSCC)
1 104
19Teledermatology - photographic
image vs face-to-face clinical
diagnosis (immediate action)
3 951
20Teledermatology - photographic
image vs face-to-face clinical
diagnosis (of malignancy)
1 90
21Teledermatology - photographic
image vs face-to-face clinical
diagnosis (immediate action or
follow-up)
1 106
22Teledermatology - photographic
image vs face-to-face clinical
diagnosis (immediate action;
registrar data)
1 796
23 Teledermatology -
photographic/dermoscopic
image vs face-to-face clinical
diagnosis (immediate action)
1 301
24 Teledermatology - live link vs
face-to-face clinical diagnosis
(diagnosis of any skin cancer)
1 107
25 Teledermatology - live link vs
face-to-face clinical diagnosis
(definitely/probably malignant)
1 107
26 Teledermatology - live link vs
face-to-face clinical diagnosis
(biopsy decision)
1 107
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Test 1. Teledermatology - photographic image vs histology (any).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 1 Teledermatology photographic image vs histology (any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jolliffe 2001a 13 9 0 118 1.00 [ 0.75, 1.00 ] 0.93 [ 0.87, 0.97 ]
Kroemer 2011 43 7 3 51 0.93 [ 0.82, 0.99 ] 0.88 [ 0.77, 0.95 ]
Moreno Ramirez 2005 27 1 2 27 0.93 [ 0.77, 0.99 ] 0.96 [ 0.82, 1.00 ]
Silveira 2014 350 39 14 13 0.96 [ 0.94, 0.98 ] 0.25 [ 0.14, 0.39 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 2. Teledermatology - dermoscopic image vs histology (any).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 2 Teledermatology dermoscopic image vs histology (any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kroemer 2011 39 5 7 53 0.85 [ 0.71, 0.94 ] 0.91 [ 0.81, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 3. Teledermatology - photographic + dermoscopic image vs histology (any).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 3 Teledermatology photographic + dermoscopic image vs histology (any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Arzberger 2016 11 9 0 3 1.00 [ 0.72, 1.00 ] 0.25 [ 0.05, 0.57 ]
Borve 2015 168 302 0 346 1.00 [ 0.98, 1.00 ] 0.53 [ 0.49, 0.57 ]
Massone 2014 7 2 0 23 1.00 [ 0.59, 1.00 ] 0.92 [ 0.74, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 4. Expert face-to-face (visual inspection (VI) + dermoscopy) vs histology (any).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 4 Expert face-to-face (visual inspection (VI) + dermoscopy) vs histology (any)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jolliffe 2001a 13 7 0 124 1.00 [ 0.75, 1.00 ] 0.95 [ 0.89, 0.98 ]
Kroemer 2011 46 6 0 52 1.00 [ 0.92, 1.00 ] 0.90 [ 0.79, 0.96 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. Teledermatology - photographic image vs histology (invasive melanoma or atypical intraepidermal
melanocytic variantsi).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 5 Teledermatology photographic image vs histology (invasive melanoma or atypical intraepidermal melanocytic variantsi)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kroemer 2011 5 2 0 97 1.00 [ 0.48, 1.00 ] 0.98 [ 0.93, 1.00 ]
Moreno Ramirez 2005 5 0 1 51 0.83 [ 0.36, 1.00 ] 1.00 [ 0.93, 1.00 ]
Warshaw 2010b 24 869 17 604 0.59 [ 0.42, 0.74 ] 0.41 [ 0.38, 0.44 ]
Wolf 2013 53 73 1 32 0.98 [ 0.90, 1.00 ] 0.30 [ 0.22, 0.40 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. Teledermatology - dermoscopic image vs histology (invasive melanoma or atypical intraepidermal
melanocytic variants).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 6 Teledermatology dermoscopic image vs histology (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ferrara 2004 5 2 2 3 0.71 [ 0.29, 0.96 ] 0.60 [ 0.15, 0.95 ]
Kroemer 2011 5 3 0 96 1.00 [ 0.48, 1.00 ] 0.97 [ 0.91, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. Teledermatology photographic + dermoscopic image vs histology (invasive melanoma or atypical
intraepidermal melanocytic variants).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 7 Teledermatology photographic + dermoscopic image vs histology (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bowns 2006 17 11 7 221 0.71 [ 0.49, 0.87 ] 0.95 [ 0.92, 0.98 ]
Congalton 2015 46 23 2 57 0.96 [ 0.86, 0.99 ] 0.71 [ 0.60, 0.81 ]
Coras 2003 13 2 3 27 0.81 [ 0.54, 0.96 ] 0.93 [ 0.77, 0.99 ]
Grimaldi 2009 5 11 0 219 1.00 [ 0.48, 1.00 ] 0.95 [ 0.92, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. Expert face-to-face (VI + dermoscopy) (invasive melanoma or atypical intraepidermal melanocytic
variants).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 8 Expert face-to-face (VI + dermoscopy) (invasive melanoma or atypical intraepidermal melanocytic variants)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Coras 2003 14 2 2 27 0.88 [ 0.62, 0.98 ] 0.93 [ 0.77, 0.99 ]
Kroemer 2011 5 1 0 98 1.00 [ 0.48, 1.00 ] 0.99 [ 0.95, 1.00 ]
Warshaw 2010b 30 543 11 930 0.73 [ 0.57, 0.86 ] 0.63 [ 0.61, 0.66 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. Teledermatology - photographic + dermoscopic image vs histology (invasive melanoma).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 9 Teledermatology photographic + dermoscopic image vs histology (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Piccolo 2000 9 0 2 32 0.82 [ 0.48, 0.98 ] 1.00 [ 0.89, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. Expert face-to-face (VI + dermoscopy) vs histology (invasive melanoma).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 10 Expert face-to-face (VI + dermoscopy) vs histology (invasive melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Piccolo 2000 8 1 3 31 0.73 [ 0.39, 0.94 ] 0.97 [ 0.84, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 11. Teledermatology - dermoscopic image vs histology (acral melanoma).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 11 Teledermatology dermoscopic image vs histology (acral melanoma)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Piccolo 2004 5 3 1 68 0.83 [ 0.36, 1.00 ] 0.96 [ 0.88, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 12. Teledermatology - photographic image vs histology (basal cell carcinoma (BCC)).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 12 Teledermatology photographic image vs histology (basal cell carcinoma (BCC))
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jolliffe 2001a 9 4 0 127 1.00 [ 0.66, 1.00 ] 0.97 [ 0.92, 0.99 ]
Kroemer 2011 27 5 3 69 0.90 [ 0.73, 0.98 ] 0.93 [ 0.85, 0.98 ]
Moreno Ramirez 2005 22 1 1 33 0.96 [ 0.78, 1.00 ] 0.97 [ 0.85, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 13. Teledermatology - dermoscopic image vs histology (BCC).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 13 Teledermatology dermoscopic image vs histology (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kroemer 2011 24 5 6 69 0.80 [ 0.61, 0.92 ] 0.93 [ 0.85, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
148Teledermatology for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Test 14. Teledermatology - photographic + dermoscopic image vs histology (BCC).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 14 Teledermatology photographic + dermoscopic image vs histology (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bowns 2006 19 9 10 218 0.66 [ 0.46, 0.82 ] 0.96 [ 0.93, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 15. Expert face-to-face (VI + dermoscopy) vs histology (BCC).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 15 Expert face-to-face (VI + dermoscopy) vs histology (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jolliffe 2001a 9 3 0 132 1.00 [ 0.66, 1.00 ] 0.98 [ 0.94, 1.00 ]
Kroemer 2011 29 4 1 70 0.97 [ 0.83, 1.00 ] 0.95 [ 0.87, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 16. Teledermatology - photographic image vs histology (cutaneous squamous cell carcinoma (cSCC)).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 16 Teledermatology photographic image vs histology (cutaneous squamous cell carcinoma (cSCC))
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kroemer 2011 9 1 1 93 0.90 [ 0.55, 1.00 ] 0.99 [ 0.94, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 17. Teledermatology - dermoscopic image vs histology (cSCC).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 17 Teledermatology dermoscopic image vs histology (cSCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kroemer 2011 6 0 4 94 0.60 [ 0.26, 0.88 ] 1.00 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. Expert face-to-face (VI + dermoscopy) vs histology (cSCC).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 18 Expert face-to-face (VI + dermoscopy) vs histology (cSCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Kroemer 2011 9 2 1 92 0.90 [ 0.55, 1.00 ] 0.98 [ 0.93, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 19. Teledermatology - photographic image vs face-to-face clinical diagnosis (immediate action).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 19 Teledermatology photographic image vs face-to-face clinical diagnosis (immediate action)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jolliffe 2001b 99 100 44 553 0.69 [ 0.61, 0.77 ] 0.85 [ 0.82, 0.87 ]
Mahendran 2005 54 16 0 36 1.00 [ 0.93, 1.00 ] 0.69 [ 0.55, 0.81 ]
Shapiro 2004 24 0 0 25 1.00 [ 0.86, 1.00 ] 1.00 [ 0.86, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 20. Teledermatology - photographic image vs face-to-face clinical diagnosis (of malignancy).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 20 Teledermatology photographic image vs face-to-face clinical diagnosis (of malignancy)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Oliveira 2002 8 2 0 80 1.00 [ 0.63, 1.00 ] 0.98 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 21. Teledermatology - photographic image vs face-to-face clinical diagnosis (immediate action or
follow-up).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 21 Teledermatology photographic image vs face-to-face clinical diagnosis (immediate action or follow-up)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Mahendran 2005 69 16 0 21 1.00 [ 0.95, 1.00 ] 0.57 [ 0.39, 0.73 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. Teledermatology - photographic image vs face-to-face clinical diagnosis (immediate action;
registrar data).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 22 Teledermatology photographic image vs face-to-face clinical diagnosis (immediate action; registrar data)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Jolliffe 2001b 131 217 12 436 0.92 [ 0.86, 0.96 ] 0.67 [ 0.63, 0.70 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. Teledermatology - photographic/dermoscopic image vs face-to-face clinical diagnosis (immediate
action).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 23 Teledermatology photographic/dermoscopic image vs face-to-face clinical diagnosis (immediate action)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Manahan 2015 32 28 3 238 0.91 [ 0.77, 0.98 ] 0.89 [ 0.85, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Teledermatology - live link vs face-to-face clinical diagnosis (diagnosis of any skin cancer).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 24 Teledermatology live link vs face-to-face clinical diagnosis (diagnosis of any skin cancer)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Phillips 1998 4 4 2 97 0.67 [ 0.22, 0.96 ] 0.96 [ 0.90, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 25. Teledermatology - live link vs face-to-face clinical diagnosis (definitely/probably malignant).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 25 Teledermatology live link vs face-to-face clinical diagnosis (definitely/probably malignant)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Phillips 1998 3 4 2 98 0.60 [ 0.15, 0.95 ] 0.96 [ 0.90, 0.99 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 26. Teledermatology - live link vs face-to-face clinical diagnosis (biopsy decision).
Review: Teledermatology for diagnosing skin cancer in adults
Test: 26 Teledermatology live link vs face-to-face clinical diagnosis (biopsy decision)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Phillips 1998 9 13 2 83 0.82 [ 0.48, 0.98 ] 0.86 [ 0.78, 0.93 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Cross-tabulation of included studies against target condition assessed, by type of images used for teledermatology
Studies of diagnostic accuracy -TD vs histology FTF dxa
vs histology
TD
vs expert FTF
Study Any skin cancer Melanomab BCC cSCC Action
Arzberger 2016 Photo/Derm
(excise or not)
- - - - -
Borve 2015 Photo/Derm (dx
as malignant/
possibly malig-
nant)
- - - - -
Bowns 2006 - Photo/Derm (dx
as MM/MiS)
Photo/Derm (dx
as BCC)
- - -
Congalton 2015 - Photo/Derm
(excise or not)
- - - -
Coras 2003 - Photo/Dermc
(dx as MM/MiS)
- - dx as MM -
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Table 1. Cross-tabulation of included studies against target condition assessed, by type of images used for teledermatology
(Continued)
Ferrara 2004 - Dermonly (dx as
MM/MiS)
- - - -
Grimaldi 2009 - Photo/Dermc
(excise or not)
- - (GP dx as suspi-
cious for malig-
nancy; data not
included)
-
Jolliffe 2001a Photo onlyc (dx
as any SC)
< 5 MM Photo onlyc (dx
as BCC)
- dx as any SC
dx as BCC
-
Kroemer 2011 Photo onlyc
Derm onlyc (dx
as malignant)
Photo onlyc
Derm onlyc (dx
as MM/MiS)
Photo onlyc
Derm onlyc (dx
as BCC)
Photo onlyc
Derm onlyc (dx
as cSCC)
dx as malignant
dx as MM/MiS
dx as BCC
dx as cSCC
-
Massone 2014 Photo/Derm (dx
as malignant)
- - - - -
Moreno Ramirez
2005
Photol only (dx
as malignant)
Photo only (dx as
MM/MiS)
Photo only (dx as
BCC)
- - -
Piccolo 2000 - Photo/Dermc
(dx as MM)
- - dx as MM -
Piccolo 2004 - Dermonly (dx as
MM)
- - - -
Silveira 2014 Photo only (dx as
malignant)
- - - - -
Warshaw 2010b - Photo onlyc (dx
as MM/MiS)
- - dx of MM/MiS -
Wolf 2013 - Photo only (dx as
atypical)
- - - -
Studies of referral accuracy - TD vs expert FTF decision
Jolliffe 2001b - - - - - Clin only (refer
or not)
Mahendran
2005
- - - - - Clin only (excise
or not)
Manahan 2015 - - - - - Clin/Derm (see
FTF)
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Table 1. Cross-tabulation of included studies against target condition assessed, by type of images used for teledermatology
(Continued)
Oliveira 2002 - - - - - Clin only (dx as
malignant)
Phillips 1998 - - - - - Live link
(dx as any SC;
definitely/proba-
bly malignant/
excise or not)
Shapiro 2004 - - - - - Clin only (excise
or not)
BCC: basal cell carcinoma; clin: clinical; cSCC: cutaneous squamous cell carcinoma; Derm: dermoscopic images; dx: diagnosis;
FTF: face-to-face; GP: general practitioner; MiS: melanoma in situ (atypical intraepidermal melanocytic variants); MM: invasive
melanoma; Photo: photographic images; SC: skin cancer; TD: teledermatology.
aFace-to-face diagnosis by an expert/dermatologist unless otherwise stated.
bAll include melanoma in situ as disease positive apart from Piccolo 2000 and Piccolo 2004, which reported detection of invasive
melanoma only.
cIncluded a direct comparison with expert face-to-face diagnosis versus histology.
Table 2. Summary estimates of sensitivity and specificity for teledermatology
Index test,a target con-
dition
Studies Cases/number of partici-
pants
Summary sensitivity (95%
CI) %
Summary specificity (95%
CI) %
Teledermatology photo-
graphic image, any
4 452/717 94.9
(90.1 to 97.4)
84.3
(48.5 to 96.8)
Teledermatology photo-
graphic/dermoscopic
image, MM + MiS
4 93/664 85.4
(68.3 to 94.1)
91.6
(81.1 to 96.5)
Teledermatology photo-
graphic image vs histol-
ogy, BCC
3 62/301 93.5
(84.0 to 97.6)
95.8
(92.4 to 97.7)
BCC: basal cell carcinoma; CI: confidence interval; MM + MiS: invasive melanoma and atypical intraepidermal melanocytic variants.
aReference standard was histology for all comparisons.
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Table 3. Direct comparisons of teledermatology with face-to-face diagnosis of melanoma and other types of skin cancer
Study Sensitivity (true positives/cases) % Difference
(95% CI)
Specificity (true negatives/non
cases) %
Difference
(95% CI)
Any skin cancer
Teleder-
matology photo-
graphic image
Expert face-to-
face
Teledermatol-
ogy
photographic
image
Expert face-to-
face
Jolliffe 2001a 100 (13/13) 100 (13/13) 0.00
(-2.28 to 2.28)
92.9 (118/127) 94.7 (124/131) -1.74
(-8.18 to 4.49)
Kroemer 2011 93 (43/46) 100 (46/46) -0.06
(-0.17 to 0.02)
88 (51/58) 90 (52/58) -0.02
(-0.14 to 0.10)
Teled-
ermatology der-
moscopic image
Expert face-to-
face
Teled-
ermatology der-
moscopic image
Expert face-to-
face
Kroemer 2011 85 (39/46) 100 (46/46) -0.15
(-0.28 to -0.04)
91 (53/58) 90 (52/58) 0.02
(-0.13 to 0.09)
Invasive melanoma or atypical intraepidermal melanocytic variants
Teleder-
matology pho-
tographic + der-
moscopic image
Expert face-to-
face
Teleder-
matology pho-
tographic + der-
moscopic image
Expert face-to-
face
Coras 2003 81 (13/16) 88 (14/16) -0.06
(-0.32 to 0.20)
93 (27/29) 93 (27/29) 0.00
(-0.16 to 0.16)
Teled-
ermatology der-
moscopic image
Expert face-to-
face
Teled-
ermatology der-
moscopic image
Expert face-to-
face
Kroemer 2011 100 (5/5) 100 (5/5) 0.00
(-0.43 to 0.43)
98 (97/99) 99 (98/99) -0.01
(-0.06 to 0.04)
Warshaw 2010b 59 (24/41) 73 (30/41) -0.15
(-0.33 to 0.06)
41 (604/1473) 63 (930/1473) -0.22
(-0.26 to -0.19)a
Invasive melanoma
Teleder-
matology pho-
tographic/der-
Expert face-to-
face
Teleder-
matology pho-
tographic/der-
Expert face-to-
face
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Table 3. Direct comparisons of teledermatology with face-to-face diagnosis of melanoma and other types of skin cancer
(Continued)
moscopic image moscopic image
Piccolo 2000 81.8 (9/11) 72.7 (8/11) 9.10
(-25.2 to 41.2)
100 (32/32) 96.9 (31/32) 3.13
(-7.90 to 15.7)
Basal cell carcinoma
Teledermatol-
ogy photo-
graphic image
Expert face-to-
face
Teledermatol-
ogy photo-
graphic image
Expert face-to-
face
Jolliffe 2001a 100 (9/9) 100 (9/9) 0.00
(-29.9 to 29.9)
97.0 (127/131) 97.8 (132/135) -0.83
(-5.60 to 3.68)
CI: confidence interval.
adenotes statistically significant difference.
A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
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(Continued)
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-assisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Glossary of terms
Term Definition
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that may
progress to an invasive melanoma; includes melanoma in situ and lentigo maligna
Atypical naevi Unusual looking but non-cancerous mole or area of darker pigmentation of the
skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the
control of cell growth. BRAF mutations (damaged DNA) occur in around 40%
of melanomas, which can then be treated with particular drugs
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF-mu-
tated metastatic melanoma
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(Continued)
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a
microscope, measured in millimetres from the top layer of skin to the bottom of
the tumour
Congenital naevi A type of mole found on infants at birth
Dermoscopy Whereby a handheld microscope is used to allow more detailed, magnified, ex-
amination of the skin compared to examination by the naked eye alone
False negative A person who is truly positive for a disease, but whom a diagnostic test classifies
them as disease-free
False positive A person who is truly disease-free, but whom a diagnostic test classifies them as
having the disease
Histopathology/histology The study of tissue, usually obtained by biopsy or excision, e.g. under amicroscope
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study.
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which in-
cludes malignant cells but with no invasive growth. May progress to an invasive
melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells)
that travels around the body to help fight disease; they are located throughout the
body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as
’moles.’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of indi-
vidual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the blood-
stream or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a mi-
croscope
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health
Mortality Either the condition of being subject to death; or the death rate, which reflects
the number of deaths per unit of population in relation to any specific region, age
group, disease, treatment or other classification, usually expressed as deaths per
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(Continued)
100, 1000, 10,000 or 100,000 people
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g.
urology, oncology, pathology, radiology and nursing). Cancer care in the National
Health Service (NHS) uses this system to ensure that all relevant health profes-
sionals are engaged to discuss the best possible care for that patient
Prevalence The proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might affect the
patient’s prognosis
Receiver operating characteristic (ROC) analysis The analysis of an ROC plot of a test to select an optimal threshold for test
positivity
Receiver operating characteristic (ROC) plot A plot of the sensitivity and 1minus the specificity of a test at the different possible
thresholds for test positivity; represents the diagnostic capability of a test with a
range of binary test results
Recurrence When new cancer cells are detected following treatment. This can occur either at
the site of the original tumour or at other sites in the body
Reference standard A test or combination of tests used to establish the final or ’true’ diagnosis of a
patient in an evaluation of a diagnostic test
Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a handheld device or a
static unit) that can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of people with a disease
who have that disease correctly identified by the study test
Specificity The proportion of people without the disease of interest (in this case with benign
skin lesions) who have that absence of disease correctly identified by the study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into inter-
nationally agreed categories
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or
physical examination
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer
cells throughout the body rather than targeting 1 specific area
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Appendix 3. Content of algorithms used to assist melanoma diagnosis by visual inspection alone
ABCD (Friedman 1985; Rigel 1993;
Pehamberger 1993)
ABCDE (Carli 1994; Cristofolini 1994;
Thomas 1998; Benelli 1999; Benelli 2001;
Abbasi 2004)
BCD (McGovern 1992)
Seven-point checklist (MacKie 1985;
MacKie 1990; Keefe 1990)
Seven-point checklist (revised) (MacKie
1990; Healsmith 1994)
A - asymmetry
• variable centripetal growth of
melanocytes (Friedman 1985)
• “geometrical asymmetry in two axes
of the tumour” (Benelli 1999; Benelli
2001; Thomas 1998)
• “one half does not match the other
half ” (McGovern 1992); not separately
scored in study “because we believed that
asymmetry and border irregularity were
linked”
B - irregular borders
• irregular shape with notching or
scalloping of border (Friedman 1985)
• “edges are ragged, notched, or
blurred” (McGovern 1992)
• “irregular and notched” (Cristofolini
1994)
• “unsharp or ill-defined or angular”
(Thomas 1998)
• “ragged or indented” (Benelli 1999;
Benelli 2001)
C - colour
• variable pigmentation, multiple
colours; various of hues of brown, also
black, blue, red and white (Friedman
1985)
• “pigmentation is not uniform;
shades of tan, brown and black are present
with dashes of red, white, or blue”
(McGovern 1992)
• “mottled-haphazard display”
(Cristofolini 1994)
• “presence of at least two different
colours within the lesion (with the
exception of the usual symmetrical
darkening of the lesion in its centre)”
(Benelli 2001; Thomas 1998)
• “multiple colours” (Abbasi 2004)
D - diameter ≥ 6 mm
• all studies agree
• sensory change, (greater awareness of
the lesion or mild itch);
• diameter of ≥ 1 cm;
• growth of the lesion;
• an irregular edge;
• irregular pigment with different
shades of brown and black in the lesion;
• inflammation
• crusting, oozing or bleeding.
Presence of ≥ 3 suggestive of melanoma
MacKie 1990, Mackie 1991, and
Healsmith 1994 describe the revised crite-
ria as:
Major signs
• Change in size
• Change in shape
• Change in colour
Minor signs
• Inflammation
• Crusting or bleeding
• Sensory change
• Diameter ≥ 7 mm
“a patient with a pigmented lesion with any
one of themajor signs should be considered
for referral and that the presence of any of
the minor signs should be a further stimu-
lus to referral.” (MacKie 1990)
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(Continued)
E - evolution
• “changes in pigmentation”
(Cristofolini 1994)
• “enlargement of the surface (and not
in height) of the lesion; anamnestic
criterion based on the patient’s description
of the natural history of the lesion”
(Thomas 1998)
• “elevation, enlargement or change in
the colour of the lesion” (Benelli 1999;
Benelli 2001)
• “evolving (with respect to size, shape,
shades of colour, surface features, or
symptoms)” (Abbasi 2004)
McGovern 1992 described 7 characteristics
as: “increasing size, variegation, inflamma-
tion, irregular outline, greater than 1cm di-
ameter, itch, bleeding.”
These are expanded on in MacKie 1990,
who described the original (MacKie 1985)
criteria as:
• sensory change, often described as a
greater awareness of the lesion but also as
a mild itch;
• diameter of ≥ 1 cm;
• growth of the lesion;
• an irregular edge;
• irregular pigment with different
shades of brown and black in the lesion;
• inflammation (a reddish tinge within
the lesion);
• crusting, oozing or bleeding.
• ≥ 3 criteria should prompt referral
(MacKie 1990)
Appendix 4. Proposed sources of heterogeneity
1. Population characteristics
• General versus higher risk populations
• Participant population: primary/secondary/specialist unit
• Lesion suspicion: general suspicion/atypical/equivocal/NR
• Lesion type: any pigmented; melanocytic
• Inclusion of multiple lesions per participant
• Ethnicity
2. Index test characteristics
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• Nature of, and definition of, criteria for test positivity
• Observer experience with the index test
• Approaches to lesion preparation (e.g. the use of oil or antiseptic gel for dermoscopy)
3. Reference standard characteristics
• Reference standard used
• Whether histology-reporting meets pathology-reporting guidelines
• Use of excisional versus diagnostic biopsy
• Whether two independent dermatopathologists reviewed histological diagnosis
4. Study quality
• Consecutive or random sample of participants recruited
• Index test interpreted blinded to the reference standard result
• Index test interpreted blinded to the result of any other index test
• Presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the
reference test or by the same reference test with selection dependent on the index test result)
• Use of an adequate reference standard
• Overall risk of bias
Appendix 5. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
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25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
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77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
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11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
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63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
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12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
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64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
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116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
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#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
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#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
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S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
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S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
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vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
Appendix 6. Full-text inclusion criteria
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
• BCC or epithelioma
• cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC or cSCC (other terms include
pigmented skin lesion/nevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC or cSCC
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
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(Continued)
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscopy
• Smartphone/mobile phone applications
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
• Tests to improve histopathology diagnose
• LND
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLMB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
For diagnostic studies
• Exclude if any disease-positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease-negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
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(Continued)
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
Appendix 7. Quality assessment (based on QUADAS-2)
The QUADAS-2 checklist was tailored to the review topic as follows below (Whiting 2011).
Participant selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo
a test should be included in a study, allowing for the intended use of that test within the context of the study. We considered studies that
separately sampled malignant and benign lesions to have used a case-control design; and those that supplemented a series of suspicious
lesions with additional malignant or benign lesions to be at unclear risk of bias.
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion sites, or that
excluded lesions on the basis of image quality or lack of observer agreement (e.g. on histopathology) to be at high risk of bias.
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion populations,
such as melanocytic, nodular, high risk or restrictions by size or to lesions that had been excised to be of high concern for applicability.
For teledermatology, lesions selected from referred populations rather than selected by general practitioners (GPs) in a primary care
setting were also judged to be high concern for applicability.
Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to
contribute disproportionately to estimates of test accuracy, especially if they are at particular risk of having skin cancer. We considered
studies that include a high number of lesions in relation to the number of participants in the study to be less representative than studies
conducted in a more general population of participants (i.e. if the difference between the number of included lesions and number of
included participants is greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to the
result of the reference standard is a key means of reducing bias. For prospective studies and retrospective studies that used the original
index test interpretation, the diagnosis will by nature be interpreted and recorded before the result of the reference standard is known;
however, studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low
risk of bias, we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation.
An item was also added to assess the presence of blinding between interpretations of different algorithms; however this item was not
included in the overall assessment of risk of bias.
Prespecification of the index test threshold was considered present if the study clearly reported that the threshold used was not data
driven, i.e. was not based on study results. Studies that did not clearly describe the threshold used but that required clinicians to record
a diagnosis or management decision for a lesion were considered to be unclear on this criterion. Studies reporting accuracy for multiple
numeric thresholds, where receiver operating characteristic (ROC) analysis was used to select the threshold, or that reported accuracy
for the presence of independently significant lesion characteristics with no separate test set of lesions were considered at high risk of
bias.
In terms of applicability of the index test to the review question, we required images for teledermatology assessment to be acquired in
primary settings by GPs or other primary care staff rather than by expert dermatologists or medical photographers in a specialist setting.
We also required diagnosis to be made by a single observer as opposed to a consensus decision or mean across multiple observers.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion charac-
teristics that were considered to be indicative for melanoma, for basal cell carcinoma (BCC) or for cutaneous squamous cell carcinoma
(cSCC), particularly where established algorithms or checklists were not used. Studies were considered of low concern if the threshold
used was established in a prior study or sufficient threshold details were presented to allow replication.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of
level of clinical suspicion of melanoma. In reality, both partial and differential verification bias are likely. Partial verification bias may
occur where histology is the only reference standard used, and only those participants with a certain degree of suspicion of malignancy
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based on the result of the index test undergo verification, the others either being excluded from the study or defined as being disease-
negative without further assessment or follow-up, as discussed above.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious
lesions. A typical example of verification bias in skin cancer occurs when investigators do not biopsy people with benign-appearing
lesions but instead follow them up for a period of time to determine whether any malignancy subsequently develops (these would
be false-negatives on the index test). We defined an ’adequate’ reference standard as: all disease-positive people having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease-
negative participants have received a histological diagnosis, with up to 20% undergoing at least three months’ follow-up of benign-
appearing lesions.
A further challenge is the potential for incorporation bias, i.e. where the result of the index test is used to help determine the reference
standard diagnosis. It is normal practice for the clinical diagnosis (usually by visual inspection or dermoscopy) to be included on
pathology request forms and for the histopathologist to use this diagnosis to help with the pathology interpretation. Although inclusion
of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation
of the histopathology reference standard is not normal practice, and enforcement of such conditions would significantly limit the
generalisability of the study results. For studies comparing teledermatology against a histological reference standard, this item was
therefore scored but did not contribute to the overall risk of bias. For studies comparing teledermatology against a face-to-face expert
diagnosis, however, this item was scored and did contribute to overall risk of bias.
In judging the applicability of the reference standard to our review question, scored studies as high concern around applicability if
they used expert diagnosis (with no follow-up) as a reference standard in any patient, or did not report histology interpretation by a
dermatopathologist.
Flow and timing domain (4)
In the ideal study, the acquisition of images for the teledermatology diagnosis and the reference standard diagnosis should be made
consecutively or as near to each other in time as possible to avoid changes in lesion over time. We have defined a one-month period as
an appropriate interval between application of the index test and the reference standard (either histological or face-to-face). For studies
using clinical follow-up, a minimum three-month follow-up period has been defined as at low risk of bias for detecting false-negatives.
This interval was chosen based on a study showing that most false-negative melanomas will be diagnosed within three months of the
initial negative index test although a small number will be diagnosed up to 12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were excluded
following recruitment.
Item Response (delete as required)
Participant selection (1) -risk of bias
1. Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2. Was a case-control design avoided?
(note: a diagnostic case-control study separately recruits par-
ticipants according to selected final diagnoses, e.g. those with
melanoma, with BCC, with severe dysplasia and with mild dys-
plasia ANDwill usually deliberately sample certain numbers from
each group such that the overall case mix of included participants
and disease prevalence is not reflective of usual care.)
Yes - if case-control design clearly not used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not clearly described or you have any concerns that
the authors have not selected a series of participants
3. Did the study avoid inappropriate exclusions, e.g.
• ’difficult to diagnose’ lesions not excluded
• lesions not excluded on basis of disagreement between
evaluators or histopathologists
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.
g. ’difficult to diagnose’ lesions, OR where disagreement between
evaluators was observed
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(Continued)
Unclear - if not clearly reported but there is suspicion that difficult
to diagnose lesions may have been excluded
Could the selection of participants have introduced bias?
If answers to all of questions 1. AND 2. AND 3. ’Yes’
If answers to any 1 of questions 1. OR 2. OR 3. ’No’
If answers to any 1 of questions 1. OR 2. OR 3. ’Unclear’
Risk is low
Risk is high
Risk is unclear
Participant selection (1) -concerns regarding applicability
1. Are the included participants and chosen study setting appro-
priate to answer the review question, i.e. are the study results gen-
eralisable?
This item is not asking whether exclusion of certain participant
groups might bias the study’s results (as in ’Risk of bias’ above),
but is asking whether the chosen study participants and setting are
appropriate to answer our review question. Because we are looking
to establish test accuracy in both primary presentation and referred
participants, a study could be appropriate for 1 setting and not
for the other, or it could be unclear as to whether the study can
appropriately answer either question
Yes - if participants included in the study appear to be generally
representative of those who might present in a usual practice set-
ting
No - if study participants were restricted to those in lesion sub-
groups, e.g. melanocytic only, or small lesions only, if only excised
lesions were included, or lesions were selected from referred pop-
ulations rather than selected by general practitioners in a primary
care setting
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2. Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
If the answer to question 1. and 2. ’Yes’
If the answer to question 1. or 2. ’No’
If the answer to question 1. or 2. ’Unclear’
Concern is low
Concern is high
Concern is unclear
Index test (2) -risk of bias (to be completed per test evaluated)
1. Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
the reference standard result or, for prospective studies, if index
test is always conducted and interpreted prior to the reference
standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2. Was the diagnostic threshold at which the test was considered
positive (i.e. melanoma, BCC or cSCC present) prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results), i.e. results were not data driven
No - if thresholdwas not prespecified butwas selected after analysis
of results usually to maximise sensitivity or specificity (or both),
or multiple thresholds were tested
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(Continued)
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
Could the conduct or interpretation of the index test have intro-
duced bias?
For NC and BPC studies
If answers to questions 1. and 2. ’Yes’
If answers to either questions 1. or 2. ’No’
If answers to either questions 1). or 2. ’Unclear’
For WPC studies
If answers to all questions ’Yes’
If answers to any 1 question ’No’
If answers to any 1 of questions is ’Unclear’
For NC and BPC studies
Risk is low
Risk is high
Risk is unclear
For WPC studies
Risk is low
Risk is high
Risk is unclear
Index test (2) -concern about applicability
1. Was the test applied and interpreted in a clinically applicable
manner?
Yes - in-person evaluation and single observer result present
No - image based, or mean or consensus result presented, or both
Unclear - if cannot tell
2. Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
using pattern recognition and those using checklists or algorithms
to aid test interpretation
Yes - if the criteria for diagnosis of the target disorder were re-
ported in sufficient detail to allow replication. If the study does
not describe the threshold in detail BUT evaluates an established
test/algorithm AND provides a citation to a previous study of the
test in the Methods or Results, then respond Yes
No - if the criteria for diagnosis of the target disorder were not
reported in sufficient detail to allow replication
Unclear - if some but not sufficient information on criteria for
diagnosis to allow replication were provided. If the study does not
describe the threshold in detail BUT evaluates an established test/
algorithm but with NO citation to a previous study of the test in
the methods, then respond Unclear
3) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by≥ 1 speciality accredited derma-
tologists, or by examiners of any clinical background with special
interest in dermatology and with any formal training in the use
of the test
No - if the test was not interpreted by an experienced examiner
(see above)
Unclear - if the experience of the examiner(s) was not reported
in sufficient detail to judge OR if examiners described as ’Expert’
with no further detail given
N/A - if system-based diagnosis, i.e. no observer interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
If answers to questions 1., 2. AND 3. ’Yes’
If answers to questions 1., 2. OR 3. ’No’
If answers to questions 1., 2. OR 3. ’Unclear’
Concern is low
Concern is high
Concern is unclear
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Reference standard (3) -risk of bias
1). Is the reference standard likely to correctly classify the target
condition?
a) Disease positive - ≥ 1 of:
• Histological confirmation of the target disorder following
biopsy or lesion excision
• Clinical follow-up of benign appearing lesions following
the application of the index test, leading to a histological
diagnosis of the target disorder of interest:
◦ ≥ 3 months for melanoma or cSCC
◦ ≥ 6 months for BCC
b) Disease negative - ≥ 1 of:
• Histological confirmation of absence of the target disorder
following biopsy or lesion excision in ≥ 80% of disease-negative
participants
• Clinical follow up of benign appearing lesions following
the index test in up to 20% of disease negative participants of:
◦ ≥ 3 months for melanoma or cSCC
◦ ≥ 6 months for BCC
a) Disease positive
Yes - if all disease-positive participants underwent 1 of the listed
reference standards
No - if a final diagnosis for any disease-positive participant was
reached without histopathology
Unclear - if themethod of final diagnosis was not reported for any
disease-positive participant OR if the length of clinical follow-up
usedwas not clearOR if a clinical follow-up reference standardwas
reported in combination with a participant-based analysis and it
was not possible to determinewhether the detectionof amalignant
lesion during follow-up is the same lesion that originally tested
negative on the index test
a) Disease negative
Yes - if≥ 80% of benign diagnoses were reached by histology and
up to 20% were reached by clinical follow-up of for a minimum
of 3 (or 6) months following the index test
No - if > 20% of benign diagnoses were reached by clinical follow-
up of a minimum of 3 (or 6) months following the index test OR
if clinical follow-up period was less than 3 (or 6) months
Unclear - if the method of final diagnosis was not reported for
any participant with benign or disease-negative diagnosis
2. Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies. Response to the item will not be
incorporated into the overall risk of bias assessment for comparisons
against a histological reference standard as histopathology interpre-
tation is usually conducted with knowledge of the clinical diagnosis
(from visual inspection or dermoscopy (or both)). Response to the item
will be incorporated into the overall risk of bias assessment for com-
parisons against a face-to-face reference standard
For studies comparing teledermatology against a histological
reference standard
Yes - if the histological reference standard diagnosis was reached
blinded to the index test result
No - if the histological reference standard diagnosis was reached
with knowledge of the index test result
Unclear - if blinded reference test interpretation was not clearly
reported
If the histopathologist is described as ’blinded’ with no further
detail as to whether the blinding applies to both index test or to
clinical information (prior testing), we will assume that blinding
is to the index test result only, unless further detail is provided
For studies comparing teledermatology against a face-to-face
expert diagnosis
Yes - if the face-to-face reference standard diagnosis was described
as interpretedwithout knowledge of the teledermatology diagnosis
(e.g. the remote and face-to-face diagnosis was made by 2 different
dermatologists)
No - if the face-to-face reference standard diagnosis wasmade with
knowledge of the teledermatology diagnosis or was made by the
same dermatologist within a month of the remote image-based
diagnosis
Unclear - if it is not possible to tell whether knowledge of the tele-
dermatology diagnosis could have influenced the reference stan-
dard diagnosis
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Could the reference standard, its conduct, or its interpretation
have introduced bias?
For comparisons against a histological reference standard:
If answer to question 1. ’Yes’
If answer to question 1. ’No’
If answer to question 1. ’Unclear’
For comparisons against a face-to-face reference standard:
If answers to questions 1. AND 2. ’Yes’
If answers to questions 1. OR 2. ’No’
If answers to questions 1. OR 2. ’Unclear’
For comparisons against a histological reference standard:
Risk is low
Risk is high
Risk is unclear
For comparisons against a face-to-face reference standard:
Risk is low
Risk is high
Risk is unclear
Reference standard (3) -concern about applicability
1. For studies comparing teledermatology/face-to-face clinical di-
agnosis to histology, was histology interpretation carried out by
an experienced histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less-experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
not reported
2. For studies comparing teledermatology to face-to-face diagno-
sis, was the clinical diagnosis carried out by an experienced ob-
server?
Yes - if face-to-face interpretation was reported to be carried out
by an experienced dermatologist
No - if face-to-face interpretation was reported to be carried out
by a less-experienced dermatologist
Unclear - if the experience/qualifications of the face-to-face clin-
ician were not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
If answer to either questions 1. or 2. ’Yes’
If answer to either questions 1. OR 2. ’No’
If answer to either questions 1. OR 2. ’Unclear’
Concern is low
Concern is high
Concern is unclear
Flow and timing (4): risk of bias
1. Was there an appropriate interval between index test and refer-
ence standard?
a) For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1month?
b) If the reference standard includes clinical follow-up of border-
line/benign appearing lesions, was there a minimum follow-up
following application of index test(s) of:
• ≥ 3 months for melanoma or cSCC
• ≥ 6 months for BCC?
a)
Yes - if study reports ≤ 1 month between index and reference
standard
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
b)
Yes - if study reports ≥ 3 (or 6) months follow-up
No - if study reports < 3 (or 6) months follow-up
Unclear - if study does not report length of clinical follow-up
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2. Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if > 1 reference standard was used
Unclear - if not clearly reported
3. Were all participants included in the analysis? Yes - if all participants were included in the analysis
No - if some participants were excluded from the analysis
Unclear - if not clearly reported
Could the participant flow have introduced bias?
For NC and BPC studies
If answers to questions 1. AND 2. AND 3. ’Yes’
If answers to any 1 of questions 1. OR 2. OR 3. ’No’
If answers to any 1 of questions 1. OR 2. OR 3. ’Unclear’
Risk is low
Risk is high
Risk is unclear
Comparative domain: for BPC orWPC (or both) of index tests or testing strategies (i.e. > 1 index test applied per participant)
Index tests
1. Was each index test result interpreted without knowledge of
the results of other index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
N/A - if only 1 index test was evaluated
2. Was the interval between application of index tests≤ 1 month? Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report interval between index tests
Clinical applicability of comparison
1.Were both tests applied and interpreted in a clinically applicable
manner?
-
BPC: between-person comparison; BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; N/A: not applicable; NC:
non-comparative; WPC: within-person comparison.
Appendix 8. Summary study details
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Author and year
Outcome
Study type
County
Setting
Participants (le-
sions)
Inclusion crite-
ria
Store and
forward teleder-
matology
Image acquisi-
tion
Image interpre-
tation
Diagnostic de-
cision
Face to face di-
agnosis
Method of diag-
nosis
Diagnostic de-
cision
Reference stan-
dard
Final diagnoses
Prevalence (ma-
lignant)
Excluded
participants
(from final
analysis)
Studies of diagnostic accuracy (TDvs histology)
Arzberger 2016
Any
NC
P-CS
Secondary
Austria
20 (23)
Moderate-
to-high risk of
melanoma based
on:
• personal or
first-degree
relative history
of melanoma;
• history of
dysplastic naevi;
• > 5 atypical
naevi;
• > 100
naevi;
• lesion
suspicious for
melanoma.
Clinical and der-
moscopic images
acquired in sec-
ondary care with
dig-
ital camera cou-
pled with der-
moscope (equip-
ment described)
4 remote teleder-
moscopy experts
(dermatologists)
evaluated the to-
tal body images
and dermoscopic
images, and gave
a recommenda-
tion for each le-
sion
De-
cision recorded:
“self-mon-
itoring”, “short-
term
monitoring” and
“excision”
Not evaluated Histology
Malignant
MM: 8; MiS: 1;
BCC: 2
BN: 12
0.478
Of 70 eligible
participants only
20 were excised;
no information
reported on the
50 participants
who had expert
dx
Borve 2015
Any
BPC
P-CS
Primary and sec-
ondary
Sweden
772 (816)
People with ≥
1 skin lesions of
concern requir-
ing referral to a
dermatologist
(Ac-
curacy was com-
pared to a con-
trol group of an
equal number of
consecutive par-
Clinical and der-
moscopic images
acquired in pri-
mary care byGPs
using
smartphone dig-
ital camera and
portable dermo-
scope using an
iPhone 4 with a
Not evaluated Histology plus
expert
Malignant:MM:
19; MiS: 16;
cSCC: 17; BCC:
109
Benign: dysplas-
tic: 89; BN: 236;
SK: 125; other
benign: 137
86 ex-
cluded from TD
group (including
4 with poor im-
age quality, 21 <
18 years old, 50
’no shows;’ other
reasons also pro-
vided)
*Authors
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ticipants referred
from other
PHCs via the tra-
ditional pa-
per-based refer-
ral system during
the same period;
data included in
this review.)
PHCs that regu-
larly referred pa-
tients with skin
lesions of con-
cern were invited
to participate
FotoFinder
Handyscope app
4 Remote der-
matologists
reviewed images
along with
clinical informa-
tion on an online
platform and se-
lected from stan-
dardised triage
responses
Decision
recorded:
• benign,
malignant or
unclear
• malignancy
as possible dx
• priority
given (high: < 2
weeks; medium:
< 4 weeks; low:
8-12 weeks),
management
(none, medical
therapy,
destructive
therapy or
surgery)
• dermoscopic
description
*AK: 61
*cSCC (in situ):
7
0.281
included in situ
cSCC and AK as
D+; could only
be disaggregated
for threshold of
malig-
nancy as any dif-
ferential dx
Bowns 2006
MEL
BCC
WPC tests
P-CS
Specialist unit
UK
NR (256)
Peo-
ple (with skin le-
sions) who were
either referred to
the 2-week wait
or ’target’ clin-
ics, or those ini-
tially referred to
the normal out-
patient
service but who
were diverted by
the consul-
tant on the ba-
sis of the referral
Clinical and der-
moscopic images
acquired in sec-
ondary care at a
Medical Photog-
raphy
Department us-
ing a digital cam-
era (equipment
not described)
3 inde-
pendent derma-
tologists assessed
the images along
with clinical in-
Not evaluated Histology plus
expert dx
Malignant:
MM: 19;MiS: 5;
BCC: 29; cSCC:
16; other malig-
nant: 1
*Severely dys-
plastic naevi: 3;
BN: 64; *BD/in
situ SCC: 9; SK:
70; solar kerato-
sis: 12; *severely
dysplastic
11 excluded: 7
wrong lesion im-
aged, 3 histol-
ogy already un-
dertaken, 3 im-
age file lost
*Authors include
these as D+ for
malignancy; data
excluded
from our ’Any’
skin cancer anal-
yse (author con-
tacted)
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form formation
Decision
recorded:
• most likely
dx
• level of
confidence in dx
• malignant
vs benign
• recommendation
on whether they
would wish to
see the
participant
solar keratosis: 3;
other benign: 25
0.332
Congalton 2015
MEL
NC
P-CS
Secondary and
private
New Zealand
99 (129) excised
Full sample:
310 participants
(613 lesions)
All par-
ticipants referred
with skin lesions
suspicious
formelanoma as-
sessed at
a Virtual Lesion
Clinic for triage,
instead of be-
ing seen FTF at
a hospital clinic.
Only those ex-
cised could be in-
cluded
Clinical and der-
moscopic images
acquired in sec-
ondary care us-
ing a digital cam-
era coupled with
dermoscope
2 experienced
dermatologists
reviewed partici-
pant details and
images re-
motely using the
MoleMapDiag-
nose software
De-
cision recorded:
management de-
cision;
• specialist
assessment or
excision of the
lesion needed
• reimage in
3 months
• discharge
to GP, e.g. for
cryotherapy or
topical therapy
• self-
monitoring and
• lesion of no
concern
Not evaluated Histology plus
expert dx
MM: 47;
melanoma
metas-
tases: 1*; BCC:
40; cSCC: 9 (in-
cluding in situ*)
Benign: 32
0.403
1 participant was
excluded from
further analysis
because he at-
tended the VLC
after the referred
lesion had been
excised
*1
MMMets incl as
D+; cannot dis-
aggregate in situ
SCC; data ex-
cluded from our
’Any’ skin cancer
analysis
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Coras 2003
MM
WPC-tests
P-CS
Secondary and
private
Germany
NR (46)
Pigmented skin
lesions undergo-
ing excision due
to
dx of melanoma
or atypical ne-
vus, to rule out
melanoma or at
the participant’s
request
Clinical and der-
moscopic images
acquired at pri-
vate clinic us-
ing digital cam-
era coupled with
dermoscope
1 dermatologist
evaluated the im-
ages and made a
dx based on the
images and his-
tory of the par-
ticipant
Decision
recorded:
• lesion dx
3 partici-
pating dermatol-
ogists with ex-
perience in der-
moscopy estab-
lished a clinical
dx based on pat-
tern analysis af-
ter personal con-
sultation
with the partic-
ipant in their
private practice
clinics
Histology
MM: 16
Benign: 29
0.356
Reported
that many im-
ages were of poor
quality (10) and
that only
45 biopsies were
done 50 partic-
ipants who did
not have histol-
ogy excluded
Ferrara 2004
MEL
NC
CCS
Unspecified
NR; likely Italy
NR (12)
12 melanocytic
lesions with der-
moscopic images
(a single image
per case) and ac-
companying his-
tological
material were re-
trieved from our
consultation files
Dermoscopic
images acquired
using a film or
digital cam-
era coupled with
dermoscope; set-
ting for lesion ac-
quisition unclear
Stored im-
ages were viewed
on a standard-
resolution colour
monitor
by 3 remote con-
sultants in a sin-
gle session. Der-
moscopic images
presented first
(dx recorded by
single observer),
followed by his-
tological
image (for teled-
ermatopathol-
ogy dx)
, the original his-
tological dx from
the consultation
file was then pre-
sented (appar-
Not evaluated Histology
MM: 4; MiS: 3
’Benign:’ 5 (incl
junctional ne-
vus: 1; reed nae-
vus: 1; blue nae-
vus: 1; actinic
lentigo: 1; SN: 1)
0.583
NR
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(Continued)
ently along with
the original clini-
cal dx). “Dermo-
scopic-patho-
logical remarks”
were made and
finally a consen-
sus dx
was reached by 2
consultants; the
latter was taken
as a second ’gold
standard’ for the
study
Decision
recorded:
• lesion dx
Grimaldi 2009
MM
Case series
WPC-tests
P-CS
Primary and sec-
ondary
Italy
197 (235)
Cutaneous pig-
mented
lesions with dig-
ital images for-
warded by pri-
mary care physi-
cians to a referral
centre for confir-
mation of dx
Clinical and der-
moscopic images
acquired in pri-
mary care using
a digital cam-
era coupled with
dermoscope. All
photographed
lesions uploaded
from the periph-
eral units to the
central research
unit for telediag-
nosis
Images appraised
at the reference
unit by derma-
tologist and plas-
tic surgeons
numbers NR)
Decision
recorded:
• ’needing
control’ (i.e.
periodic
observation
programme) vs
’needing
surgery’ (e.g.
radical removal,
Each of 13 GPs
was asked to for-
mulate a writ-
ten first judge-
ment of every le-
sion before digi-
tal acquisi-
tion using visual
inspection alone
and then follow-
ing dermoscopy.
The evaluation
method followed
the ABCD rule
of der-
moscopy accord-
ing to Nachbar
et al (Nachbar
1994)
Decision
recorded:
• benign vs
suspicious for
malignancy
Histol-
ogy plus follow-
up (208 diag-
nosed as benign
after 6 months’
follow-up)
MM: 5
Benign: 230
0.021
NR
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sentinel lymph
node biopsy,
reconstructive
surgery, other
therapies)
Jolliffe 2001a
Any
BCC
WPC-tests
P-CS
Specialist unit
UK
138 (144)
People
referred by their
GP for derma-
tological assess-
ment of a pig-
mented lesion at
the PLC
Images acquired
at PLC using a
single chip video
camera. The im-
age was archived
using
proprietary soft-
ware and images
were transmitted
through a Fast
Screen
Machine2 video
overlay card and
viewed alongside
clinical
information on a
15 inch monitor
(observer qualifi-
cations and ex-
pertise NR)
Decision
recorded: clinical
dx
1 dermatologist
at the PLC made
a clinical dx (±
the use of der-
moscopy) based
upon informa-
tion in the refer-
ral letter and ex-
amination find-
ings
Histology
MM: 2; LM: 2;
BCC: 9
Atypical: 5; BN:
89; SK: 9; solar
lentigo: 7; blue
naevus: 4; SN: 2;
other: 15
0.090
In 4 cases (2.7%)
it was impossi-
ble to make a dx
from the image,
due to poor im-
age quality
Kroemer 2011
MEL
BCC
cSCC
Any
WPC-tests
P-CS
Secondary
Austria
88 (113)
People self-
referred or re-
ferred to general
outpatient clinic
at the Depart-
ment of Der-
matology, Medi-
cal University of
Graz, Graz, Aus-
tria by a local
doctor for evalu-
ationof a skin tu-
mour
Clinical and der-
moscopic images
(up to 3 each
per participant)
acquired by der-
matolo-
gist in secondary
care using a mo-
bile phone cam-
era (Nokia N73
with Dermlite II
Pro).
Images reviewed
by 1 board-cer-
tified dermatolo-
gist with clinical
expertise
in TD and der-
moscopy; images
FTF clinical dx
at gen-
eral dermatology
outpatient clinic
by a single der-
matologist. Not
clearly reported;
most likely visual
inspection of the
skin (± use of
dermoscopy)
. No algorithm
described
Histology
MM: 1; MiS: 1;
BCC: 30; cSCC:
10, LM: 3; mel
mets: 1; SK: 6;
AK: 17; BD: 1;
BN: 15; other:
19
0.058
9 lesions (8 par-
ticipants); 3 par-
ticipants
declined partici-
pation. Of 322
clinical and 278
dermoscopic im-
ages, 2 clinical
and 18 dermo-
scopic images
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reviewed blinded
to each other
Decision
recorded:
• lesion dx
(benign
melanocytic,
benign non-
melanocytic,
malignant
melanocytic and
malignant non-
melanocytic skin
tumours).
• recorded 1
primary and 1
differential dx
Massone 2014
Any
NC
P-CS
Private care
Austria
112 (121)
Full sample:
690 (962)
People un-
dergoing a 2-day
’health screening
holiday’ as part
of a preventive
medical screen-
ing
programme; im-
ages acquired by
GPs for any sus-
picious skin le-
sions.Only those
recom-
mended for exci-
sion or FTF as-
sessment by TD
were included
Clinical and der-
moscopic images
acquired in pri-
mary care using
a digital camera
coupled with a
dermoscope. Im-
ages were
reviewed blinded
to other infor-
mation by 2 der-
matol-
ogists within 48
hours (“No per-
sonal pa-
tients’ data were
transmitted; pa-
tients were iden-
tified only
by a progressive
number.”
Decision
recorded:
• correct dx
of malignancy
• TD
decisions for full
sample included
• image
quality
Histology plus
expert clinical dx
Malignant: MM
2; BCC 5
Dysplastic
11; SK 4; *AK 1;
other 3
*authors consid-
ered AK as D+;
could be disag-
gregated and
considered D-
0.25
82/121 partici-
pants lost to fol-
low-up) i.e. no
histology dx, in-
cluding 4 con-
sidered to have
melanoma and 8
with BCC
-
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• lesion
group: benign
melanocytic or
non-
melanocytic;
malignant
melanocytic or
non-
melanocytic
• dx
• management
decision
◦ no
further
treatment or
follow-up in 3, 6
or 12 months
interval
◦ referral to a local
dermatologist
for FTF
examination
◦ excision in case
of suspected
malignancy
Not evaluated
Moreno Ramirez
2005
MEL
BCC
Any
NC
R-CS
Specialist unit
Spain
108 referred to
PLC, 57 partic-
ipants included
in the final anal-
ysis (57)
People with pig-
mented, circum-
scribed le-
sions fulfilling ≥
1 of the
following crite-
ria:
• a changing
lesion (’ABCD
changes’)
• recent
lesion (< 3-year
history)
• multiple
lesions (> 20
melanocytic
naevi counted
by the GP)
Pho-
tographic images
acquired in pri-
mary care using
a digital cam-
era. Images eval-
uated at PLC by
a dermatologist
alongside clinical
information
Decision
recorded:
• lesion dx
(including MM,
BCC, BN,
multiple
melanocytic
naevi (> 20
naevi as seen on
Not evaluated His-
tology plus fol-
low-up (follow-
up period NR)
Malignant: MiS:
1; BCC: 23; LM:
3;
dysplastic: 16;
BN: 8; blue nevi:
4
0.105
Dif-
ficult to dx cases
excluded (n=13)
, those with ’ma-
lignant or suspi-
cious lesions’ (n
= 28)
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• symptomatic
lesion (pain,
itching,
bleeding)
• patient
concern about
moles
teleconsultation)
, atypical naevus,
LM, etc.)
• suggested
management
(’referral’ or
’non-referral’* to
the FTF clinic)
*obviously
benign were not
referred; all other
cat-
egories were rou-
tinely referred to
the PLC for FTF
assessment
Piccolo 2000
MM
WPC tests
P-CS
Unspecified
Austria (Graz)
40 (43)
People with pig-
mented skin le-
sions selected be-
cause of their
diagnostic diffi-
culty and subse-
quently excised
for a histopatho-
logical
evaluation
Clinical and der-
moscopic images
acquired in sec-
ondary
care using a der-
moscopic digital
camera. Images
stored on a pro-
totype TDwork-
station and dis-
tributed to re-
mote centres via
email together
with basic partic-
ipant data (ini-
tials, age, sex and
site of the lesion)
. Observers in-
cluded 6 derma-
tologists, 2 res-
idents in der-
matology, 1 in-
ternist, 1 GP, 1
oncologist
Decision
recorded:
NR
All lesions were
examined with a
dermatoscope by
1 expert derma-
tologist
during the FTF
clinical dx (most
likely in a sec-
ondary care set-
ting).No specific
algorithm used
Histology
MM: 11
SK: 3, BN: 25;
angiokeratoma:
1; lentigines: 3
0.259
Poor quality in-
dex test image
(all images scor-
ing 4 were ex-
cluded from the
study)
Piccolo 2004
MEL
NC
R-CS
Unspecified
Images selected
from University
People with
melanocytic
acral lesions
Der-
moscopic images
acquired in sec-
ondary
care using a der-
- Histology
Malignant: MM
(acral): 6; acral
melanocytic
None reported
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of Graz Austria
andUniversity of
L’Aquila Italy
73 (77)
moscopic digital
cam-
era. Images anal-
ysed along with
information on
age, sex and le-
sion site on a
computer moni-
tor by each der-
matologist (11; 5
rated highly ex-
perienced in der-
moscopy,
2 medium expe-
rience and 4 low
level of experi-
ence)
Decision
recorded:
• acral
melanoma vs
atypical lesions
(considered
atypical when ≥
6 of the 11
observers made
this dx)
• categorised
according to the
’Saida’
classification.
• management
recommenda-
tion (digital
dermoscopy
follow-up or
surgical
excision)
naevi: 71
0.078
Silveira 2014
Any
Non-
comparative
P-CS
Community
Brazil
NR (416)
People with skin
lesions that were
determined to be
suspicious after a
direct
visual inspection
by a physician
at a Community
Mobile Preven-
Photographic
images acquired
in a community
set-
ting using a dig-
ital camera. Im-
ages were coded,
stored and sub-
mitted at ran-
- Histology plus
expert (52 were
diagnosed by ex-
pert opinion)
Malignant:MM:
5; BCC: 286,
cSCC: 59; ma-
lignant other: 14
Benign dx: 52
21were excluded
from the study
because of poor
quality photos,
23were excluded
be-
cause of incom-
plete data pre-
venting the iden-
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tion Unit (pro-
viding screening
the local people
for prostate, cer-
vical and skin
cancers
dom to 2 oncol-
ogists at Barretos
CancerHospital,
blinded to the
MPU physician’s
dx and pathol-
ogy report but
with age, skin
type and lesion
site provided
Decision
recorded:
Management de-
cision
• a
malignant
lesion,
oncological
treatment is
indicated
• a benign
lesion, no
treatment
required
• unknown
• a low-
quality image
0.875 tification of the
participant
Warshaw 2010b
MEL
Full methods re-
ported in
Warshaw 2009a
and Warshaw
2009b which re-
ported data for
primary lesions
only
WPC
P-CS
Secondary
USA
NR/1514
(2152
participants with
3021 le-
sions enrolled in
full trial; 1685 le-
sions were biop-
sied)
People with pig-
mented and
non-pigmented
lesions enrolled
at the Depart-
ment of Veteran
Affairs dermatol-
ogy clinic who
required (or re-
quested) removal
of ≥ 1 skin neo-
plasms (’high-
risk group’) and
participants who
were referred to
general der-
matology clinic
by non-derma-
tology healthcare
providers
for evaluation of
Macro im-
ages* and PLD
images were ob-
tained for
each lesion by re-
search staff on at-
tendance at Der-
matology clinic.
Contact immer-
sion dermoscopy
images also ob-
tained for a sam-
ple of pigmented
lesions
1 of 3 board-cer-
tified dermatolo-
gists with clinical
expertise in der-
moscopy were
randomly as-
Clinical as-
sessment by 1 of
11 staff derma-
tologists; history
obtained in usual
manner and clin-
ical examination
could include all
options nor-
mally available in
the clinical set-
ting (e.g. pal-
pation, diascopy,
dermoscopy)
Recorded:
• 1 primary
dx from a choice
of 17 common
diagnoses (2×2
extracted for
Histology
(board-certified
dermatopathol-
ogist)
MM: 41; BCC:
410; cSCC: 240
Benign ker-
atoses: 223; DN:
154; AK:
145; BN: 138;
cysts: 73; benign
appendageal tu-
mours: 35;
lentigines:
29; benign vas-
cular neoplasms:
26
0.042
171 lesions in
histopathologic
categories with <
25 lesions
*Paper presented
accuracy data for
each image type;
underlying data
to allow con-
struction of 2×2
tables obtained
from author only
for macro images
for primary dx of
MM/MiS
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a skin neoplasm
(lower-risk
group). Biopsied
lesions only were
included; and for
the 2010 paper,
only lesion cate-
gories with ≥ 25
lesions
signed to review
a macro package
alone or with a
PLD image
along with stan-
dardised partici-
pant and lesion
history.
Images of all le-
sions for a single
participant visit
(i.e. ≥ 1 le-
sion per partici-
pant) were evalu-
ated by the teled-
ermatologist in a
single session
Recorded:
• 1 primary
dx (2×2
extracted for
MM/MiS),
• ≤ 2
differential
diagnoses
• management
plan
MM/MiS)
• ≤ 2
differential
diagnoses
• management
plan (remove/
biopsy/destroy,
observe/reassure,
antifungal
treatment,
antibiotic
treatment, anti-
inflammatory
treatment)
Wolf 2013
MEL
WPC
CCS
Secondary
USA
NR (159)
People with pig-
mented
lesions that were
considered atyp-
ical in clinical ap-
pearance by ≥ 1
derma-
tologist and for
which a clear his-
tological dx had
been rendered by
a board-certified
dermatopathol-
ogist (inva-
sive melanoma,
MiS, lentigo, be-
nign nevus, DF,
SK and haeman-
gioma). Ex-
cluded equivocal
Photographic
images acquired
in routine sec-
ondary care prior
to skin lesion re-
moval). 4 appli-
cations for
smartphone de-
vices were eval-
uated including
1 store and for-
ward application
(app
4) which can be
run on a smart-
phone or from
awebsite. Images
sent to a board-
certified derma-
- Histology
Melanoma: 44;
MiS: 16
Benign dx: 34;
SK: 20; lentigo:
8; haemangiona:
2; DF: 4
0.34
29 not evaluable
excluded from
analysis
“send another
photograph” or
“unable to cat-
egorize,” consid-
ered these images
to be unevalu-
able in our anal-
ysis
(390 im-
ages for possible
inclusion in this
study. We ex-
cluded 202 as be-
ing of poor im-
age quality, con-
taining identifi-
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di-
agnoses and spe-
cific lesion types
tologist (number
NR) for evalu-
ation within 24
hours
Decision
recorded:
• “atypical”
(test positive) or
“typical” (test
negative)
• other
options included
“send another
photograph” or
“unable to
categorize”
able participant
information
or features, or
lacking sufficient
clinical or histo-
logical informa-
tion.)
Studies of referral accuracy (TD vs FTF dx)
Jolliffe 2001b
Refer/no referral
NC
P-CS
Secondary
UK
611 (819)
People referred
to the dermatol-
ogy departments
of the Royal Free
Hospital or
the Whittington
Hospital dur-
ing the study pe-
riod by their GPs
for assessment of
a pigmented le-
sion were seen in
clinic
Pho-
tographic images
acquired in sec-
ondary care us-
ing a single chip
video camera
Im-
ages were viewed
alongside GP re-
ferral infor-
mation indepen-
dently by 2 der-
matologists and
a registrar sev-
eral months fol-
lowing the FTF
encounter
Decision
recorded:
• refer or not
(action); “On
the basis of the
image and the
referral
information
each doctor
made a decision
as to whether
the particular
Not evaluated as
an index test
Expert opinion
(in clinic dx by
the registrar and
1 of either of the
2 consultants)
Clinical di-
agnoses: MM: 9;
BCC: 19; LM: 1
SK: 152;
BN: 361; atypi-
cal: 112; congen-
ital: 27; DF: 25;
solar lentigo: 23;
KA: 1; angioma:
18; AK: 13; SN:
1; blue: 2; other:
56
Clinical dx: 3.
6%
Action needed:
17.5%
23 poor-qual-
ity images (lesion
referred on the
basis of poor pic-
ture quality
rather
than known clin-
ical need)
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lesion warranted
a referral or not.
”
Mahendran
2005
Action/no action
WPC-tests
P-CS
Primary and sec-
ondary
UK
163 (163)
GPs recruited
consecutive un-
selected partici-
pants with suspi-
cious skin lesions
whom they refer
to the dermatol-
ogy department
in their normal
practice
Photographic
images acquired
in primary care
by the GP using
a digital camera
(Nikon Coolpix
950 digital cam-
era (1200 × 1600
pixel resolution).
Images reviewed
by 1 of 2 consul-
tant dermatolo-
gists along with
clinical informa-
tion
Decision
recorded:
• dx or
differential dx
(2×2 cannot be
extracted)
• hypothetical
management
plan
(reassurance;
minor
operation, no
action but
further review
appointment
required); 2×2
extracted for 2
thresholds
◦ book
for minor
operation
(immediate
action) vs not
◦ book
for minor
operation or
book further
Not evaluated as
an index test
Expert
clinical dx (un-
clear but appears
to be by the same
TD consultants
within 2 weeks)
Consultant diag-
noses (not his-
tologically con-
firmed)
MM: 4,
BCC: 37; cSCC:
4; AK: 10; BD:
7; SC: 4; LM: 1;
atypical: 6; SK:
27; BN: 20; DF:
11; other: 36
Malignant: 27.
6%
Action required
(FTF): 65.1%
57
(35%) excluded
as no TD de-
cision could be
made; 24 (15%)
poor-quality im-
ages; 33
(20%) needed to
be seen FTF
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review
appointment
(immediate
action or FU) vs
no action
Manahan 2015
Action (see FTF
or not)
NC
P-CS
Community
Australia
49/340
People aged 50-
64 years at high
risk of
melanoma (fair
skin type, pre-
vious skin ex-
cisions, personal
or family his-
tory) recruited
via the ’QSkin’
study or volun-
teers who com-
pleted question-
naire and who
had a suitable
smartphone.
Participants in-
structed to sub-
mit “photos of
moles or spots
that they ’did not
like the look of,
” and were given
instruc-
tions about how
to select lesions
based on asym-
metry and colour
Study
participants used
Handyscope
FotoFinder der-
moscope smart-
phone
attachment
(FotoFinder
Systems GmbH,
Bad Birn-
bach, Germany)
and Handyscope
app, to obtain
and send mag-
nified lesion im-
age along with
a second clinical
(macro) image to
ver-
ify the anatom-
ical site of each
skin lesion
1 teledermatolo-
gist recorded:
• a primary
dx, with up to 2
differential
diagnoses (could
not extract 2×2),
and
• whether
clinical skin
examination
(FTF) was
required (action)
.
Not evaluated as
an index test
Clinical skin ex-
amination by a
dermatology reg-
istrar under su-
pervision of the
derma-
tologist who un-
dertook the tele-
diag-
nosis. The same
management op-
tions were
recommended in
the FTF consul-
tation
FTF di-
agnoses (not his-
tologically con-
firmed):
BCC: 13; SCC/
IEC: 1
Atypical naevus:
4; BN: 165; SL:
22; SK: 81
Non-pig-
mented: AK: 34;
DF: 2; other: 18
8/58 partici-
pants did not at-
tend for FTF ex-
amination; 1/58
without age re-
striction; 32/341
lesions did not
appear to have a
primary TD dx
Oliveira 2002
dx (malignant vs
not)
NC
P?-CS
Primary
Brazil
90/90
People with sus-
pect dermatolog-
ical condi-
tions identified
by an assistant
nurse who had
undergone train-
Lesions pho-
tographed by the
nurse using
a Kodak DC265
Zoom digital
camera
Not evaluated as
an index test
Within 1 week
the same derma-
tologist saw the
participant in-
person. Partici-
pants were re-
2 lesions without
a tele-dx
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ing to identify
potentially ma-
lignant skin le-
sions.Only those
who attended for
FTF assessment
were included
2-hour training
in the use of
the camera was
provided and in-
cluded instruc-
tion on the in-
stallation of the
camera’s software
and transfer-
ring the images
to the computer.
Images were sent
by nurse with
an electronic case
report form and
included her di-
agnostic impres-
sion whether the
lesion was non-
malignant or
malignant
All cases were as-
sessed the cases
remotely
by a dermatolo-
gist prior to the
in-person evalu-
ation and
assessed asmalig-
nant or benign
ferred for biopsy
when skin can-
cer was the sus-
pected dx. The
in-person assess-
ments by the der-
matologist (and
the biopsy results
in a few cases)
were used as ref-
erence
Malignant: 8
Benign: 84
9
were referred for
biopsy of whom
5 attended, in-
cluding 1 SCC
and 3 BCC
Phillips 1998
Dx SC
Malignant/
probably malig-
nant
Excise
NC
P-CS
Community
USA
51/107
People attending
4 skin can-
cer screenings at
community hos-
pitals in ru-
ral eastern North
Carolina. Partic-
ipants were given
a choice of hav-
ing a total body
examination,
only the sun-ex-
posed skin, or a
specific lesion(s)
evaluated by the
on-site physician
Live-link TD us-
ing: a full-body
camera, a lens for
viewing the le-
sions close up,
and a magnify-
ing
lens that allowed
even closer views
as well as exam-
ination with po-
larised light. It is
not
clear who oper-
ated the cameras
during the tele-
consultations. If
a complete pa-
Not evaluated as
an index test
All
participants were
first evaluated by
the on-site physi-
cian who
recorded specific
lesions on an im-
age of the human
body and dx/
management de-
cisions as per re-
mote observer
Target condition
(FTF diagnoses)
Malignant:
BCC: 2; SCC: 3;
LM: 1
None reported
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tient skin exam-
ination was per-
formed
in-person, repre-
sentative lesions
were selected by
the on-site physi-
cian for evalua-
tion by the re-
mote physician
Decision
recorded:
• most likely
dx for a given
lesion
• the degree
of concern that a
specific lesion
was malignant;
and
• whether to
do a biopsy of
the lesion
Benign:
SK: 27; BN: 32;
AK: 14; lentigo:
10; other: 30
Shapiro 2004
Biopsy
NC
P-CS
Secondary
USA
49 (NR)
Only
people with skin
growths
that posed a true
diagnostic chal-
lenge selected by
PCP (board cer-
tified in internal
medicine since
1984)
Pho-
tographic images
acquired in pri-
mary care by net-
work commu-
nity primary care
physician using
a digital cam-
era. Reviewed by
a board certified
academic derma-
tologist for teled-
ermatolog-
ical consultation
alongside clinical
information
Decision
recorded:
• dx or
differential dx
(cannot extract
2×2)
• indication
for sampling
Not evaluated as
an index test
Expert (local
dermatologist in
private practice)
23 underwent
biopsy: BCC: 5;
cSCC: 4; benign:
17
Assumed benign
(no biopsy): 23
(including 1 par-
ticipant who re-
fused biopsy)
Malignancy:
18%
Action recom-
mended: 49%
11 (4 failed to
present for
FTF assessment,
4 saw a differ-
ent FTF derma-
tologist, 1 died,
and 2 underwent
evaluation of dif-
ferent lesions by
the SAF teled-
ermatologist and
FTF dermatolo-
gist)
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biopsy (action:
excise or not)
• reason for
biopsy
(management
plan included
15 options
including 3
biopsy plans
(rule out
malignancy,
establish a dx or
cosmetic
purposes)
ABCD: asymmetry, border, colour, differential structures; BCC: basal cell carcinoma; BN: benign naevi; BPC: between-person com-
parison; CCS: case control study; cSCC: cutaneous squamous cell carcinoma; D+: disease positive; DF: dermatofibroma; dx: diagnosis;
FTF: face-to-face; GP: general practitioner; IEC: intraepithelial carcinoma; KA: keratoacanthoma; LM: lentigo maligna; MEL: invasive
melanoma or atypical intraepidermal melanocytic variants; MiS: melanoma in situ; MM: malignant (invasive) melanoma; NR: not
reported; P-CS: prospective case series; PHC: primary health care; PLC: pigmented lesion clinic; PLD: polarised light dermoscopy;
SAF: store-and-forward; SK: seborrhoeic keratosis; TD: teledermatology; WPC: within-person comparison.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Due to the small number of studies available, a single review has been produced that evaluated the accuracy of teledermatology in
all skin cancers; this replaces the two reviews intended in the protocols to separately address cutaneous melanoma and keratinocyte
cancers.
Primary objectives and primary target condition have been changed from detection of cutaneous invasive melanoma alone and detection
of BCC or cSCC as per the two protocols, to the detection of any skin cancer, as the appropriate triage of any malignant skin lesion to
specialist care is the key issue for teledermatology. The detection of the target condition of invasive melanoma alone has instead been
included as a secondary objective.
Heterogeneity investigations and sensitivity analyses were limited by the data available.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology); however, due to volume of evidence retrieved from database searches and time restrictions we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic. In terms of analysis, restriction to
analysis of per participant data was not performed due to lack of data.
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